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In recent years, much effort has been directed towards the development of new 
strategies for the efficient synthesis of libraries of peptidomimetics as potential 
therapeutic leads. The solid phase inverse synthesis of peptides (N-.C) has only 
received a fraction of the attention given to the classical (C--+N) solid phase 
assembly of peptides due to oxazolone-induced epimerisation. However, rather than 
trying to prevent its formation we have demonstrated how the peptide-derived 5(411)-
oxazolone can be used effectively as an ideal precursor to a range of 
peptidomimetics. 
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Scheme 1 General strategy for solid phase peptidomimetic synthesis via 5(4H)-oxazolones 
The development of a suitable strategy for the solid phase synthesis of inverse 
peptides is described and investigated as a valuable route into C-terminally modified 
peptides. This methodology is then applied to the construction of the polymer-
supported 5(411)-oxazolone II and various transformations thereof have been 
examined, often with solution phase comparisons. 
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ill-defined due to second order effects 
Iva isovaline 
JR infra red 
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Figure 1 Numbering system for dipeptide-derived 5(4H)-oxazolones 
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1.1 Solid Phase Chemistry 
1.1.1 General Introduction 
In 1963, Bruce Merrifield laid the foundations for what was to emerge as the solid 
phase and combinatorial chemistry revolution, by introducing a method for 
assembling peptides where the C-terminal amino acid residue was covalently bound 
to a polymer support.' This innovative technology made a dramatic impact on 
peptide chemistry, facilitating the stepwise construction of long chain polypeptides 
otherwise unattainable due to solubility and purification problems. Since then, solid 
phase synthesis has achieved wider recognition in areas such as oligonucleotide 
chemistry2  and has more recently been applied to the synthesis of small molecule 
libraries. 3 
The main features which have contributed to the popularity of solid phase chemistry 
are well known. For instance, since the solid support is ultimately filtered, excess 
reagents can be used to drive the reaction to completion. Resin-bound intermediates 
are often more stable and easier to handle than their solution-phase counterparts and 
tedious purification protocols become obsolete, with product isolation achieved by 
simply washing away excess reagents and by-products. Finally, and perhaps most 
significantly, in terms of its application to combinatorial chemistry and library 
synthesis, the process is readily amenable to automation. 
As with any technology, there are limitations. The resin beads themselves are often 
fragile and care must be taken with regard to agitation and thermal stability. Time 
and effort is required to develop the synthetic strategy, as solution phase chemistry 
does not always translate directly to solid phase, especially bearing in mind that the 
choice of linker and support will dictate the range of solvents and reagents tolerated. 
Extra steps are required for initial attachment and final cleavage of the compound 
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from the support. In addition, to ensure reactions reach completion, reaction times 
are often long and since excess reagents are employed, cost and toxicity should also 
be considered. Perhaps the most frustrating aspect of working on the solid phase, 
however, is the lack of effective procedures for on-resin analysis. There have in fact 
been numerous advances in this area over the last decade, 4-6 leading to a rapidly 
growing array of available techniques, but there are still many shortcomings and 
these will be exemplified throughout the course of this thesis. 
1.1.2 Resins and Linkers 
In solid phase synthesis the starting material requiring elaboration is anchored to the 
polymer support (resin) via a linker (Figure 2). These components are crucial to the 
success of the synthesis and must be chosen carefully, with respect to the synthetic 
conditions, when developing a solid phase strategy. 7 
starting 	 further 
material elaboration 
Figure 2 General system for solid phase synthesis 
1.1.2.1 Resin 
A great deal of research has been directed towards adapting existing chemical 
transformations for use in solid phase strategies, 812 however, it is important not only 
to consider the manipulations carried out on supported compounds, but also the 
nature of the support itself. 13 Fundamental issues, such as the accessibility of the 
functional sites to the solution phase reagents and the functionality required to attach 
the linker, together with mechanical stability and chemical compatibility, should be 
given particular attention. 
The two polymer supports which feature primarily in the literature are polystyrene-
divinylbenzene copolymer and those that combine polyethylene glycol with 1-2 % 
cross-linked polystyrene, although the desire to perform reactions under increasingly 
diverse conditions has led to the continuing development of alternative support 
2 
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materials. 14" 5  Polystyrene resins (Figure 3) are the least expensive supports 
available, as well as being relatively stable with generally high loading capacities. 
However, they are also poorly solvated in protic solvents and swelling is 
fundamental for reagent accessibility, with more than 99 % of the functional groups 
lying within the bead. 16 These limitations have provided the impetus for the 
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Figure 3 Polystyrene as a solid support 
The research detailed in this thesis was carried out predominantly with 









Figure 4 Funtionalised SynPhase TMMD  crown 
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These crowns are principally surface supports comprising a derivatised graft of 
methacrylic acid-dimethylacrylamide copolymer on a polyethylene crown. This 
alternative support technology overcomes some of the limitations of conventional 
polymer resins as there is no requirement for swelling, individual weighing, 
excessive washing and filtration. Problems of impurities due to resin degradation 17 
are also avoided. 
1.1.2.2 Linkers 
The linker exists as a cleavable handle with the purpose of tethering the starting 
compound to the support for synthetic manipulation, before finally releasing the 
desired product after completion of the synthesis. The choice of linker is critical to 
the solid phase process and there are many criteria which must be fulfilled. Essential 
prerequisites include stability to all the reagents and conditions employed during the 
synthesis, while maintaining the capacity for selective cleavage to deliver the intact 
target with correct terminal functionality. Attachment to the polymer and starting 
material should be facile and high yielding, with the linker molecule itself readily 
available at low cost. Some other desirable features include those which may 
facilitate reaction monitoring, asymmetric induction, sequential or partial release and 
the potential for reuse. 
The first linkers were based on the benzyl ether/ester protecting group, the acid 
lability of which could be increased to the desired level by introducing ortho and 
para methoxy substituents on the aromatic ring. 18 In the same way, many of the 
current linkers are modified versions of solution phase protecting groups and are 
themselves considered bifunctional protecting groups which are often, but not 
necessarily, orthogonal to those employed to protect the resin-bound growing 
compound. 
The linker imposes many of its own limitations to the synthetic strategy in terms of 
stability, cleavage and functionality thereafter. As a consequence, there has been a 
great interest in developing increasingly sophisticated linkers to overcome these 




1.1.3 Combinatorial Chemistry 
1.1.3.1 Introduction 
Solid phase synthesis, when combined with combinatorial chemistry, has found one 
of its main applications in the field of drug discovery. With the advent of new high 
throughput screening technologies and advances in molecular biology and genome 
sequencing leading to the identification of more and more protein targets, the 
demand for diverse collections of compounds to screen against these targets has 
soared. The realisation emerged that combinatorial chemistry, defined by Gallop 21 as 
the "systematic and repetitive covalent connection of a set of different 'building 
blocks' of varying structures to each other to yield a large array of diverse molecular 
entities," together with solid phase synthesis, could hold the key for accelerated drug 
discovery. Thus united, solid phase synthesis and combinatorial chemistry have 
emerged as a very powerful tool for the identification of biologically active 
compounds with therapeutic value. 22-24 
1.1.3.2 Solid phase combinatorial chemistry as a tool for drug discovery 
The significant impact that solid phase combinatorial chemistry has made on drug 
discovery to date, has not yet been fully evident due to the unavoidable time lag 
resulting from extensive clinical and toxicology trials of drug candidates. In addition, 
successful strategies and their subsequent screening results, tend to be withheld from 
the public domain until intellectual property has been secured. Consequently, it is 
only in recent years that industry has begun to disclose details of successful drug 
candidates, finally establishing combinatorial chemistry as a valuable tool for drug 
research. 25 
For example, Pfizer developed a solid phase strategy for the synthesis of 
diketopiperazines (Scheme 2).26 They used a split and mix combinatorial 
methodology to generate a library of 1000 substituted analogues of type 1. Screening 
and deconvolution of this library lead to the identification of a number of 
biologically active components which displayed an affinity for the neurokinin-2 
receptor, e.g. 2. 
5 
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R3 = amino acid side chain 
(J- OH =Wang Resin 
Scheme 2 Pfizer diketopiperazine combinatorial library - reagents and conditions: (i) mix and split 
(ii) piperidine, DMF (iii) R 2CHO, NaBH(OAc)3, DCM, sonicate (iv) BocHNCHR 3CO2H, PyBrOP, 
DIPEA, DCM (v) TFA (vi) toluene, i 
1.1.3.3 Library generation 
Library generation effectively falls into two categories: random and biased. Random 
libraries are generally used for lead identification by generating molecular diversity 
through the incorporation of a diverse range of functional groups to create novel 
compounds with no particular basis. Biased libraries, are mechanism or structure-
based and may be employed for rational drug discovery, or lead optimisation, where 
rapid access to SAR (structure-activity relationship) information is required. Apart 
from the quantity of information and speed at which it can be acquired, the very 
nature of combinatorial chemistry makes one of its major benefits the relative ease of 
re-synthesising any compounds which are identified as hits. This is in direct contrast 
to natural products leads, many of which are highly complex structures incorporating 
a host of stereogenic centres and often only accessible through tedious multi-step 
syntheses. Preparing diverse analogues of these leads for SAR studies becomes, 
therefore, both costly and time-consuming. 
The growing number of classical reactions which have been translated from solution 
to solid phase82 and the range of automation available, 7 have together helped to 
establish solid phase combinatorial chemistry as a key tool in the drug discovery 




Much of the original combinatorial chemistry practised by the pharmaceutical 
industry originated from research based on the solid phase synthesis of peptides. 21 ' 27 
This is hardly surprising considering the pharmacological importance of peptides, 
the large and accessible variety of structurally diverse amino acid building blocks, 
together with the well-established coupling techniques available. 
Peptides themselves have limited utility as bioavailable therapeutic agents due to 
their undesirable pharmacokinetics. 28 For instance, they generally display poor oral 
activity, possibly due to a lack of specific transport systems and high molecular 
weight. They are very susceptible to proteolytic degradation in the gastro-intestinal 
tract and serum and are rapidly excreted by the liver and kidneys. 
All these factors render peptides unlikely candidates for pharmaceutical 
development. Instead, recent focus has centred on both non-oligomeric, small 
molecule compound libraries, 3 ' 23 which will not be discussed any further here, and 
peptidomimetic research. 
1.2 Peptidomimetics 
1.2.1 Peptidomimetics in Drug Discovery 
1.2.1.1 Background 
Peptidomimetic research involves the discovery of peptide analogues that maintain 
the ability to bind to peptide receptors but which have greater bioavailability, 
biostability and possibly greater selectivity than endogenous or synthetic peptide 
ligands. 
The distinct feature of peptides which is so advantageous is their ability to present an 
effectively infinite number of pharmacological profiles through the diverse range of 
acidic, basic, hydrophobic/hydrophilic, and aromatic side chains they can display. 
7 
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Peptidomimetics (Figure 5) can be described as modified peptides which mimic the 
3D array of side-chains of the key amino acids in the parent peptide i.e. peptides 
incorporating unnatural or pseudo amino acids and which can imitate or block the 
biological effect of their peptide prototypes at the receptor level. Potential 
advantages of such mimics over their peptide counterparts include an improved 
resistance to proteolysis, as well as increased lipophilicity and thus enhanced 
bioavailability. However, an ideal peptidomimetic must also display high receptor 
affinity and selectivity if it is to satisfy the required pharmacological criteria. 
Furthermore, with the development of sophisticated crystallography and NMR 
techniques, peptidomimetic ligands of receptors or enzymes may be rationally 
designed to inhibit or enhance a specific activity, depending on the therapeutic 
requirement. 
1.2.1.2 Categories and preparation 
0 2 R3 
cHJ , H 
0 	R 	
H 	II 
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0 R 
PEPTIDE 
R1 0 	 R3 
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Figure 5 Some examples ofpeptidomimetic structures 
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Many methods of manipulating peptide structures so as to maintain their activity 
while improving their pharmacological profile, have been explored. 3,22,29,30  Some 
popular modifications include using amino acid analogues e.g. a,ct-dialkylated (3) 
(1.2.2), N-alkylated 31 (4), a,f3 unsaturated (5) (1.2.3) as well as 13- and D-amino 
acids. 
Conformational restrictions can be incorporated into peptide structures to form 
peptidomimetics. Since these conformationally restricted derivatives 32 e.g. cyclic or 
bridging dipeptide analogues of the type 6, are no longer recognised by peptidases 
they display improved metabolic stability. 
Backbone modifications are also used as a method of achieving protease resistance 
and increasing in vitro half-life. There are many examples including the peptidic 
oligourea (7) which was the basis of a 160 member pilot library by Burgess, 33 the 
oligomeric mimetic with a phosphodiester backbone 34 (8), retro-inversomers 35 ' 36 
where D-amino acids are incorporated and the direction of the peptide chain reversed 
(9), as well as vinylogous peptides 37 (10) and isosteric replacements of the amide 
bond. 
1.2.1.3 Peptidomimetics as therapeutic agents 
Over the last thirty-five years or so, numerous biologically active peptides e.g. 
somatostatin, substance P, angiotensin II, enkephalin and cholecystokinin, have been 
discovered and their structures determined. These neurotransmitters, 
neuromodulators and hormones not only play a vital role in terms of their biological 
function but also serve as valuable templates for the development of new selective 
drugs with enhanced pharmacokinetics. 29 Veber describes how some of the 
peptidomimetic methodologies, described above, have been employed for generating 
modified versions of a number of native neuropeptides. 28 
In addition, there are many examples of successful peptidomimetic drug candidates, 
from both solution and solid phase syntheses, now appearing in the literature. 38 ' 
IN 
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1.2.1.4 Closing remarks 
Three of the methods for modifying peptides, described above (1.21.2), have been 
examined in more detail during the course of this research and discussed in Chapter 
4. Brief introductions to these selected classes of peptidomimetics follow, primarily 
with respect to solid phase development. 
1.2.2 Peptides Incorporating a,a-Dialkylated Amino Acids 
1.2.2.1 Background 
An example of a family of naturally occurring peptides in this category are the 
Peptaibols.42  These amphipathic microbial peptide antibiotics contain an unusually 
high proportion of a,a-dialkylated amino acids, including Aib and D-Iva (Figure 6) 
as well as having a C-terminal amino alcohol and an acylated N-terminus. 
H2N (OH 	 H2N fl 0H 
Aib 	 D-Iva 
(a-amino isobutyric acid) 	 (D-isovaline) 
Figure 6 a-ci-Dialkylated amino acids from the naturally occurring peptaibols 
Incorporation of these hindered amino acid residues into the frameworks of the 
Peptaibols is thought to contribute to their ability to form trans-membrane helical ion 
channels. 42  Non-proteinogenic a-alkylated amino acids have a remarkable influence 
on the conformation of the small peptides into which they are incorporated. For 
instance, research has shown that peptide analogues of this type, which possess an a-
methyl substituent, appear to induce 3 and a-helical secondary structures, 43 
whereas in derivatives where the two substituents are longer chain alkyls, more 
extended secondary conformations are favoured. 44 Thus, the restricted 
conformational flexibility imposed by the second a—C substituent in such 
10 
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peptidomimetics can be exploited as a means to investigate enzyme mechanisms and 
may also serve to alter the biological activity of the peptide analogue. 
Dialkylation at the a-C is also expected to increase resistance to enzyme degradation 
and thus improve biological half-life. For example, Yokum et al. reported the 
synthesis of a series antimicrobial a,ct-dialkylated amino acid rich peptides with in 
vivo anti-brucellae activity. 45 
1.2.2.2 Synthesis 
Although many examples of synthetic routes towards a,a-disubstituted amino acids, 
both racemic and enantiopure, have been reported, 4652 incorporation of these units 
into peptide molecules has proven more troublesome. 5355 
Peptides containing a,a-dialkylated-a-amino acids may be prepared by introducing 
the suitably protected C disubstituted amino acid at the appropriate stage during 
classical peptide synthesis. However, steric hindrance at the dialkylated carbon 
centre, along with the poor nucleophilicity displayed by the hindered amino 
component, serve to impede this process. Forcing conditions, such as elevated 
temperatures and long reaction times may be employed, but this tends to result in 
epimerisation of the C-terminal residue. 55 
Heimgartner47 ' 56  sought to overcome the problems by using 2,2-disubstituted-3-
amino-2H-azirines as highly activated amino acid equivalents in the role of amino 
coupling element. The so-called azirine/oxazolone method is depicted on the 
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Figure 7 Heimgartner 's azirine/oxazolone method 
Coupling of the C-terminal peptide with the highly reactive 3-amino-2H-azirine (11) 
proceeded quantitatively at 0 - 25 °C. Very mild hydrolysis (3 M HCl, THF/11 20, 25 
°C), of the peptide amide 12 to the acid 13 could be achieved, thus avoiding 
oxazolone-induced epimerisation, provided N-methyl anilide (R 3 = Me, R4 = Ph) was 
used. The ring strain of azirine derivative 11 provided sufficient activation to obviate 
the necessity for activation of the carboxy-terminus, which generally results in 
undesirable epimerisation (1.3.1). Activation to facilitate coupling of a second amino 
component was carried out via DCC-mediated cyclisation to the 5(411) oxazolone 
(14). This activated peptide derivative (1.3) is amenable to aminolysis, yielding the 
desired dialkylated peptide derivative. Unfortunately, epimerisation of the activated 
oxazolone 14 was observed since long reaction times and elevated temperatures were 
required to facilitate coupling of the sterically hindered amino component. This 
problematic side reaction, which is discussed in greater detail in section 1.3.1, 
however, may be suppressed by utilising a combination of additives such as HOBt 
and copper (II) chloride. 57 ' 58 Further chain extension was then achieved by 
deprotection and coupling of another 2,2-disubstituted-3-amino-2H-azirine to finally 
yield the desired peptidomimetic. This method has since been extended to a number 
of other useful dialkylated peptide derivatives. 59,60 
The advantages of this strategy are evident, but its proficiency as an efficient solid 
phase route has yet to be investigated. 
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Most reported synthetic methods for the synthesis of a,a-dialkylated peptide 
analogues involve incorporation of individually modified amino acids during normal 
peptide synthesis. In contrast, O'Donnell and co-workers 61 ' 62 have reported a 
procedure whereby the new side chains are built into the peptide backbone during 
synthesis, using a method for the formation of C-C bonds under mild conditions. 
They describe the use of Schiff base activated amino acids as a new procedure for 
the a-alkylation of terminal peptidic amino acid residues on solid phase. 
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Scheme 3 O'Donnell's "di-UPS" 
a-Alkylation of the resin-bound Schiff-base ester (15) was achieved using BEMP as 
a base with the desired electrophile (e.g. alkyl halide) at room temperature. 
Transimination with hydroxylamine furnished free amine 16, followed by coupling 
or protection to extend or terminate the peptide chain. Final cleavage from the resin 
released the a,a-dialkylated peptide derivative in greater than 50 % yield. Although 
a number of disubstituted peptide derivatives were prepared using this solid phase 
unnatural peptide synthesis procedure ("di-UPS"), a distinct drawback of this 
methodology is its lack of stereoselectivity, since it results in the formation of 
epimeric peptides. 
1.2.3 Peptidomimetics Containing Dehydroamino Acid Residues 
1.2.3.1 Background 
Nature provides many examples of biologically active peptides containing 
dehydroamino acid residues (17). 6364 Analogues of many peptides incorporating 
a,-unsaturated residues, have been used to determine SARs through the modified 
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bioactivities they exhibit. Tentoxin (Figure 8), for instance, is a cyclic tetrapeptide 
which incorporates a Z-aj-dehydro-N-methyl phenylalanine residue and displays 
phytotoxic properties. Produced by Alternaria tenuis, this biologically active peptide 
promotes chiorosis in the developing seedlings of a number of flowering plants and 
has thus attracted the attention of many research groups. 63 As a result, many 
synthetic routes to Tentoxin and its analogues have been reported, 65 '66 addressing 
some of the problems associated with the synthesis of dehydropeptides (1.2.3.2). 
R 







Figure 8 Peptide analogues incorporating dehydroamino acid residues 
Incorporation of an a,3-dehydroamino acid moiety into a peptide skeleton, has thus 
been shown to influence the reactivity and conformation of the resulting peptide 
analogue. 63 
a43-dehydroamino acids are also useful synthons in peptide chemistry, facilitating 
the preparation of a-keto acids, and various peptide amides. Furthermore, 
asymmetric hydrogenation of dehydropeptide analogues is an established method for 
the preparation of optically pure a-amino acids and peptides, 67 with examples of this 
now being reported on the solid phase. 68 
1.2.3.2 Synthesis 
A wide array of approaches have been reported for the preparation of dehydroamino 
acids and peptides, 63''67 although very few have exploited solid phase synthesis as a 
means of accessing these analogues in a combinatorial fashion. 69'70 
The most popular route employed, which also mimics the biosynthetic process, is J3- 
elimination, which can be performed on complete peptide amino acid residues, such 
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as serine and threonine, at the end of the synthesis. Since the presence of an a,13 
double bond in an amino acid residue leads to weak nucleophilicity of the enamine 
and poor reactivity of the carboxylic group, introducing the dehydro unit at the end 
of the synthesis circumvents the problems associated with coupling these unreactive 
dehydro derivatives. Many of the methods reported for the preparation of 
dehydroamino acids via 13-elimination63 are low yielding and involve the generation 
of unstable amino acid derivatives. Miller, however, was able to overcome these 
limitations by developing an isourea-mediated 13-elimination process for the 




y¼J 	 (i) 
	
: NR3 
CbzHN 	 R 
	
CbzHN 	 R 
	






Scheme 4 Isourea-mediated /3-elimination - reagents and conditions: (i) R 4NCNR3 , CuC1 
Stammer has also reported a very convenient means of accessing dehydroamino 
acids and peptides via 5(4H)-oxazolone intermediates. 72,73  This method, which 
involves the direct oxidation of the dipeptide-derived 5(4H)-oxazolone with DDQ, is 
discussed in greater detail along with its successful application to this research in 
section 4.2.1. 
1.2.4 C-Terminally Modified Peptides 
1.2.4.1 Background 
In solid phase peptide synthesis, the majority of linkers tether the growing peptide 
chain to the support via the C-terminal carbonyl as an ester or amide, releasing the 
free carboxyl group on cleavage. However, amongst the vast range of natural 
peptides and biologically active analogues, exist many examples of peptides with 
functionalised C-termini. For instance Neuropeptide Y (NPY) and FMRFamide both 
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contain C-terminal amides. NPY, one of the most abundant neurohormones in the 
mammalian central and peripheral nervous systems, is a 36-mer with a C-terminal 
tyrosinamide which has been confirmed as essential for its receptor affinity. 74 
Likewise, the C-terminal amide of the molluscan regulatory tetrapeptide, 
FMRFamide, is an important structural requirement for its biological activity. 75 
Furthermore, it has already been mentioned (1.2.2.1) that the naturally occurring 
peptide antibiotics, the Peptaibols, possess C-terminal amino alcohols. Some other 
functionalities which have been observed include alcohols, esters, ethers, aldehydes, 
N-alkylamides, NN-dialkylamides, hydrazides, trifluoromethyl ketones, 
mercaptoalkylamides, thioamides and thioesters. 76 Head-to-tail cyclic peptides, 
possessing no carboxy-terminus as such, also fall into this category and their 
biological significance is also particularly evident. 77 
Introducing a different functional group at the C-terminus, may render a molecule 
less susceptible to carboxypeptidases. It may also improve the capacity for crossing 
various biological barriers and even enhance both solubility and substrate specificity. 
C-terminally modified peptides, therefore, constitute an important class of 
peptidomimetics which hold great potential for both mechanistic probes and 
pharmaceutical development. C-terminal peptide esters have also found application 
in peptide synthesis as substrates for enzyme-catalysed fragment coupling 
reactions. 78 
1.2.4.2 Synthesis 
As a result of the growing interest in this field, many solid phase routes into C-
terminally modified peptide analogues have been established. For example, a number 
of linkers have been developed to enable direct access to peptide aldehydes, 79 
amides80 ' 8 ' and p-nitroanilides. 82  However, it would be more desirable to develop a 
system which would enable a large variety of functional groups to be incorporated at 
the C-terminus of the supported peptide, in a combinatorial manner. One obvious 
route would be to assemble peptides in the non-conventional direction (N-C), leaving 
the C-terminus exposed to be manipulated as required. Even though this method 
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risks oxazolone-induced epimerisation (1.3) it has been examined by a number of 
groups and will be discussed in more detail in Chapters 2 and 3. 
Two other successful methods for introducing C-terminal modifications are 
Bradley's 'internal resin capture' approach 83 and Barany's 'backbone amide linker' 
(BAL) strategy, 84 both of which are described below. 
Bradley and co-workers devised an inversion/modification strategy applicable to a 
range of C-terminally modified peptides. The peptide chain was first assembled in 
the conventional (C-N) direction, thus exploiting all the benefits of this well-
established methodology, but was subsequently inverted such that the peptide still 
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Scheme 5 Reagents and conditions: (i) Fmoc-Lys(Boc)-OH, DIC, HOBt (ii) 20 % piperidine, DMF 
(iii) diallylpyrocarbonate, Et3N (iv) 25 % TFA, DCM (v) 4-(4-hydroxymethyl-3-methoxyphenoxy)- 
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butanoic acid (HMPB), DIC, HOBt, DCM (vi) Fmoc peptide chemistry (vii) 20, pyridine, DMF (viii) 
Pd(PPh3)4, dimedone, DCM : THF (1: 1) (degassed) (ix) PyBroP, DMAP, DIPEA, DCM (x) 1 % TFA, 
DCM 
The basic strategy involved coupling 4-(4-hydroxymethyl-3-methoxyphenoxy)-
butanoic acid to the c-amino group of 18, before assembling the desired peptide 
sequence using standard Fmoc peptide chemistry to give 19. Carbonate 20 was then 
coupled and simultaneous deprotection of the allyl carbonate (Abc) and allyl ester, 
followed by cyclisation, furnished the resin-bound cyclic peptide 21. Treatment with 
1 % TFA effected cleavage of the highly acid labile HMPB linker, exposing the C-
terminus to yield the polymer supported inverted peptide 22. The free carboxyl group 
was then activated, giving rise to slight oxazolone-mediated epimerisation (1.3), 
modified and cleaved using 95 % TFA to yield the desired C-terminally modified 
peptide (Scheme 6). 
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Cleaved linker = HMPB - X = 0, n = 1 
Cleaved linker = Rink X = N, n = 2 
ccD = peptide chain 
Scheme 6 Reagents and conditions: (i) RNH 2 (4 eq), PyBroP (2 e, DIPEA (2 cci), DCM (ii) 95 % 
TFA, DCM (iii) cyanuric chloride, DMF 
When the HMPB linker was employed, as previously shown (Scheme 5), the 
carboxyl group delivered on cleavage was activated and treated with amine to afford 
the corresponding amide 23 (Scheme 6). When the Fmoc-Rink linker (p-{a-(1-[9H-
fluoren-9-yl] -methoxyformamido)-2,4-dimethoxybenzyl] -phenoxyacetic acid) was 
used in place of HMPB, acidic cleavage gave the primary amide 24, or treatment 
with cyanuric chloride in DMF followed by cleavage furnished the peptide nitrile 25. 
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A broad array of C-terminally modified peptide analogues were prepared using this 
methodology. 83 
A particularly attractive feature of the inversion method is that it is considered to be 
'self purifying'. Only those peptides which undergo successful internal resin capture 
(cyclisation) to 21 (Scheme 5) will remain on the resin during treatment with 1 % 
TFA, therefore, any peptides or impurities attached to the support solely via the 
HMPB linker will being cleaved and washed away leaving the pure product bound to 
the support. 
The alternative BAL approach adopted by Barany et al. 84'85 not only offers a general 
route to a wide range of C-terminally modified peptides, but may also be applied to 
the synthesis of cyclic peptides, modified amino sugars and small organic molecules. 
The basic crux of the strategy is attachment of analogues to the polymer support via 
an jX  backbone amine (Scheme 7), leaving both termini free for elongation or 
manipulation. 
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Scheme 7 Reagents and conditions: R' = CO2CH2CHCH, R2, R3 & R4 = amino acid side chain, X = 
Cl, CF3CO2 or CH3C6H5S03, Prot = Tr or Ddz, (i) TFA/H 20/DCM (2:1:97 Tr; 3:1:96 Ddz) (ii) 
FmocNHCHR4CO2H, PyAOP, DIPEA, DMF 
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The BAL handle (28) was prepared by coupling 5-(4-f6rmyl-3,5-
dimethoxyphenoxy)-valeric acid (PALdehyde) (26) with aminomethyl polystyrene or 
PEG, followed by a one-pot, on-resin reductive amination. Acylation of the 
secondary amine nucleophile was slower than with a primary amine, nonetheless, 
coupling of the second amino acid residue to yield 29 could be achieved using a 
number of coupling conditions. Standard C-N peptide elongation was then used to 
assemble the desired polypeptide chain, before cleavage from the resin. A number of 
C-terminal peptide analogues were prepared by this strategy 85 using different starting 
amino acid derivatives instead of 27 (Scheme 8). 
For instance a peptide alcohol was prepared in high purity by coupling 
phenylalaninol tert-butyl ether to the BAL handle, before chain extension and 
cleavage. In the same way, a C-terminal aldehyde was synthesised by starting with 
glycinal dimethylacetal and Leu-enkephalin dimethylamide was obtained by 
coupling leucine dimethylamide hydrochloride salt as the first amino acid residue. 
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Scheme 8 Some applications of the BAL handle approach 
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Further useful applications of this approach, including the formation of head-to-tail 
cyclic peptides 30, are illustrated in Scheme 8. 
1.2.5 Closing Remarks 
As illustrated, the term peptidomimetic covers a broad range of structurally diverse 
compound types. These different analogues have a variety of applications, but all 
bear the common potential for development as therapeutic agents. Although many 
sophisticated routes to each type of peptide analogue have been reported, there still 
remains a demand for an efficient, general, solid phase system, applicable to the 
combinatorial synthesis of a whole variety of peptidomimetics. 
Thus, the aim of this research was to develop a solid phase system which would 
provide access to a wide range of peptidomimetic structures. The dipeptide-derived 
5(411)-oxazolone was selected as an ideal synthon. 
1.3 5(411)-Oxazolones 
1.3.1 General Overview 
5(4I1)Oxazo lones t, of the general structure 31, may be regarded as anhydrides of N-
acyl amino acids. This class of heterocycle has received periodic bursts of interest 
since the preparation of the first unsaturated oxazolone (32) by Plöchl, over a century 
ago. 86 Erlenmeyer, after determining the correct structure of Plöchl's new 
heterocycle, was the first to establish unsaturated oxazolones, coined Erlenmeyer 
azlactones, as useful intermediates for the synthesis of a-keto and a-amino acids. 87 
The late 1940s witnessed a revived interest in the chemistry of 5(411)-oxazolones, 
when the thiazolidine-oxazolone structure was implicated, albeit erroneously, in the 
chemistry of penicillin. However, the research prompted by this proposal, together 
with more recent investigations, has served to establish the 5(411)-oxazolone as a 
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Figure 9 5(4H) oxazolone. general structures 
Not surprisingly, 5(4H)-oxazolones are not held in quite such high regard in the field 
of peptide chemistry, where they have been ascribed as the primary cause of 
racemisation during peptide synthesis. 91 In order for peptide coupling to take place, it 
is necessary to activate the carboxy component prior to aminolysis, and it is at this 
stage that the optical purity of the growing peptide chain is in danger of being 
compromised. Activated acylamino acids and peptides undergo base-catalysed 
cyclisation to 5(411)-oxazolones as depicted in Figure 10. These oxazolones may be 
considered activated derivatives of peptides, and are thus susceptible to aminolysis 
with amino acid nucleophiles, ultimately leading to peptide chain elongation. 
However, 5(41-I)-oxazolones also spontaneously racemise via the resonance 
stabilised pseudoaromatic anion 33 leading to undesirable epimeric peptide products. 
In contrast, when the acyl substituent of the activated carboxy component is an 
alkoxycarbonyl protecting group e.g. Boc, Cbz or Fmoc, racemisation is not only 
limited, but aminolysis occurs at a faster rate. Thus, solid phase peptides synthesised 
in the C-N direction using activated Cbz-protected carboxy components suffer little 
or no detectable racemisation. It is for this reason that inverse (N-C) peptide 
synthesis has been neglected in favour of C-N synthesis, since elongation in the 
inverse direction requires activation of the C-terminal residue which is not protected 
from oxazolone-mediated racemisation. Nonetheless, studies into the mechanism of 
this racemisation procedure have enabled the development of a range of additives 
which have different suppression effects on the rate of racemisation, 57 ' 58 indicating 
that racemisation free N-C peptide coupling may become commonplace in the not 
too distant future. 
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Figure 10 Racemisation via 5(4H)-oxazolones 
Although perceived as a limitation, the racemisation of 5(411)-oxazolones, which 
proceeds at a faster rate than nucleophilic ring-opening, has facilitated their use as 
substrates for dynamic kinetic resolution. Indeed, there has been a recent wave of 
reports describing the use of 5(411)-oxazolones as valuable precursors for the 
preparation of optically active cc-amino acids. For instance, many groups have 
studied the enzymatic-catalysed enantioselective ring-opening of 2-phenyl 5(411)-
oxazolones as a route into optically active amino acid derivatives. 92-96 Other 
examples of the use of 5(4H)-oxazolones in this manner include, dynamic resolution 
using chiral catalysts, 97 crystallisation-induced resolutions 98 and asymmetric 
transformations catalysed by chiral ligand complexes. 99 
As already stated, 5(41f)-oxazolones are useful intermediates for the synthesis of a 
diverse range of compounds. Most of the research reported, however, focuses on the 
use of 2-phenyl 5(411)-oxazolones, with various substituents at the C4 position, 
including aryl-and alkylidene unsaturated derivatives. Many of these transformations 
will be discussed further in Chapter 5, as potential areas for future research, 
however, the particular oxazolone derivative at the basis of this research is the 
dipeptide-derived 5(4H)-oxazolone (34). This intermediate may well prove a useful 
means of accessing a range of therapeutically desirable peptidomimetics. 
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1.3.2 Dipeptide-Derived 5(4H)-Oxazolones 
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Figure 11 Dipeptide-derived 5(4H)-oxazolone 	 - 
The dipeptide-derived oxazolone (34) can be readily prepared by dehydration of a 
dipeptide or peptide chain which is unprotected at the C-terminus. This reaction is 
usually achieved by the use of acetic anhydride or DCC. However, in terms of solid 
phase research the carbodiimide activation is preferable, since harsh conditions are 
not usually compatible with commonly used peptide linker systems. 
The dipeptide-derived oxazolone was selected as a useful synthon for two main 
reasons. Firstly, deprotonation under mild conditions affords the enolate which is 
amenable to alkylation, thus providing a route into a,a-dialkylated amino acids and 
peptides (1.2.2). It was also predicted, that because the original oxazolone contains a 
stereogenic centre at Cl', asymmetric induction may be observed during the 
alkylation step, with the success of this depending on the substituent R'. 
The second feature of the oxazolone to be exploited was its susceptibility to 
nucleophilic ring opening, which can be achieved using a number of nucleophiles, 
(4.2.1). Thus, after elaboration of the resin-bound oxazolone moiety, aminolysis can 
be effected with a range of nucleophiles, to afford an array of C-terminally modified 
peptide analogues. 
As well as examining the potential for alkylating the 5(411)-oxazolone, a further 
elaboration to be investigated was the DDQ-induced oxidation at the C4 position 72 as 
a means of accessing dehydropeptides (1.2.3). All these transformations, alkylation, 
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oxidation and ring-opening, will be discussed in greater detail in the relevant 
sections in Chapter 4. 
1.4 Conclusions and Aim of Project 
Given the significance of combinatorial solid phase chemistry and peptidomimetic 
structures in the drug discovery process, along with the beneficial features of the 
dipeptide-derived 5(411)-oxazolone moiety, the aim of the research was to use the 
resin-bound oxazolone as a versatile precursor to numerous peptide analogues as 
depicted below (Figure 12). 
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Figure 12 General strategy - peptidomimetic libraries via supported 5(4H)-oxazoloie intermediates 
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2. Results and Discussion I 
2.1 Inverse Peptide Synthesis 
2.1.1 General Overview 
As advanced in Chapter 1, C-terminally modified peptides hold S a great deal of 
potential as therapeutically active peptidomimetics. Many of the strategies employed 
for the synthesis of these peptide analogues have already been outlined (1.2.4.2), but 
an alternative general approach, and perhaps the most obvious route, is via the direct 
assembly of peptides in the N-C direction. This method not only leaves the C-
terminus free to be functionalised or capped as required, but can also be used to 
facilitate fragment coupling (the process of condensing partial sequences of the 
target peptide, rather than constructing the whole chain in a stepwise manner). 
Inverse (N-C) peptide synthesis has been largely ignored in favour of the 
conventional C-N peptide elongation, due to the danger of oxazolone-mediated 
racemisation (Figure 10). Nevertheless, there have still been a number of attempts at 
developing suitable conditions for the N-C construction of peptides as a route into 
valuable C-terminally modified peptide analogues. A few examples are described 
below. 
After Merrifield's seminal publication in 1963' of a radical new method for the 
synthesis of peptides covalently anchored to an insoluble support, Letsinger' 00 ' 10 ' 
was the first to investigate the feasibility of performing solid phase peptide synthesis 
in the N-C direction. He describes using "popcorn" polymer (polystyrene 0.5 % 
crosslinked with divinylbenzene) to synthesise leucylglycine (36) via the mixed 
anhydride method illustrated in Scheme 9. 
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Scheme 9 Reagents and conditions: (i) phosgene, benzene (ii) HC1-Leu-OEt, Et 3N, DMF, 2.5 h (iii) 
0.8 M NaOH, MeOH, acetone, 3 h (iv) isobutyl chioroformate, Et 3N, toluene (v) TSA-Gly-OBz, 
Et3N, DMF, 2.5 days (vi) 15 % HBr in acetic acid 
The leucine derivative was coupled to the activated support, deprotected and treated 
with isobutyl chloroformate to afford the carboxylic-carbonic anhydride 35. 
Aminolysis with glycine benzyl ester p-toluenesulfonate, followed by cleavage and 
deprotection furnished the target dipeptide 36. 
This was the only reported instance of N-C directed solid phase peptide synthesis 
until seven years later when Merrifield and Felix 102 described the inverse synthesis 
of a tetrapeptide using the acyl azide method outlined in Scheme 10. 
Recognising the potential of peptide synthesis in this unconventional direction as a 
route into C-terminally modified peptides, Merrifield's objective was to determine a 
method for the efficient, racemisation-free coupling of peptides. At this time, the 
azide method, 103  originally pioneered by Curtius at the turn of the century, was 
considered to be completely racemisation free. Indeed, although recent evidence 
suggests that racemisation does occur under certain conditions, it is still less prone 
than most other coupling methods available. Merrifield and Felix adopted the 
Rudinger and Honzl 104  approach to azide coupling, utilising amino acid Boc-
hydrazides (1 -aminoacyl-2-tert-butyloxycarbonylhydrazines) as protected amino 
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components that could be converted to reactive amino acid azides in two steps. The 
general solid phase strategy is outlined below (Scheme 10). 
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Scheme 10 Reagents and conditions: (i) Et 3N, CHCI 3 (ii) 4 M HC1-dioxane, 23 °C, 30 mm (iii) n-
butyl nitrite, THF, -30 °C, 1 h (iv) 40a R3 = NHNHBoc or 40b R3 = OC(CH3) 3 , THF, -30 then 0 then 
25 °C (v) HBr-TFA or HF 
The amino acid Boc-hydrazide (37) was first linked to the support and then 
deprotected to yield the hydrochloride salt of the resin-bound amino acid hydrazide 
(38). Conversion to the azide (39) was achieved by treatment with n-butylnitrite in 
THF, suitably activating it for coupling with the next amino acid Boc-hydrazide 
residue (40a). After this coupling procedure, the deprotection, activation and 
coupling steps were repeated, until the desired peptide chain had been constructed. 
Finally, the C-terminal residue was coupled as the tert-butyl ester (40b), before 
concomitant deprotection and cleavage from the resin using HBr in TFA. Merrifield 
and Felix demonstrated the versatility of this methodology by synthesising the 
tetrapeptide Leu-Ala-Gly-Val both in a stepwise manner and by fragment coupling 
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of the two dipeptide components. The latter strategy resulted in a higher yield of 
cleaved product, highlighting the advantages of fragment condensation over 
consecutive stepwise elongation. 
The numerous side reactions associated with the use of peptide hydrazides and 
azides are well documented, 103  the most common being Curtius rearrangement to 
isocyanates, leading to urea containing peptides and secondly decomposition to 
amides, resulting in chain termination. Merrifield and Felix also studied the stability 
of the leucine azide and observed that although there was no evidence of 
rearrangement, there was some decomposition of the azide at 4 °C. These problems 
provide an explanation for why the "racemisation-free" acyl azide method has been 
superseded as a routine method for stepwise peptide synthesis, by other methods 
such as carbodiimide and phosphonium-mediated coupling. Indeed, in their closing 
remarks the two authors recommend that due to solvent limitations and poor yields, 
the azide approach should not be considered as "a general replacement for solid 
phase peptide synthesis", but rather be regarded as a "valuable supplement" to this 
field of chemistry. 
More recent work by Sharma et al. 105  utilises trialkoxy silyl esters and DIC/HOBt 
activation to perform inverse peptide syntheses, before in situ modification to 
peptide analogues e.g. alcohols. The basis of their strategy is the stability of the silyl 
derivatives between pH 4 and 8, rendering them immune to hydrolysis under the 
conditions of peptide bond formation, yet easily removed by either acidic or basic 
conditions. The peptides Leu-Ala-Gly-Val and leucine-enkephalin were synthesised 
in this way. Both were obtained in good yield and required minimal purification. 
Hydrophobic sequences were also synthesised using BOP as the activating agent, 
with good yields of high purity products. Furthermore, no protection of hydroxy-
functionalised side-chains was required. The method was extended to fragment 
condensation and also to the preparation of some C-terminally modified peptides 
including analogues based on leucine-enkephalin. Racemisation, normally a major 
drawback in inverse peptide synthesis, was also considered, but careful examination 
of the leucine-enkephalin product indicated that racemisation had not occurred. 
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A completely different approach, adopted by Jakube et al. 106  exploits the reverse 
hydrolysis potential of proteases which are normally responsible for breaking down 
the very peptide chains chemists labour to synthesise. Polypeptides are synthesised 
in the N-C direction in the ribosome, but unfortunately ribosomal peptidyl 
transferase is only active in vivo, and therefore precludes its use in in vitro systems. 
Instead, Jakube and co-workers have demonstrated how the cysteine protease 
clostripain, along with other enzymes, can be used to synthesise a tetrapeptide (Lys-
Tyr-Arg-Ser) comprised exclusively of unprotected trifunctional amino acids in high 
yield (62 %). The advantages of employing enzymes for such couplings are that 
reaction conditions are mild and free from racemisation and there is no need to 
employ side chain protection. There are also limitations associated with this method, 
however, including the restrictive specificity of proteases and the obvious risk of 
proteolytic degradation of the starting peptide or product. 
An approach which appeared particularly promising as an efficient means of 
accessing inverse peptides on the solid support, was the method reported by 
Dressman et al., 107  outlined in the following section (2.1.2). 
2.1.2 Solid Phase Synthesis of Hydantoins 
In 1996, Dressman and co-workers described a novel approach for the solid phase 
synthesis of hydantoin libraries. The main crux of their strategy involved N terminal 
linkage to a support, elongation in the N-C direction followed by base catalysed 
cyclisation, effecting simultaneous cleavage from the polymer support as depicted in 
Scheme 11. 
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Scheme 11 Solid phase synthesis of hydantoins - reagents and conditions (i) BSA, DMAP, DMF, RT, 
48 h; MeOH (ii) DCC, HOBt, R4NH2, DMF, RT, 24 h (iii) Et3N, MeOH, 55-88 °C, 48 h 
A series of free amino acids (42) were dissolved in DMF with the aid of N,O-
bis(trimethylsilyl)acetamide (BSA; 10 eq) and gentle heating. Coupling to the 
activated carbonate (41) was carried out in the presence of DMAP (2 eq) to afford 
the corresponding resin-bound amino acid derivative (43). After amide formation 
(44), the novel cyclisationlcleavage step was accomplished with excess Et 3N at 
elevated temperatures to afford the desired hydantoins (45). By utilising 20 amino 
acids and more than 80 primary amine building blocks, Dressman and co-workers 
were able to synthesise a library of 800 individual hydantoins for biological 
screening. 
The feature of this strategy that seemed particularly attractive was the use of free 
amino acid residues, obviating the laborious synthesis of specifically protected 
amino acid building blocks. The authors also noted that a relatively diverse range of 
amino acids was tolerated by the chemistry. 
Given the benefits and apparent suitability of the Dressman system, the decision was 
made to adopt this methodology as a means of accessing dipeptide-derived 5(411)-
oxazolones on the solid support. 
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2.2 Linker 
2.2.1 Choice of Linker 
As previously discussed (1.1.2.2) the choice of linker is paramount in determining 
the success of a solid phase synthetic strategy. Considerations include ease of 
attachment, stability during compound elaboration and facile selective cleavage to 
yield the correct terminal functionality. 
The popular acid-labile alkoxybenzyl alcohol resin (Wang linker) (46 - polystyrene-
bound) was first introduced 18 for the synthesis of protected peptide fragments 
containing a free carboxyl group, via an ester linkage to the carboxy terminus. It has 
since been used to attach a wide range of functionalities, by first activating, then 
derivatising with a variety of nucleophiles. 19 The lability of acid-cleavable linkers 
depends on the relative stability of the cation formed on cleavage, compared to the 
protonated linker. The electron-donating para-oxygen on the Wang linker, stabilises 
the cleavage-induced cation, thus enabling mild acidic cleavage with 50 % 
TFAIDCM. The "Wang-type" linker (47) developed by Bradley for the solid phase 
synthesis of polyamines, 108-110 incorporates an amide bond adjacent to the benzylic 
ether. The author noted that attachment to the polymer via this functionality, rather 
than the benzylic ether of Wang, led to fewer side products, presumably a feature of 
the relative acid stabilities of these two moieties. Bradley's polystyrene-bound 
"Wang type" linker (47), denoted hereafter as PS-HMPA, since it can be derived 
from the reaction of 4-(hydroxymethyl)-phenoxyacetic acid with aminomethyl 








Figure 13 Comparison of Wang and "Wang-type" linker systems 
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The HMPA linker (47) has also been reported by others' 5 ' 116 for use in peptide 
synthesis, where attachment is via an ester bond to the C-terminus of either a 
reference amino acid or the growing peptide chain. Amines, however, may be 
coupled to activated PS-HMPA via a urethane, which is stable to the conditions 
required for activation of the first residue and continued peptide synthesis. Initial 
anchoring to aminomethyl polystyrene resin can be achieved using standard peptide 
coupling conditions and on completion of the synthesis, the linker can be cleaved 
readily with 50 % TFA to deliver the desired amino terminus after in situ 
decarboxylation. In light of these many features, we opted for Bradley's PS-HMPA 
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Figure 14 Target polymer-supported 5(4H)-oxazolone, tethered via the HMPA linker 
An added attraction of this linker system, is its structural similarity to the Cbz 
protecting group, facilitating valid comparisons with solution phase investigations on 
Cbz-protected dipeptide-derived 5(411)-oxazolones. 
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2.2.2 Preparation of Resin-Bound HMPA Linker 
2.2.21 Synthesis of 4-(hydroxymethyl)phenoxyacetic acid (49) 
4-(Hydroxymethyl)-phenoxyacetic acid (49) is commercially available, but 
expensive, so was instead prepared from 4-hydroxybenzyl alcohol and methyl 













0 	 49 
Scheme 12 Reagents and conditions: (i) Nal, K2CO3,  DMF (ii) 4 M LiOH (acij, THF 
The formation of methyl 4-(hydroxymethyl)phenoxyacetic acid (48) proceeded 
selectively, with no evidence of the corresponding 4-(hydroxybenzyl)oxyacetic acid 
arising from nucleophilic attack by the methoxide anion. Alkaline hydrolysis, using 
lithium hydroxide monohydrate, gave the crude acid, which was recrystallised to 
afford 49 in 41 % yield. The poor yield at this stage is thought to be a feature of the 
work up (unoptimised), as the reaction itself appears to proceed smoothly by tic. 
NH2 	+ 	
0) ':;e-.._-- ::j 	 50 	1II1OH 




Scheme 13 Reagents and conditions: (i) DIC, HOBt, DCM, DMF (ii) N 2H4.H20, DMF 
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Standard peptide coupling reagents DIC and HOBt were used to couple 49 to 
aminomethylated polystyrene resin (Scheme 13). However, analysis of the resin 
sample by JR gave a very distinctive and unexpected ester stretch (Vmax  1757 cm') 
indicating that the resin bound alcohol had reacted with excess activated acid to yield 
the ester 50. This was confirmed by gel phase 13C NMR analysis (Figure 15). 
0 
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Figure 15 Gel phase ' 3CNMR of 50 
The resin-bound ester was hydrolysed using hydrazine monohydrate to give the 
desired PS-HMPA linker 47 in quantitative yield, confirmed by JR and gel phase ' 3C 
NMR (Figure 16). 
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Figure 16 Gel phase ' 3CNMR of47 
It is interesting to note that no mention of this side reaction was made by Bradley et 
al., even though the same reaction conditions, with the exception of DMF, were 
employed.' 2  It is possible, therefore, that if 50 was formed, then activation with p-
nitrophenyl chioroformate would instead yield 51 (Figure 17). Further reaction 
would proceed as normal, with the only difference being release of the extra 
contaminant 52 on cleavage. 
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Figure 17 Possible cleavage products if ester formation undetected 
2.3 Preparation of Supported 5(4H)-Oxazolones via Vt Strategy 
The decision was made to synthesise the direct precursor of the target 5(411)-
oxazolone, by coupling a commercially available dipeptide, in order to confirm the 
viability of this approach before investigating a stepwise route. Therefore, in an 
analogous way to that used by Bradley, 112 PS-HMPA (47) was first activated by 
treatment with excess p-nitrophenyl chloroformate and pyridine in DMF to afford the 
reactive carbonate (53) (Spectrum l)o" (Scheme 14). At this stage it was possible to 
obtain an approximate loading of the activated linker using p-nitrophenol analysis 
(6.3.4.2), which detects the amount ofp-nitrophenol released on treatment with 20 % 
piperidine in DMF. A loading of 1.0 mmol/g was calculated which indicates a yield, 
accounting for weight gain (6.3.4.3), of 100 %*t  based on the loading quoted by the 
manufacturer of the aminomethyl polystyrene used. 
see section 6.3.4.3 for explanation of loading notation 
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Scheme 14 Reagents and conditions: (i) p-nitrophenyl chioroformate, pyridine, DCM (ii) Val-Phe, 
BSA, DMAP, DMF (iii) EDCI, DCM (iv) L-valine, BSA, DMAP, DMF (v) L-phenylalanine, BSA, 
DMAP, DMF; 54/55a derived from direct dipeptide coupling; 54155b derived from stepwise coupling 
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The unprotected dipeptide valinylphenylalanine (Val-Phe; 2 eq) was dissolved in 
DMF, using BSA (10 eq) and sonication at elevated temperatures, according to the 
method used by Dressman et al. •107  Coupling was achieved by addition of the 
dipeptide solution to carbonate 53 (Scheme 14), which was pre-swollen in DMF, 
along with DMAP (4 eq), followed by agitation for 15 h. A yellow solution indicated 
successful displacement of the p-nitrophenol group and IR and gel-phase ' 3C NMR 
analysis confirmed complete disappearance of the carbonate moiety. Acidic 
cleavage, followed by ES-MS verified the presence of the desired dipeptide (mlz 265 
MH), however it was apparent from the number of other signals present in the mass 
spectrum and the poor quality of the NMR spectrum that the product was not pure. 
Nevertheless, the resin-bound dipeptide (54a) was treated with a solution of EDCI in 
DCM, promoting cyclisation to afford the target resin-bound oxazolone (55a). The 
success of this step was apparent from the distinctive stretch in the IR spectrum (Vmax 
1825 cm- ') corresponding to the oxazolone carbonyl. ES-MS analysis of resin-bound 
5(411)-oxazolones is not so informative, however, since acidic cleavage from the 
resin results in almost complete hydrolysis of the oxazolone back to the original 
dipeptide. Additional confirmation of the presence of the oxazolone was achieved by 
ring-opening with an amine nucleophile e.g. benzylamine and ESMS analysis of the 
resulting derivative (6.10.8). 
Similarly, the stepwise coupling of two free amino acids was attempted, as this 
would facilitate preparation of a diverse series of dipeptide-derived oxazolones on 
the solid phase (Scheme 14). Since the p-nitrophenyl moiety had facilitated loading 
analysis during initial activation of the linker, it was hopedthe activation of the first 
resin-bound amino acid (56) could be achieved via the mixed carboxylic-carbonic 
acid anhydride (57),117  in a similar method to Letsinger'°° (Scheme 9). Once 
activated, nucleophilic attack would be directed towards the carbonyl of the original 
carboxy component, since the second carbonyl group suffers diminished reactivity 
due to resonance with the two flanking oxygen atoms. Aminolysis with a second 
amino acid residue would, therefore, yield the desired resin-bound peptide (54b), 
with release ofp-nitrophenol. 
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Spectrum 3 Gel phase ' 3C NMR of 55b 
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Thus, coupling of the free amino acid residue, L-vahne, was achieved in a similar 
manner to the dipeptide (Scheme 14). On-resin analysis techniques, such as JR and 
gel-phase ' 3C NMR, along with cleavage and ES-MS indicated successful coupling 
to yield 56, but once again the purity of the product was a concern (Spectrum 2).0P 
Activation was accomplished using the same conditions employed to activate the 
starting linker affording the proposed intermediate 57. JR analysis, along with p-
nitrophenol analysis (0.71 mmollg, 82 %) confirmed the presence, of the aryl-nitro 
group, but the gel phase 13C NMR proved difficult to interpret due to poor resolution 
permitting assignment of only some diagnostic peaks with others remaining 
unidentified. In addition, ES-MS analysis of the cleavage product gave a mass ion 
corresponding to the active ester as opposed to the carboxylic-carbonic acid 
anhydride. This observation may well be due to decarboxylation during acidic 
cleavage followed by re-association of the amino acid and 4-nitrophenol. Solution 
phase mixed anhydrides are renowned for their poor stability and are rarely isolated. 
It is therefore likely that the resin-bound anhydride was obtained but that analysis of 
the solution cleavage products is futile, due to immediate decomposition. 
Coupling of the second free amino acid residue did, however, confirm that the resin 
had been successfully activated since the target resin-bound dipeptide was obtained, 
albeit, as indicated by IR, NMR and ES-MS, in an impure form. Cyclisation to the 
resin-bound 5(41-f)-oxazolone (55b) was effected in the same manner as with 55a, 
affording the desired product (Spectrum 3),0P  albeit impure. 
It was also discovered at this stage, that the PS-HMPA linker (47) may be recycled 
after acidic cleavage, by simple hydrolysis of the cleavage-induced TFA ester to the 
benzyl alcohol, using hydrazine hydrate. The isolated resin bound HMPA linker may 
then be reactivated and used in the synthetic procedure with no apparent detrimental 
effect on reaction yields, although the starting loading is generally lower. 
Although, the target resin-bound 5(411)-oxazolone had indeed been successfully 
synthesised by this method, the evident low purity of the coupling products was of 
concern and was investigated as follows. 
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2.4 BSA-Assisted Coupling of Free Amino Acids 
Resin-bound valine (56) was activated in the usual manner and treated with a series 
of free amino acids and the dipeptide Val-Phe, all of which had been dissolved in 








57 	 NO2 
0  




[ products - Table I 
Scheme 15 Reagents and conditions: (i) p-nitrophenyl chioroformate, pyridine, DCM (ii) nucleophile, 
BSA, DMAP, DMF (iii) TFA/DCMIH2O (9:10:1) 
After cleavage, all the products were analysed by ES-MS, which in each case 
indicated the main product to be the desired di/tri-peptide but with many higher 
oligomers present as significant impurities. The findings are tabulated on the 
following page (Table 1). 
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Product Nucleophile 	 ES-MS of cleavage mixture 
58 	 desired product 	 by-products 
m/z 	peptide (MW) 	m/z 	peptide (MW) 
a 	Val 	217 	Val-Val 	118 	Val 
316 	Val-Val-Val 
H3N 	 OH 
O /\ 
b 	Phe 	265 	Val-Phe 
N 












C 	 Leu 	231 	Val-Leu 118 Val 
132 Leu 
I JJ 217 Val-Val 
H3N 	ff : 	OH 245 Leu-Leu 
\ 330 Val-Val-Leu 
344 Val-Leu-Leu 
d 	Ser 	205 	Val-Ser 105 a Ser 
118 Val 
® I 	JL 217 Val-Val 
H3N 	fl OH 










N 	 463 	Val-Val-Val-Phe 
H 
511 	Val-Phe-Val-Phe 
Table 1 Cleavage products from BSA-assisted coupling. a) W c.f. MH 
42 
Results and Discussion I 
These results indicate that the free amino acids are over-reacting at each coupling 
stage to yield, for instance Val-Val and Val-Phe-Phe. There is also evidence of 
incomplete coupling, where some amino acid residues are coupling directly to free 
active sites on the resin during the second cycle, as opposed to the activated resin-
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Figure 18 Mass spectrum of 58c illustrating over-coupled impurities 
In order for this to be taking place, some sort of activated amino acid derivative must 
be formed after the initial coupling, allowing aminolysis to afford the doubly- and 
triply-coupled products observed. 
One possibility may involve the p-nitrophenol released on aminolysis, condensing 
with the coupled residue to yield an active ester, which could subsequently suffer 
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sufficiently activated 
towardsfurther coupling? 
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seems unlikely, because although it is possible to prepare active esters of free amino 
acids in situ, 118 this procedure requires addition of an activating reagent, most 
commonly DCC. 
Another proposal concerns the addition of a large excess of BSA, used to improve 
the poor solubility of the free amino acids. The BSA aids dissolution by silylating the 
carboxy terminus to yield the trimethyl silyl ester (59) and it is proposed that in the 
presence of DMAP, the coupled derivative (60) may be sufficiently activated to 
promote further aminolysis to yield the over-coupled products observed (Scheme 
16). 
Scheme 16 Proposed role of BSA in amino acid coupling 
If this second proposal is indeed true, the reason why these extra couplings were not 
eluded to by Dressman et al., can be explained by close examination of their 
hydantoin synthesis. The hydantoin strategy can be described as 'self-purifying', 
meaning that only those nucleophiles which undergo successful cyclisation to form 
hydantoins are simultaneously cleaved from the support, leaving any over- or under-
coupled products bound to the resin. Cleavage products, thus obtained are 
consequently very pure. However, a high purity accompanied by a poor yield, 
implies a significant proportion of product not amenable to cyclisation-induced 
cleavage i.e. over- or under-coupled by-products. As predicted, the yields obtained 
via the Dressman system were often poor (12 - 76 %) relative to the purity of the 
cleavage products (> 90 % in most cases). This presents sound evidence that the 
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over- and under-coupling observed in this synthesis, may well be occurring during 
the hydantoin synthesis, since any impurities formed will not be released from the 
resin and hence remain undetected. 
Léger and co-workers" 9 attempted to use the BSA analogue, bistrimethylsilyl 
trifluoroacetamide (BSTFA), to enhance the solubility of an unprotected 
phenylalanine residue. They hoped to solvate the amino acid via the trimethylsilyl 
ester in order to prepare a library of dipeptides with C-terminal capping groups. 
However, although preparation of this derivative did facilitate coupling between the 
amino acid and resin-bound Boc equivalent, the yields obtained were very poor and 
an alternative procedure involving lithium salts was reported. Unfortunately, this 
method was also beset with its own limitations and did not appear to be suitable with 
regard to this work. 
A number of other solvent systems were examined in an attempt to find suitable 
conditions for the dissolution of free amino acids, which would also be compatible 
with reaction conditions and resin swelling requirements, without success. Focus 
instead shifted to developing an alternative strategy where problems of poor 
solubility and over-coupling could be avoided. 
2.5 Conclusions 
2.5.1 Future Potential 
Although these attempts to couple free amino acids in the inverse direction did not 
prove fruitful at the time of investigation, a modified solution phase synthetic route 
has since come to light, which may hold the key for future success in this area. 
In a recent publication, Mitin and Ryadnov 120 describe how the problems of 
solubility and racemisation can be overcome, and subsequently demonstrate how free 
amino acids can be used effectively for the inverse synthesis of peptides in solution. 
The free amino acids residues were successfully dissolved in 3 M solutions of either 
Ba(C104)
21 
 Ca(C104)2 or Ca(NO 3)2 in DMF. They could then be coupled to the Cbz- 
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protected N terminal amino acid residue via EDCI (1.5 eq)-mediated activation in the 
presence of HOBt (1 eq) and CuC1 2 (0.5 eq). The combination of CuC1 2 and HOBt is 
reported to suppress completely oxazolone-mediated racemisation 58 during peptide 
synthesis using cardodiimide activation. A number of penta-peptides were 
synthesised in high yields (81 - 95 %) using this approach, which was also extended 
to fragment coupling. 
Unfortunately, this appealing procedure was reported too late to be examined in the 
scope of this work, but certainly appears to hold potential for the inverse synthesis of 
optically pure peptides, especially if extended to the solid phase. 
2.5.2 Change of Strategy 
Considering the problems associated with the first strategy employed, the decision 
was made to adopt an entirely different approach using protecting groups in order to 
circumvent the problems of amino acid solubility and unwanted over-coupling. A 
paper by Bayer et al. 121  appeared to offer a promising alternative (3.1.1). 
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3. Results and Discussion H 
3.1 Solid Phase N-C Peptide Synthesis - Successful Approach 
3.1.1 Inverse Solid Phase Peptide Synthesis using 9-Fluorenylmethyl Esters 
Among the various methods developed for the inverse synthesis of peptides (2.1) the 
strategy reported by Bayer and co-workers 12 ' seemed to provide a possible solution 
to the problems encountered during the previous approach (2.3). 
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Scheme 17 Bayer's method for the inverse (N-C) peptide synthesis - Reagents and conditions: (i) X-
AA 1 -OFm (X = TSA or TFA)t, DIPEA, DCM (ii) 20 % piperidine, DMF (iii) acetic acid, DCM (iv) 
HOBt, DIC, DMF or TBTU, NMM, DMF (v) HOBt-AA 2-OFm (vi) continued inverse peptide 
synthesis - R = amino acid side chain 
Their approach, depicted in Scheme 17, involved the stepwise coupling of amino 
acid 9-fluorenylmethyl (Fm) esters to the activated C-terminus of the growing, 
polymer-bound, peptide chain. The first residue was tethered via its N-terminus to 
the polymer-supported trityl linker (61), before being subjected to a sequence of 
steps involving deprotection, neutralisation and activation. Amino acid derivatives 
were then coupled as their HOBt salts, with the Fm ester protection facilitating UV 
loading analysis in the same way as Fmoc protection (3.1.2). 
If amino acid HC1 salts were employed, the yield of coupled product suffered a significant reduction 
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In classical peptide synthesis, the carboxy coupling component is in excess in 
solution, thus shifting the equilibrium in favour of coupling. However, during 
inverse synthesis, the activated C-terminal residue is the resin-bound component and 
in order for the coupling reaction to be high yielding, it is imperative that the 
activation step itself reaches virtual completion. 
In an attempt to achieve the obligatory high yields, Bayer et al. examined two 
principle methods for C-terminal activation: HOBt/DIC and TBTU/NMM (Scheme 
17). Of the two methods, TBTU/NMM was found to be more efficient, with only 
minimal by-product formation. However, unlike the more acidic HOBt activation, 
TBTU activation appeared to promote increased susceptibility to oxazolone-
mediated racemisation (1.3.1). 
Overall, the comprehensive study carried out by Bayer et al. provided a promising 
approach for the N-C synthesis of peptides as a route into resin-bound oxazolone 
derivatives. The protecting group strategy not only serves to prevent the undesirable 
multiple-coupling which had been a limitation of the first strategy employed 
(Chapter 2), but also facilitates loading analysis of polymer-supported intermediates. 
As a method for activation, the more efficient TBTU/NMM approach was selected 
over the HOBtJDIC protocol, since the normal disadvantage of oxazolone-induced 
racemisation was not perceived as a drawback, as the resin-bound oxazolone was 
ultimately the target synthon. Thus, the decision was made to examine this method 
on the PS-HMPA system as a viable strategy for solid phase N-C peptide and thus 
5(4H)-oxazolone synthesis. 
3.1.2 Preparation of Standard Amino Acid Building Blocks 
The 9-fluorenylmethyl (Fm) ester (63) has been reported a number of times in 
relation to side chain amino acid protection. 122,123  As a protecting group it is an 
extension of the extensively used solid phase N-terminal Fmoc protecting group (62) 
pioneered by Carp mo et al. 124 (Figure 19). The ester displays the same advantageous 
features as the related Fmoc group, but enjoys far much less attention, doubtless as a 
consequence of the popularity of C-N directional peptide synthesis compared to N-C. 
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The main benefits exhibited by both these groups are orthogonality with other 
popular protecting groups e.g. Boc, together with facile cleavage that can be 
achieved using 20 % piperidine in DMF. Moreover, the UV active dibenzofulvene, 
which is released upon cleavage, can be used to quantify resin loadings (6.3.4.1). 
This method of loading analysis has been established as the one of primary methods 












Figure 19 9-Fluorenylmethyl derived protecting groups 
In order to prepare the required building blocks, selected Boc-amino acids were first 
protected as their Fm esters (64a-e) by condensation with 9-fluorenylmethanol in the 
presence of DMAP (Scheme 18).121  The N-terminal Boc groups were cleaved by 
treatment with TFA. Addition of p-toluenesulfonic acid allowed in situ preparation 
of the TSA salts (65a-e), which could be isolated by simple trituration with ether. 125 
Amino acid residues which were to be coupled directly to the activated resin were 
used as their TSA salts, however, amino acid residues required for subsequent 
couplings were converted to their HOBt derivatives (66a-d). In order to perform the 
salt exchange, the potassium salt of HOBt (KOBt) (67) was prepared by stirring 
equimolar amounts of HOBt hydrate and potassium hydroxide in absolute ethanol. 
Solvent removal afforded the desired salt 67. The HOBt salts were then prepared by 
addition of KOBt to a solution of the amino acid TSA salt, resulting in precipitation 
of potassium tosylate. After filtration, the solution was concentrated and trituration 
with copious ether, in most cases, yielded the desired HOBt salt (66a-d) in moderate 
yield. Unfortunately, as a consequence of the poor solubility of the majority of the 
HOBt salts prepared, 'H NMR analysis proved ineffective. 
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Scheme 18 Reactions and conditions: (i) 9-fluorenylmethanol, DCM, DMAP, 0 °C - RT (ii) TFA, 
TSA (iii) KOBt (67), MeOH; R = amino acid side-chain 
TSA and HOBt salts of valine, phenylalanine, glycine, alanine and leucine Fm esters 
were prepared in good yields (Table 2). It was found that direct conversion to the 
TSA salt, without purification of intermediates, followed by simple trituration from 
ether was the most efficient protocol, as can be exemplified by the two yields quoted 
for the synthesis of TSA-Phe-OFm (65a, R = CH2Ph) (Table 2). 
Entry Amino acid 
building block (AA) 
Boc-AA-OFm TSA-AA-OFm HOBt-AA-OFm 





60% 65a 96% 66a 86% 
N/Ab 91 W 
2 
BocHN 	CO2H 
64b N/A" 65b 87 % 66b 56% 
BocHNCO2H 
64c N/A" 65c 96W 66c N/AC 
4 
BocHN 	CO2H 
64d&' N/A" 65d Ai 78W 66d 17%d 
5 
BocHN 	CO2H 
64e Al N/A" AW 65e 99 % - - 
Table 2 Synthesis of building blocks: a) % yield over two steps b) crude product reacted on without 
purifying c) trituration unsuccessful, therefore reacted as crude solution in DMF d) trituration 
inefficient, therefore in situ exchange attempted during coupling 
50 
Results and Discussion II 
Glycine (R = H) and leucine (R = CH 2CH(CH3)2) posed the main problems with 
respect to HOBt salt formation. In each case trituration, after salt exchange, proved 
problematic. HOBt-Gly-OFm (66c) was therefore prepared in the usual manner, but 
reacted successfully as a crude solution in DMF. In contrast, in situ exchange of 
TSA-Leu-OFm (65d) to the corresponding HOBt salt (66d) was attempted during the 
coupling reaction, with only moderate success. 
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Scheme 19 Reactions and conditions: (i) TSA-AA,-OFm, DMAP, DMF (ii) 20 % piperidine, DMF 
(iii) 3 % acetic acid, DCM (iv) TBTU, NMM, DMF (v) HOBt-AA,-OFm (vi) EDCI, DCM; 69a R' = 
CH(CH3)2 , R2 = CH2Ph; 69b R' = CH(CH3)2 , R2 = H 
The first amino acid residue Fm ester derivative was coupled as its TSA salt to 
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neutralisation and activation were carried out as described by Bayer, before coupling 
of the second amino acid Fm ester as its HOBt salt to yield the corresponding 
dipeptide (69). 
Resin-bound dipeptide Val-Phe-OFm (69a) was prepared in this way and unlike the 
attempts detailed in Chapter 2, no over-coupled by-products were observed. Instead, 
gel phase 13C NMR analysis for both PS-HMPA-Val-OFm (68) (Spectrum 4)0)  and 
PS-HMPA-Val-Phe-OFm (69a), gave very high quality spectra, with no starting 
material being observed. Furthermore, LC-MS analysis of each intermediate 
indicated that both intermediates had been formed in high purity e.g. (Spectrum 5)0 
At the dipeptide stage, two options for proceeding exist (Scheme 19). If the sequence 
of deprotection, neutralisation, activation and coupling of HOBt-AA-OFm is 
repeated, continued peptide elongation may be achieved. Alternatively, the dipeptide 
may serve as the precursor to the target resin-bound 5(4H)-oxazolone. This latter 
transformation is demonstrated and extended in the following chapter (4.1.2). 
In order to demonstrate the applicability of this inverse system and confirm the 
purity of the products obtained, the tripeptide Val-Gly-Phe-OFm (71) was 
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Scheme 20 Reactions and conditions: (i) 20 % piperidine, DMF (ii) 3 % acetic acid, DCM (iii) 
TBTU, NMM, DMF (iv) HOBt-Gly-OFm, DMF (v) HOBt-Phe-OFm, DMF (vi) TFA, DCM, H20 
(9:10:1) (vii) preparative HPLC purification elution gradient (6.4.3 Table 9) a) LC-MS elution 
gradient A (6.4.2 Table 7) b) see Figure 20 
The dipeptide Val-Gly-OFm (69b) was synthesised in the same manner as Val-Phe-
OFm (69a), except as already mentioned, a crude solution of HOBt-Gly-OFm (66c) 
was employed. At this stage, rather than performing a cyclisation to yield the resin-
bound 5(4H)-oxazolone, peptide synthesis was continued by coupling HOBt-Phe-
OFm (66a) to afford the tripeptide 70. Each solid phase intermediate up till this point 
had been fully and satisfactorily characterised using the on-resin techniques available 
eg Spectrum 60". In addition, an aliquot (4 - 6 mg) of each resin sample was cleaved 
and analysed by ESMS and LC-MS. However, in order to obtain a solution for 'H 
NIMR, a larger resin sample (70 mg) of the tripeptide (70) was cleaved and purified 
by semi-preparative HPLC (6.4.3). The purified tripeptide product was analysed by 
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'H NMR to give the desired spectrum (Figure 20) as clear evidence of the success of 
this approach. 
1 
iJU 	1dLLLLL J1iIJ 
Figure 20 'HNMR spectrum ofpurfled Val-Gly-Phe-OFm 71 
3.2 Linker Modification 
3.2.1 Comparison of Wang and HMPA Linkers 
In order to test the applicability and versatility of this inverse approach further, it 
was decided to synthesise a library of diverse tripeptides and C-terminally modified 
dipeptides (3.3.3). However when synthesising even the smallest library, cost and 
availability of starting materials are both important factors to be considered. It was 
with this in mind that the Wang linker was considered as an alternative to the HMPA 
linker, upon which all the previous investigations had been performed. The Wang 
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HMPA (47) precursor, aminomethylated polystyrene resin, of comparable size and 
loading e.g. £26 and £34 respectively per 5 g (0.5 - 1.2 mmolIg)"°. The decision 
was therefore made to adopt the PS-Wang linker system as a cheaper and faster 
alternative, especially since large quantities of resin would be required for the library 
synthesis and further studies. 
3.2.2 Inverse N-C Approach Using the Wang Linker System 
Thus PS-Wang (46) was activated in the same manner as the PS-HMPA system to 
yield the activated carbonate 72 in 100 %* yield (0.91 mmol/g) (Scheme 21). The 
dipeptides PS-Wang-Val-Phe-OFm (74a) and PS-Wang-Ala-Leu-OFm (74b) were 
prepared in order to confirm the applicability of the Wang system to the inverse 
strategy. Both dipeptides were prepared as depicted in Scheme 21, with thorough 
analysis of each intermediate confirming the expected successful translation of the 
inverse methodology between the two, highly similar linker systems (Spectra 7 & 
8).° 
NO 
JJOH 	(I) 	 I 
0 	
46 	 o4r  72 
0 R 1 	0 	 0 R 
(vi) 
0 R2 0 
0 C, r~ 74a-b 	 4;-____•_' 	73a-b 
Scheme 21 Reagents and conditions: (i) p-nitrophenyl chioroformate, pyridine, DCM (ii) TSA-AA 1 -
OFm, DMF (73a R' = CH(CH3)2, 73b R' = CH,) (iii) 20 % piperidine, DMF (iv) 3 % acetic acid, 
DCM (v) TBTU, NMM, DMF (vi) HOBt-AA2-OFm (74a R' = CH(CH3)2 , R2 = CH2Ph, 74b R' = 
CH3, R2 = CH2CH(CH3)2) 
Essentially the only problem encountered was the coupling of Leu-OFm. Trituration 
of the HOBt salt 66d had proved fruitless, so an in situ salt exchange during the 
coupling reaction was attempted, with only moderate success. 
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3.3 Scope of Inverse Approach 
3.3.1 Combinatorial Approaches and Diversity 
The different strategies for introducing molecular diversity to compound libraries are 
well documented. 3 '21 '27  In order to test the scope and applicability of this method for 
inverse peptide synthesis, a small library of peptide analogues of the general 







r R = amino acid side achain 
X = natural or unnatural amino acid 
V = amino acid I amine capping group 
see Table 6 
Figure 21 General structure of library components 
3.3.2 Preparation of Library Building Blocks 
A range of Fm ester protected building blocks (Table 3) were prepared using the 
method previously described (3.1.2). This series of natural and non-proteinogenic 
amino acids, were first protected as their Fm esters (76a-d), before deprotection of 
the N-termini and final exchange to the HOBt salts (78a-d). Once again, the Boc-
AA-OFm derivatives (76a-d) were isolated directly as TSA salts (77a-d), however 
trituration was not feasible for some intermediates which simply formed oils. Crude 
TSA-Acp-OFm (77b) was carried through one stage further to the HOBt salt (78b) 
where trituration once again proved futile. This intermediate was therefore coupled 
successfully as a crude solution in DMF, although the resulting dipeptide was not as 
pure as the other resin-bound intermediates. Attempted derivatisation of anthranilic 
acid in this way also proved problematic, so Boc-Abz-OFm (76d) was instead 
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purified before deprotection to form the TSA salt (77d). The synthesis, analysis and 
subsequent coupling of these derivatives were also hampered by poor solubility. 
Entry Amino acid Boc-AA-OFm TSA-AA-OFm HOBt-AA-OFm 
building block (AA) N° yield N° I % yield N° % yield 
1 76a N/AC 77a 56 %b 78a 82% 
BocHN 	CO2H 
2 76b N/AC 77b N/AC 78b N/A' , NHBoc 
CO2H 
3 -CO2H 76c N/A' 77c 87 %b 78c 87 % 
BocHN 
4 -NHBoc 76d 15% 77d 86% 78d N/AC 
LL (13%b) 
C0 2H 
Table 3 Synthesis of building blocks: a) crude product reacted on without purifying b) % yield over 
two steps c) trituration unsuccessful, therefore carried directly through to HOBt salt d) trituration 
unsuccessful, therefore reacted as crude solution in DMF e) trituration unsuccessful, therefore in situ 
exchange attempted during coupling 
These difficulties serve to highlight the problem of trying to implement generic 
procedures for structurally diverse building blocks. Commercially available building 
blocks are therefore an advantage, but in turn, restrict the diversity which can be 
incorporated. 
The C2-symmetric diamine (79) (Scheme 22) was also selected as a potential 
building block. It was hoped that incorporation of this unit into the peptide chain 
would provide access to Jacobsen and Katsuki-type ligands 126 for asymmetric 
catalysis (3.3.4). Mono-protection of the symmetrical diamine was deemed 
necessary, in order to prevent both amino groups reacting with activated resin-bound 
C-terminal residues, as this would probably result in undesirable cross-linking of the 
resin. 
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H2N NH2 	 HCI.H2NQNA0 
79 	 80 
Scheme 22 Mono-protection of symmetrical diamine - reagents and conditions: (i) 9-fluorenylmethyl 
chioroformate, diethyl ether, 0 °C 
A solution of the diamine (79) was added drop-wise to a cooled solution of 9-
fluorenylmethyl chloroformate in ether. It was hoped that 80 would precipitate 
before the second amino group could attack a further molecule of chloroformate, but 
that if a second displacement did take place, the di-protected amine would remain in 
solution. 
Slow addition of the diamine did result in the immediate formation of a white 
precipitate, which was filtered and dried. Unfortunately, the white solid proved 
insoluble in all deuterated solvents available. However, 'H and ' 3C NMR analysis of 
a suspension of the salt in d 6 DMSO did indicate that the desired product had formed, 
but that it was possible that some of the unwanted dichloride species was also 
present. In hindsight, a better method for minimising formation of the dichloride 
species, could be reverse addition of the chloroformate to an excess solution of the 
diamine. However, since the starting material was relatively expensive, it was used 
as a library building block in its crude form, as it was hoped that the solubility of the 
mono-protected species would be sufficient to allow some diffusion into the resin's 
reactive sites with the reaction being driven to completion by the resulting 
equilibrium. By the same analysis, it was predicted that the highly insoluble 
dichloride salt would remain as a suspension and no reaction would take place. The 
observed results are discussed in Section 3.3.3. 
3.3.3 Library Synthesis 
Therefore, in order to examine the scope of the synthesis, a library consisting of both 
natural and unnatural tripeptidés as well as C-terminally modified dipeptides was 
prepared using the set of building blocks described previously (3.3.2). The activated 
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polystyrene-bound Wang resin (72) was divided into two portions and derivatised as 
shown (Scheme 23). The N-terminal amino acid residues, Val-OFm and Phe-OFm, 
were coupled as their TSA salts using DMAP and DMF to give 73a and 73c, each 
with a calculated loadings of 0.45 mmol/g. Full on-resin analysis, followed by 
cleavage and ESMS confirmed that both couplings had proceeded successfully, 
leading to single peaks in the LC-MS. 
ANGOAO) 
72 




_ ANG OAN N XAR, 
74a, 8 la-i 
- (iv) 
(vi) or (vii) 
or (Viii) 
WANG OAN) ( N XAN Y 
75a-i 
73a - R = CH(CH3)2 
73c-R=CH2Ph 
74a - R = CH(CH 3)2.  X = Phe, R' = OFm 
81a - R = CH(CH3)2, X = Gly, R' = OFm 
81  - R = CH(CH3)2, X = Aib, R' = OFm 
81c - R = CH(CH3)2, X = Acp, R' = OFm 
81d - R = CH(CH3)2, X = f3-Ala, R' = OFm 
81e - R = CH2Ph, X = Gly, R' = OFm 
81f - R = CH 2Ph, X = Vat, R' = OFm 
81  - R = CH2Ph, X = 3-Ala, R' = OFm 
81h - R = CH(CH3)2, X = Abz, R' = OFm 
81i - R = CH(CH3)2, X = Phe, R' = OEt 
Y = aminoacid / amine capping group 
see Table 6 
Scheme 23 Library Synthesis - reagents and conditions: (i) TSA-Val-OFm or TSA-Phe-OFm, DMAP, 
DMF (ii) 20 % piperidine, DMF (iii) 3 % acetic acid, DCM (iv) TBTU, NMM (v) HOBt-X-OFm, 
DMF (vi) HOBt-AA,-OFm, DMF (vii) amine, HOBt.H 20, DMF (viii) TSA-AA2-OFm or HCI-AA2-
OFm, HOBt.H20, Et3N, DMF 
The two supported amino acid esters (73a & 73c) were then divided into 300 mg 
portions. Each sample was deprotected, neutralised, activated and derivatised 
_ 
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according to the protocol detailed in Table 4, to yield a variety of supported 
dipeptides (Table 4). 
Step Reagent / solvent Duration, repetition 
& vo lume  
deprotiction 20 % piperidine in DMF 3 x 15 mm / 10 ml 
wash DMF 3 x 10 ml 
neutralisation 3 % acetic acid in DCM 4 x 5 min/ 12 ml 
wash DMF 3 x 10 ml 
activation TBTU (8 eq), NMM (8 eq), DMF >-40 mm / 15 ml 
wash DMF 3 x 10 ml 
coupling 
of amino acid 
or capping 
amine 
b) HOBt-AA-OFm (6 eq), DMF or 
c) HOBt.H20 (6 eq), amine (6 eq), DMF or 
X-AA-017m, HOBt.H 20, Et3N (6 eq ea), DMF or 
HC1-Phe-OEt, HOBt.H 20, Et3N (6 eq ea), DMF 
>-15 h / 15 ml 
wash standard wash protocol (6.2.4) - 
Table 4 Protocol for inverse N-C library synthesis - coupling of second and subsequent building 
blocks to resin bound protected peptide 73a & 73c - a) ml/300 mg resin b) building block = amino 
acid (AA) (6.8.3) c) building block = amine (RNH2) (6.9.14.2) d) building block = amino acid (AA) 
where exchange to HOBt salt has not been possible (6.9.11), X = TSA or HC1 e) ethyl ester derivative 
employed to prepare component suitable for fragment coupling 
Each supported product was analysed by IR, gel phase ' 3C NMR and Fm analysis, 
before acidic cleavage and subsequent LC-MS analysis. The spectra obtained in 
every case, apart from 81h, confirmed successful conversion to the desired product. 
The clarity of the spectra, coupled with the single peaks observed on the LC-MS 
traces, indicated that the couplings had proceeded very cleanly and in high yield 
(Spectra 9 & lO).OP Loadings in each case were high, further indicating that the 
couplings had proceeded efficiently. 
ME 
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No Resin Peptide ESMS LCMSb Fmc IR NMR Purity 
PS-HMPA MF1 R min mmollg 
%( 
74a -Val-()Fm --'-OF. 
H 





OFm 353 9.1 0.54 / 1 A 
0 
81b -Val-OFm  
H 	11 
NY H 	,. 	 OFm 381 16.9 0.43 / 1 A 
0 
raCenwie 
81c -Val -OFm H 407 
18 . 5e 
0.49 / 1 A 
0 19.2e 
- 
81d -Val-OFm 367 12.0 0.65 / / A 
o 	0 
Ph 
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OEt 293 l8.6 N/A / / A 
H o 
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Table 5 Data for resin-bound peptides formed from coupling of second amino acid building block: a) 
ES-MS after cleavage with TFA:DCM:H 20 (9:10:1) (6.4.1) b) LC-MS gradient A as detailed in 
section 6.4.2 c) after treatment with 20 % piperidine in DMF (6.3.4.1) d) estimated from LC-MS UV 
trace: A = 80-100 % e) one of two cis diastereomers f) UV spectrum did not give standard 
dibenzofulvene curve g) LC-MS gradient B as detailed in section 6.4.2. 
The failure of the anthranilic acid derivative to couple successfully is likely to be 
related to the difficulties encountered when preparing the HOBt derivative 78d 
(3.3.2) and the poor nucleophilicity of the aromatic amine. TSA-Abz-OFm (77d) 
was eventually employed in the coupling reaction and an in situ salt exchange was 
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attempted using Et 3N and HOBt hydrate. IR analysis of the resin-bound product 
displayed an absorbance at Vmax  1817 cm', indicating that the resin was probably still 
in its activated form, with no visible evidence of coupling having taken place. It is 
possible, therefore that either the nucleophilicity of the aromatic amino acid was not 
sufficient to promote coupling under these conditions, or the in situ exchange failed, 
or indeed that the failure was due to combination of both these factors. 
This library of resin-bound dipeptides was then deprotected, neutralised and 
activated as before. Once activated each supported dipeptide was treated with a 
nucleophile (Table 4). Those compounds treated with amino acid building blocks 
resulted in continued peptide elongation, others were C-terminally 'capped' with a 
variety of amines (Table 6). During the activation step, those compounds containing 
a chiral C-terminal amino acid residue (74a, 81!) became susceptible to oxazolone-
mediated racemisation, with the resulting tripeptides (75a & 75g) being obtained as 
mixtures of diastereomers that were distinguishable by LC-MS. 
As before, each resin-bound product was analysed by IR, gel phase 13C NMR, and 
where applicable, Fm analysis, before acidic cleavage followed by ESMS or LC-MS. 
There was, however, some evidence of incomplete neutralisation, with peaks in some 
of the NMR spectra corresponding to the piperidinium salt. Nevertheless, the NMR 
spectra coupled with the ESMS and LC-MS data obtained, gave clear indication that 
the main product, in each case was the target peptide or peptidomimetic, with only 
trace impurities observable (Spectra 11 & 12).°" 
Results and Discussion II 
N° Initial Peptide/C-terminally ESMS LC-MS Fm' IR ' 3C gel Purity 











H 	 H  500 205d 0.34 / 1 A 
o 	 0 
75c 81b 292 11.4 N/A / / B 
338 
75d 81c 207ef N/A / / c 
340'  
75e 81d 292 15 . 4e N/A / if B 
Ph 	 Ph 
o( 
/ N N N OFm / f 75f 81e H 	 H 	II 548 251d 0.24 A o 	 a 
Ph 	 Ph 
75g 81f o /l\ 590 
264d 
0.41 / / C 
27. Id 
Ph 
75h 81g NiOFm  472 19•4d 0.33 / 1 A 
(Ph 	o 
/ N (N NQNAOF 
75i 81e H 	 H 	H 514 1 	192d 0.04 1' X - 
Table 6 Data for resin-bound peptides formed from coupling of third building block: a) ES-MS after 
cleavage with TFA:DCM:H20 (9:10:1) (6.4.1) b) after treatment with 20 % piperidine/DMF (6.3.4.1) 
c) estimated from LC-MS UV trace: A = 80-100 %; B = 60-80 %; C = 40-60 % d) LC-MS gradient A 
as detailed in section 6.4.2 e) LC-MS gradient B as detailed in section 6.4.2 f) broad peak from two 
diastereomers g) MH/Cl 35 h) MHVC137 
The only derivative which did not appear to undergo successful coupling, in this 
instance was 75i. Although a weak product signal was observed by ESMS, no 
meaningful information could be derived from the gel phase ' 3C NMR. Fmoc 
analysis confirmed the presence of the Fmoc group and it was concluded that the 
coupling had occurred to yield 75i, but only to a very slight extent. Rather than the 
reactivity of the amine posing the problem, it is likely that lack of solubility and 
purity of the building block are to blame for the poor coupling observed. Although 
sonication at elevated temperature and addition of triethylamine were employed in 
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an attempt to aid dissolution of the amine salt, the reaction was finally carried out as 
a milky suspension. It is therefore hardly surprising that only a trace amount of the 
desired peptide analogue (75i) was detected. One way to overcome the poor 
solubility in DMF could have been to dissolve the amino salt in TFA and induce 
formation of the TSA salt before converting to the HOBt salt. Time restrictions, 
however, prevented this course of action from being investigated. 
Nevertheless, small peaks corresponding to deletion peptides i.e. those arising from 
incomplete coupling of the second amino acid residue, were detected in a few of the 
library members. However, LC-MS indicated that these impurities were minor, with 
the target product being the major peak. Product purity was estimated to be greater 
than 85 % for the majority of library members prepared using the Fm methodology. 
3.3.4 Conclusions 
Overall, it has been demonstrated that Bayer's approach for the inverse synthesis of 
peptides may be applied to the PS-HMPA and PS-Wang systems. Moreover the 
method is amenable to a wide range of building blocks, potentially leading to a vast 
array of C-terminally modified peptides, for applications in binding studies and as 
possible therapeutic agents. In addition, loading analysis is facilitated by the UV 
active Fm ester protecting group, however other esters may instead be employed to 
afford analogues, such as Val-Phe-OEt 811. These analogues may find use as 
components for the convergent syntheses of long chain peptides, using the fragment 
condensation approach. 127 
Although the advantages of this method are clear, a number of problems have also 
been noted. For instance, building block preparation is a costly, time-consuming and 
often complex process, especially if a large set of diverse units is required. 
Racemisation also poses a significant problem if long chain polypeptide analogues 
are desired. However, results describing conditions which can effect complete 
suppression of the racemisation process 58 indicate that oxazolone-induced 
racemisation will become a problem of the past. Therefore, assuming that complete 
suppression of racemisation can be achieved, the solid phase inverse synthesis 
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described may provide a long-awaited solution to the problem of direct access to C-
terminally modified peptide analogues. 
Additionally, provided the synthesis of the mono-protected diamine 80 can be 
optimised and the unit successfully incorporated into the growing peptide chain, this 
particular class of building block could lead to the development of libraries of 
diverse metal-salen complexes for asymmetric catalysis (Figure 22).126  By protecting 
one of the primary amines with the Fmoc group, the cyclic unit may then be 
incorporated into the peptide chain via the second amino group (82). Therefore, once 
the Fmoc group has been removed, peptide elongation, this time in the classical C-N 
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Figure 22 Application of library products - preparation of metal-salen catalyst 
However, in the context of this research, inverse synthesis is employed primarily as 
route into the dipeptide-derived 5(4H)-oxazolone targets. Oxazolone formation is 
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therefore necessary and not something to be avoided, with subsequent suppression of 
the racemisation process being the desirable option. 
Having established a successful route for the inverse synthesis of peptides, it then 
remained to apply this to the preparation of the resin-bound dipeptide-derived 5(411)-
oxazolone and examine its possible transformations (Chapter 4). 
Results and Discussion III 
4. Resu1;ts and IMSUSS1Oflr III 
4.1 5(411)-Oxazolones - Synthesis 
4.1.1 Solution Phase 
When developing new solid phase strategies and attempting novel transformations 
on supported intermediates, it is often very useful to perform parallel reactions in 
solution. Not only can solution phase conditions be optimised before testing on the 
supported derivatives, but the analysis obtained on pure solution phase samples can 
serve to assist the characterisation of on-resin analogues. Accordingly, those 
transformations to be investigated in terms of the solid phase 5(411)-oxazolone, were 
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Scheme 24 Solution synthesis of a dipeptide-derived 5(4H)-oxazolone 86 - reagents and conditions: 
(i) DCC, DCM, 0 °C - RT (ii) LiOH, THF, H20 (iii) EDCI, DCM; a) yield over two steps 
The Cbz-protected 5(411)-oxazolone (86) was successfully prepared in a crude yield 
of 96 % using standard peptide coupling procedures. Initial DCC-mediated coupling 
of N-protected valine and carboxy-protected phenylalanine afforded enantiopure 84 
in a crude yield of 99 %. Since it proved difficult to remove DCC and DCU 
impurities at this stage, the crude dipeptide ester was used directly in the hydrolysis 
step. Recrystallisation from chloroform furnished the pure dipeptide (85) in an 
overall yield of 50 %. DCC was found to be unsuitable for the subsequent cyclisation 
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reaction, since its use necessitated purification by column chromatography, leading 
to silica-induced decomposition. Instead, treatment with the water-soluble 
carbodiimide EDCI, promoted dehydration and cyclisation to the target 5(411)-
oxazolone (86), which was obtained as a mixture of diastereomers [d.e. 18 % (SS)]. 
Ph 
H Ph 	 (55%) 
DCM, light petroleum 	 H 	 [64 % d.e.] 
Cbz 	 o' D 	 Cbz 
reflux, s mins 	 (S,R) 





epimerisation 	 H [91 %d.e.] 
- 	 (S,5) 
86b 	remains in solution 
Scheme 25 Crystallisation-induced dynamic resolution 
At this point it is worth noting that the separation of the two diastereomers of 86 can 
be facilitated by employing crystallisation-induced dynamic resolution 98 (Scheme 
25). This effect was achieved by simply refluxing the 5(411) oxazolone in DCMllight 
petroleum (1:8) for 5 mm. On cooling, the (S,R) diastereomer (86a) precipitated out 
of solution whereas the (S,5) diastereomer (86b) was isolated on concentration of the 
mother liquor. It was also discovered that addition of one drop of Et 3N could induce 
epimerisation and thus facilitate the conversion of 86b to 86a, but not vice versa. As 
the R configuration is favoured, this method of resolution could prove a particularly 
convenient way to access unnatural D-amino acid derivatives. 
4.1.2 Solid Phase 
The target polymer supported 5(411)-oxazolone (88) may be easily obtained from the 
resin-bound dipeptide precursor (87) as shown in Scheme 26. 
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Scheme 26 Solid phase synthesis of target 5(4H)-oxazolone - reagents and conditions: (i) 20 % 
piperidine, DMF (ii) 3 % acetic acid, DCM (iii) EDCI, DCM (iv) TFA, DCM, H20 (9:10:1) 
Deprotection and neutralisation of the dipeptide derivatives 87a and 87b were 
conducted as if preparing to continue with the inverse peptide synthesis (Chapter 3). 
Analogous to the solution synthesis, cyclisation to the 5(4H)-oxazolones 88a and 
88b was then promoted by treatment with EDCI. IR  analysis gave the distinctive 
oxazolone carbonyl stretch (Vmax  = 1825 cm') as illustrated in Scheme 26 and gel-
phase 13C NMR analysis confirmed the presence of each oxazolone (88a-b) as a 
mixture of diastereomers (Spectrum 13).0P  ESMS analysis gave the mass ions 
corresponding to the hydrolysis products (MH + H20), since the acidic cleavage 
conditions induce ring-opening of the heterocycle to its peptide precursor. 
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Since oxazolones may be considered as activated ester derivatives of dipeptides, a 
further method for confirming their presence, is ring-opening with a nucleophule. If 
successful, this serves to confirm that the resin bound intermediate is indeed in an 
activated form, as well as demonstrating one of the many useful applications of 
5(4H)-oxazolones i.e. as precursors to C-terminally modified peptide analogues. 
4.2 5(41f)-Oxazolones - Transformations 
4.2.1 Ring-Opening Reactions 
4.2.1.1 General Introduction 
As mentioned above, 5(41f)-oxazolones may be considered as activated ester 
derivatives of amino acids or peptides and thus are highly susceptible to nucleophilic 
ring opening. 87 ' 88 Moreover oxazolone derivatives which are unsaturated 128 and even 
dialkylated56" 29 at the C4 position can been readily cleaved with amine nucleophiles. 
A variety of ring-opening reactions were examined on the solid phase derivatives 
(88a-b), in order to demonstrate the potential for the preparation of C-terminally 
modified peptide analogues and also the ability to continue peptide synthesis after 
elaboration of the core fragment. 
4.2.1.2 Solid phase ring-opening reactions 
The polymer-supported 5(4H)-oxazolone intermediates 88a and 88b were subjected 
to a series of nucleophilic ring opening reactions using a variety of substituted 
amines to afford a series of peptide amides (Scheme 27). 
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89a-e 
89a R 1 = H, R2 = CH2Ph (PS-Wang) 
89b R 1 = H, R2 = CH(CH3)Ph (PS-HMPA) 
89c 	= CH3, R2 = CH2Ph (PS-Wang) 
89d R 1 = H, R2 = CH3 (PS-HMPA) 
89e R 1 = H, R2 = NH2 (PS-Wang) 
= PS-HMPA- or PS-Wang- 
Scheme 27 Ring-opening of resin-bound 5(4H)-oxazolone - reagents and conditions: (i) NHR'R 2, 
DMAP, NMP (ii) TSA-Phe-OFm, DMAP, DMF (iii) Et 3N, MeOH, DMF 
The general procedure involved addition of the amine nucleophile (3 eq) and 
catalytic DMAP to a suspension of the resin which was pre-swollen in NMP. After 
agitating for at least 15 h, the resin was filtered and washed according to the standard 
procedure and analysed in the usual manner. A series of C-terminally modified 
peptides (89a 7e) were obtained using this procedure, demonstrating the variety of 
amines tolerated (Table 7). 
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No S.M. Nucleophile Ring-opened product ESMS2 LC-MS IR ' 3C gel 
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Table 7 Data for products from ring-opening of 5(4H)-oxazolone a) ES-MS after cleavage with 
TFA:DCM:H20 (9:10:1) (6.4.1) b) LC-MS gradient A as detailed in section 6.4.2 c) LC-MS gradient 
B as detailed in section 6.4.2 d) analysis not possible due to small sample 
Ring-opening reactions were also accomplished using an amino acid and an alcohol 
as the nucleophilic components (Scheme 27). The Fm ester protected amino acid was 
reacted as its TSA salt and the desired resin-bound tripeptide 90 (Table 7) was 
obtained in 61 % yield (0.23 mmollg). Attempts to effect methanolysis of 88b in the 
presence of catalytic sodium methoxide failed. However, successful alcoholysis was 
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achieved by adding catalytic Et 3N to a suspension of 88b in DMF/MeOH (l:l)t  to 
afford the peptide ester (91). These results demonstrate the further application of this 
ring-opening methodology as a means of accessing C-terminally modified peptides, 
or indeed facilitating the continuation of peptide synthesis following some other 
elaboration of the oxazolone moiety. 
4.2.1.3 Conclusions 
The ring-opening of the resin-bound 5(4H)-oxazolone has been demonstrated using 
methanol, an amino acid and a series of amine nucleophiles. The wide variety of 
nucleophiles tolerated by this system indicates that the ring-opening of 5(411)-
oxazolones may be extended to the synthesis of a whole range of C-terminally 
modified peptide analogues. 
There is, unfortunately, a clear disadvantage of this method as an independent route 
to C-terminally modified peptides. All the peptide derivatives prepared using this 
method were obtained as mixtures of diastereomers, due to racemisation of the 
5(411)-oxazolone starting material. It is hoped that the use of additives, 57 ' 58 as already 
discussed, may provide a solution to this problem by suppressing the racemisation of 
the oxazolone species. Until complete suppression has been achieved, however, this 
particular method of obtaining peptide analogues should be restricted to the use of 
peptides incorporating amino acid residues at the C-terminal position which are 
either achiral, or lack an a-hydrogen. Nevertheless, the nucleophilic ring-opening of 
oxazolone species does remain a valuable means of continuing peptide synthesis 
after modification of this moiety in some other manner. Some of these alternative 
elaborations are discussed in the following sections. 
Some further applications could include stereoselective ring-opening using a chiral 
DMAP-type catalyst97 or enzyme catalysed ring-opening. Indeed, many examples of 
the latter have been reported as routes into enantiopure a-amino acids. 9294 ' 96" 30 The 
polystyrene resin, used as the support in all the research described so far, is unlikely 
DMF was required to swell the resin 
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to be compatible with the conditions required for enzyme reaction. Therefore, a 
preliminary investigation into the possibility of using surface supports, such as 
SynPhaseTm crowns, has been conducted and is discussed in Chapter 5. 
4.2.2 Oxidation 
4.2.2.1 Solution DDQ Oxidation 
In 1978 Konno and Stammer published the first of many papers describing the use of 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone 13 ' (DDQ) for the solution oxidation of 
dipeptide-derived oxazolones. 72 '73" 28" 32 Among the number of dehydrogenating 
agents examined by the authors, DDQ was found to give the highest yield when used 
in combination with catalytic 2,4,6-collidine in DME for 24 h. Stammer and co-
workers demonstrated the oxidation of oxazolone 92, derived from Cbz-Gly-Phe-
OH, using these optimum conditions to afford 93 in 48 % yield (Scheme 28). It was 
also shown that, as in the Erlenmeyer aziactone synthesis, the double bond generated 
had the Z configuration. 
0 Ph Ph 
QAN / 	 (1) 	
Q 0 	(48%) 
H 
9 92 	 3 
0 
Scheme 28 Stammer's oxazolone oxidation - reagents and conditions: (i) DDQ, 2,4,6-collidine, DME, 
24 h 
It was hoped that the oxidation described by Stammer et al. could be applied to solid 
phase dipeptide derived oxazolones, to provide a means of accessing libraries of 
dehydropeptides. In order to obtain a solution analogue for comparisons with solid 
phase products the unsaturated oxazolone 94 was prepared according to Stammer's 
optimum conditions (Scheme 29). 
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86 	
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oAN N 
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94 	 0 
Scheme 29 Solution-phase oxidation - reagents and conditions: (i) DDQ, 2,4,6-collidine, DME, 24 h 
A solution of the N-protected dipeptide-derived 5(41-f)-oxazolone (86) in anhydrous 
DME, was treated with DDQ and 2,4,6-collidine to give a deep red solution. After 
stirring for 24 h under an inert atmosphere, the resulting red precipitate was filtered 
off and the filtrate concentrated to afford a dark red oil. The target unsaturated 
oxazolone (94) was purified using column chromatography and isolated as a white 
solid which readily decomposed when stored at room temperature. 
The unsaturated oxazolone is clearly identified not only by the lack of the C-4 proton 
in the 'H NMR spectrum, but also by the presence of a multiplet (6H  8.03-8.11 ppm) 
corresponding to the two ortho protons on the (t,13-unsaturated aromatic ring. 
Furthermore, the vinyl benzylic proton appears in the aromatic region (6 H 7.21 ppm) 
and the oxazolone carbonyl stretch in the JR suffers a shift of approximately 20-30 
cm' (Vmax  1799 cm'). High resolution mass spectrometry further confirmed 
successful oxidation, albeit in a poor yield. Since a single product was obtained, the 
double bond was assigned Z configuration, in line with the results described by 
Stammer. 73 
The poor stability and low yield of the product are obviously the main disadvantages 
of this, otherwise very convenient, reaction. The low yield is thought to be a feature 
of the poor stability of the product. However, oxidation performed on resin-bound 
intermediates obviates the need for a purification step, with product isolation being 
achieved by simple washing. In addition, resin-bound intermediates are often more 
stable than their solution phase counterparts and solid phase combinatorial chemistry 
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Scheme 30 Solid-phase DDQ oxidation - reagents and conditions: (i) DDQ, DME 
The resin-bound 5(4R)-oxazolone (88b) was pre-swollen in DME before treatment 
with an excess of DDQ. Addition of 2,4,6-collidine to the reaction slurry caused an 
instant colour change, but the resulting products gave complex spectra, indicating a 
mixture of products, so it was decided to omit this reagent and use DDQ on its 
own. 66 The resulting slurry was agitated for 15 h before being filtered and washed 
according to standard procedure. On-resin JR (Vmax = 1805 cm' - C=O oxazolone) 
(Spectrum 14)° and ' 3C NMR analysis confirmed successful oxidation to the 
unsaturated derivative 95, although the broadness and complexity of the NMR 
spectrum indicated incomplete reaction. It was found that if this product was 
subjected to the original reaction conditions for a second time, a cleaner ' 3C NMR 
spectrum was obtained. Even this spectrum was reasonably broad, possibly due to 
DDQ and DDQH impurities lingering in the rusty-coloured resin. Cleavage with 
TFAIDCMIH20 (9:10:1) followed by ESMS gave peaks corresponding to the 
hydrolysed product (MH + H20) and the hydrated and hydrolysed product (MH +2 
x H20). When anhydrous cleavage conditions were employed (50% TFA in DCM) 
the actual product mass ion (MW) was observed along with the hydrolysis product 
(MH + H20). The oxazolone starting material however, was also present to a minor 
extent in each sample, indicating that even repeated subjection to excess reagents for 
prolonged reaction times, although improved the yield, was not sufficient to drive the 
reaction to completion. 
In systems where the Wang linker is used to tether alcohols to a polymer support, the 
benzylic ether linkage has been found to be susceptible to oxidative cleavage by 
DDQ. Indeed, several publications have reported the use of DDQ as a mild 
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alternative cleavage reagent for ether-linked systems. 133-136 However, since the target 
compounds were observed on-resin and in the final cleavage mixture, even after 
prolonged reaction times, it was assumed that the urethane linked system was not 
susceptible to oxidative cleavage, presumably due to the resonance stabilisation of 
this functionality. 
4.2.2.3 Further Manipulations 
A number of ring-opening reactions were performed on the polymer-bound 
unsaturated oxazolone derivative (95) (Scheme 31). The reactions described, further 
verify the success of the oxidation to yield the solid phase dehydro derivative, as 
well as demonstrating some of the potential applications of this transformation. 
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Scheme 31 Further manipulations of afi-unsaturated resin-bound 5(4H)-oxazo/one - reagents and 
conditions: (i) Et 3N, MeOH, DMF (ii) TSA-Phe-OFm, DMAP, NMP (iii) TSA-3-Ala-OFm, DMAP, 
NMP 	(iv) 	H2, 	RhL* : 	[Rh(diPAMP)(norbornadiene)]BF 4 	(S,S); 	[Rh(Ph- 
CAPP)(norbornadiene)]BF 4 (SR) 68  
Ring-opening reactions were carried out according to the procedures employed for 
the saturated oxazolone analogues (4.2.1.2). Thus, the resin-bound dehydro 
oxazolone 95 was swollen in a mixture of MeOH and DMF (1:1) before addition of 
77 
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catalytic Et3N. Over-night agitation was followed by filtration, washing and drying 
in the usual manner. Analysis of the resin by IR and gel phase ' 3C NMR, indicated 
successful alcoholysis of the unsaturated oxazolone to afford the target dipeptide 
ester 96 (Spectrum 15).o" Acidic cleavage, followed by ESMS gave the mass ion 
corresponding to ValAzPhe OMe, giving further evidence of successful ring-
opening. LC-MS gave a single major peak corresponding to the dehydropeptide ester 
(96), with trace impurities possibly arising from DDQ-derived contaminants. 
Ring-openings were also conducted using amino acids as the nucleophilic 
components, demonstrating the application of this method for the synthesis of 
dehydropeptide analogues. In a similar way to the reaction of the saturated derivative 
(88b), the a,-unsaturated oxazolone (95) was suspended in NMP and treated with 
the TSA salt of the Fm ester protected amino acid and catalytic DMAP. Usual work 
up gave the corresponding tripeptide incorporating a dehydro-phenylalanine unit. 
The two amino acid derivatives employed were TSA-Phe-OFm (65a) and TSA--
Ala-OFm (77c), furnishing the tripeptides ValAzPhePheOFm  (97) and Val-zPhe- 
-Ala-OFm (98) respectively. LC-MS analysis of both cleavage products give a 
single peak on the LC trace with the correct corresponding mass ion. Not only did 
this confirm that the starting material had been successfully oxidised, as the 
tripeptide obtained would be two mass units greater and a mixture of diastereomers, 
but also that one configuration is favoured for the unsaturated unit. As previously 
mentioned, this is in line with the results of others 66 and it is therefore highly likely 
to be the Z isomer. 
4.2.2.4 Conclusions and Applications 
Ring-opening of the resin-bound a,13-unsaturated 5(4R)-oxazolone (95) has been 
demonstrated using different nucleophiles. Not only has this served to confirm the 
success of the oxidation reaction, but lends support to the proposal that 5(411)-
oxazolone derivatives are useful precursors to a number of desirable peptide 
analogues. For instance, alcoholysis of the unsaturated oxazolone has been shown to 
afford the corresponding dehydropeptide ester. Although useful in their own right, 
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these derivatives could also be selectively reduced 68 to afford either the L,L (99a) or 
L,D (99b) peptide ester as depicted (Scheme 31). 
Ring-opening with amino acids has also been demonstrated. If applied in a 
combinatorial manner, this methodology could used to prepare a diverse range of 
dehydropeptide analogues (Scheme 31). 
Furthermore, by applying this methodology to polymer-supported oxazolone 
intermediates, the problems of poor stability and yield have been addressed. For 
example, unlike the solution analogues, the unsaturated supported intermediates 
appear to be stable at room temperature for prolonged periods of time. In addition, 
by driving the reaction through repeated treatment with excess reagents, yields have 
been significantly improved, although still require further optimisation. 
Unsaturated oxazolone intermediates also exist as potential precursors to a number 
of other valuable compound classes. Some examples of these further applications 
will be mentioned briefly in Chapter 5. 
4.2.3 Alkylation 
4.2.3.1 Solution Phase Investigation 
R 	 R2 
N ° 	 N ° 
H 	\ / 
Ph 
100 	 R1 	34 
Figure 23 General stru ctures for alkylation studies 
Many studies have been carried out on the alkylation of 2-phenyl 5(411)-oxazolones 
(100) with varying degrees of success. 129,137-139  From this research it is also known 
that the C4 alkylation of oxazolone derivatives lacking a phenyl substituent at C2, 
proceed less efficiently. Therefore, in order to establish the optimum conditions for 
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successful alkylation at the C4 position of dipeptide-derived 5(4H)-oxazolone 
intermediates (34), previous work 140 explored the effects of a number of variables on 
the yield and diastereoselectivity of this reaction. A range of electrophiles, bases, 
additives and temperatures were examined and some conclusions which can be 
drawn from the results obtained, are summarised below: 
• an inverse relationship exists between d.e. and yield. 
• it is possible to alkylate the dipeptide derived oxazolones in yields up to 85 % and 
d.e.s up to 81 %, but not concomitantly. 
• moderate d.e.s can probably be attributed to the distance of the chiral auxiliary 
from the C4 centre at which asymmetric induction ha Ys to take place. Also, the 
pendant arm side-chain at C  is able to rotate freely so that R' (Figure 23) can lie 
above or below the plain. 
• addition of metal salts in most cases results in an increase in d.e. due to chelation 
control, but decrease in yield as the reaction proceeds less cleanly due to high 
sensitivity to temperature and stoichiometry. 
• the low reactivity of the pseudo-aromatic carbanion can be partially blamed for 
the low yields and complex mixtures formed. 
86 	0  'IX,N H 0A 	
Ph 
0 
c.f.HMPA and Wang 
linkers 
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5_1 	0 
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E = CH2C=CH2 	[ + by-products] 
Scheme 32 Alkylation of solution phase 5(4H)-oxazolone 
In order to attempt the alkylation on the solid phase oxazolone derivative 88a, it was 
first necessary to prepare solution derivatives for comparison and also attempt to 
optimise the conditions further with respect to the specific oxazolone derivative 
involved. Conditions were selected as a basis for the extended optimisation by 
considering the oxazolone derivative upon which all the solid phase studies had been 
based, along with the necessity for employing conditions which would be compatible 
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with the resin and linker system. The conditions which appeared to fit these criteria 
and which provided the best compromise of yield and diastereoselectivity were either 
sodium or potassium bis(trimethylsilyl) amide, with a reactive electrophile such as 
allyl bromide in THF at 0 °C. A number of alkylations were performed using these 
conditions, but the desired product had to be isolated from a mixture of by-products 
and thus initial yields of 101a were very poor (- 16%). 
In an attempt to optimise the conditions further, the by-products formed during the 
alkylation were examined in more detail. In this way, it was hoped that by 
identifying the main side reactions, modifications to the conditions or procedure 
could be implemented so as to prevent their formation and thus enhance the yield of 
the target 101. As described below (4.2.3.2), such scrutiny lead to the identification 
of one of the major side reactions as a dimerisation process. As a result, conditions 
were altered to hinder this process by performing the reverse addition of 86 to a 
solution of the electrophile and base. In this way, as soon as the oxazolone was 
added, it was deprotonated and the resulting enolate immediately quenched with the 
electrophile, before any self-condensation could occur. The reaction mixtures used 
were also relatively dilute to further impede the unwanted dimerisation. 
As a consequence 101a was prepared in 52 % yield with a 55 % d.e. of the (SR) 
product. Although still far from ideal, as previously-mentioned, it is known that the 
C4 alkylation of oxazolones which lack a phenyl substituent at the C2 position 
proceed less efficiently. It is also possible that the dialkylated product is susceptible 
to decomposition on silica giving rise to the poor yields observed. 
4.2.3.2 Dimerisation 
As mentioned, during the various attempts at the solution phase alkylation of 
oxazolone 86, the formation of several recurring by-products was observed. Once 
isolated, analysis by 'H NMR and mass spectrometry indicated that the major by-
product was an example of a Rugheimer dimer.' 41 " 42 Although analogues of this 
dimer (102), with a core pyrrolidine-2,4-dione structure, have been mentioned 
E:I1 
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several times in the literature,  143-148  they have received very little attention as 
molecules in their own right i.e. potential applications have not been examined. 
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Scheme 33 Dimerisation of the 5(4H)-oxazolone - reagents and conditions: (i) NaHMDS, THF, 0 °C - 
RT, concentrated (ii) as for (i) but highly dilute 
The dimerisation in this system is believed to arise due to the susceptibility of the 
oxazolone to nucleophilic attack. Deprotonation of one molecule of the oxazolone 
results in formation of the enolate, which is then free to attack the carbonyl function 
of another oxazolone molecule, initiating the rearrangement that finally gives rise to 
the dimer 102 (Scheme 33). 
In order to confirm the proposed structure, the reaction conditions were altered in 
such a way as to favour the dimerisation process and thus isolate enough material for 
further analysis. Therefore, base was added drop-wise to a concentrated solution of 
the oxazolone to encourage self condensation. Pyrrolidine-2,4-dione analogue 102a 
was obtained as a 2:1 mixture of diastereomers (Scheme 33). Once again high 
resolution mass spectroscopy gave the mass ion corresponding to the dimer structure, 
but the 'H NMR spectrum proved difficult to interpret due to its complexity. The 
reaction was therefore repeated using a very dilute solution of oxazolone 86 and the 
resulting product 102b was isolated as a single diastereomer corresponding to the 
major isomer of 102a. 
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The NMR data from both compounds (102a-b) combined with data from COSY and 
NOE experiments (Figure 25) allowed full characterisation of the major and minor 
diastereomers. Unfortunately the critical NOB information which would have 
allowed determination of the relative cross-ring geometry was not present. 
Furthermore, all attempts to obtain a crystal structure of 102a-b or analogues thereof 
failed, due to the tendency of these compounds to form fine needles unsuitable for 
crystallographic studies. Interestingly, work carried out by Leban and Colson on the 
base dimerisation of urethane-protected amino acid N-carboxanhydrides 
(UNCAS), 149 involved the isolation of 102. The crystal structure of an analogue lead 
to the geometry of 102 being assigned Z, however, differences in the synthesis and 
solvent for NMR studies prevented direct comparison. 
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Figure 24 'HNMR spectrum of 102a (2:1 mixture of diastereomers) 
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Figure 25 Maps of NOE and COSY data from analysis on both diastereomers of 102 
An interesting feature of each diastereomer of 102a displayed by the 1 H NMR is the 
presence of a single, very highly shielded benzylic proton signal (e.g. major 
diastereomer oH 0.71 ppm). It is likely that this shielding is due to the proton being 
orientated over one or sandwiched between two of the aromatic rings present in the 
dimer. The neighbouring geminal proton, however, has a vastly different chemical 
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shift (6H  4.28 ppm), indicating that although attached to the same carbon, the two 
protons are witnessing very different magnetic environments. Preliminary modelling 
studies were carried out on the four possible stereoisomers t , in an attempt to 
investigate the basic feasibility of this prediction. An example of one of the models 
obtained is shown (Figure 26) and demonstrates how, in theory, it is possible for 
these two neighbouring protons to witness the environments described. This 
hypothesis is supported further by the potential presence of a hydrogen bond (2.09 
A) which may serve to hold this core conformation in place. 
Figure 26 Model ofpotential conformation of(R.S) diastereomer of 102 
A potential application of this reaction could be to adapt the dimerisation to the solid 
phase. With one oxazolone component tethered to the resin, it may be possible to 
perform controlled dimerisations, where the solution phase oxazolone is designed to 
introduce further diversity, thus facilitating the library synthesis of Rugheimer-type 
structures for screening. 
only the valine stereochemistry is fixed 
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4.2.3.3 Alkylations on Solid Phase - Preliminary Results 
Given the moderate success of oxazolone alkylations in the solution phase, the same 
conditions were employed in an attempt to achieve better yields on supported 
intermediates. For instance, it was expected that yields could be improved further 
since dimerisation would be considerably less likely to occur between two oxazolone 
fragments bound to the same support. It was also hoped that the well-documented 
'polymer advantage' 13 of employing excess reagents to drive reactions to completion 
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Scheme 34 Attempted alkylation of supported oxazolone intermediate - reagents and conditions: (i) 
KHMDS, allyl bromide, THF 
The supported oxazolone (88a) was suspended in anhydrous THF, before addition of 
freshly-distilled allyl bromide (3 eq). A solution of KHMDS in THF (3 eq) was 
added drop-wise and the resin slurry agitated under an inert atmosphere for 16 h. 
After filtering, washing and drying, analysis of the resin indicated that the reaction 
had been unsuccessful. The distinctive oxazolone carbonyl stretch was no longer 
evident, indicating that either ring-opening or some other transformation had 
occurred. However, analysis by ESMS gave no signal corresponding to the 
dialkylated target molecule (103) or the starting material. Indeed, no major peak, as 
such, was observed and none of the other signals identified. Gel phase ' 3C NMR 
E:ri 
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analysis was also poorly resolved and too broad to derive any meaningful data, 
indicating that the conditions employed were probably not compatible with the resin. 
4.2.3.4 Conclusions 
Although the alkylation of the polystyrene-bound oxazolone was not successful in 
this instance, it merely demonstrates how conditions which prove effective for 
solution phase reactions do not always translate successfully to solid phase systems. 
For instance, it is possible that the hindered base was unable to gain adequate access 
to the functional sites within the resin, to cause deprotonation and subsequent 
alkylation. It is also feasible that the base itself was not entirely compatible with the 
polymer support employed. Furthermore, since purification is not possible it is 
essential that solid phase reactions are high yielding. Therefore, if the other by-
products observed in the solution study were still favoured, the resin-bound product 
could have been crude to the extent that any successful alkylation products were 
obscured. 
A possible route around these problems would be to use an alternative support, 
which might prove compatible with the reagents and did not require diffusion of the 
reagents into buried reactive sites. With this in mind, a preliminary investigation into 
the feasibility of employing SynPhaseTm MD crowns was conducted and is described 
in more detail in Chapter 5. 
Another potential strategy which has yet to be proved viable on solid supported 
intermediates, is the strategy described by Trost et al. •150  By using the chiral ligand 
104 and a precatalyst palladium complex 105, Trost was able to demonstrate the 
asymmetric alkylation of 2-phenyl substituted oxazolones as depicted in (Scheme 
35). Impressive yields, diastereomeric ratios (d.r.) and enantiomeric excesses (of the 
major and minor diastereomers) (e.e.) were obtained for a variety of R substituents. 
Time did not permit examination of this methodology with respect to the 
polystyrene-bound dipeptide-derived oxazolone system. Moreover, the difference in 
reactivity between 2-phenyl and dipeptide derived oxazolones has already been 
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described, indicating that direct transfer between the two systems may not prove 
altogether straight forward. 
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Scheme 35 Asymmetric alkylation of 2-phenyl 5(4H)-oxazolones - reagents and conditions: (i) [( 11 3-
C3H5PdC1)2] (105), Et3N, MeCN 
Future Work 
5. Future Work 
5.1 5(4H)-Oxazolones and Enzymes 
5.1.1 Introduction 
5(411)-oxazolones have found utility as substrates for a number of enzyme-catalysed 
transformations. For instance the enzyme catalysed dynamic resolution of these units 
as a route into optically active ct-amino acid derivatives has already been described 
(1.3.1). Furthermore, 5(411)-oxazolones have been employed as activated acyl donors 
for ct-chymotrypsin 15 ' and papain 152 catalysed peptide fragment condensations. 
The advantages of employing enzymes to catalyse such reactions include high regio-
and stereoselectivity, mild reaction conditions, lack of racemisation and minimal side 
chain protection. It would therefore be very useful if these enzyme-catalysed 
transformations could also be applied to 5(4H)-oxazolone derivatives bound to a 
polymer support. 
The polystyrene beads which were used as the support material throughout the 
investigations described, are unlikely to be suitable for transformations involving 
enzymes. For instance, not only is it unlikely that the enzymes would be able to gain 
access to the buried functional sites, but the polymer does not swell in the aqueous 
systems required for many enzyme-catalysed reactions. It was therefore necessary to 
consider using a different support, which would both allow enzyme access and be 
compatible with aqueous systems. The previously described (1.1.2.1) SynPhaseTM 
MD crowns appeared to meet the required criteria and were selected for some 
preliminary research. 
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5.1.2 Preliminary Results Using SynPhaseTM Crowns 
The inverse synthesis of the dipeptide-derived 5(411)-oxazolone was carried out in 
much the same way as it had been for the polystyrene bound derivative (Scheme 36). 
The crowns however, being surface supports, are much lower loading and require 
only very gentle agitation. Moreover, in order to fully submerge the crowns and still 
maintain a concentration suitable for the reaction a ten fold excess of reagents was 
employed. 
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Scheme 36 N-C synthesis of 5(4H)-oxazolone using SynPhase TMcrowns - reagents and conditions: (i) 
p-nitrophenyl chioroformate, pyridine, DCM (ii) 20 % piperidine, DMF (iii) 3 % acetic acid, DCM 
(iv) TBTU, NMM, DMF (v) HOBt-VaI-OFm, DMF (vi) HOBt-Phe-OFm, DMF (vii) EDCI, DCM 
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The principal difficulty encountered using the crowns was the lack of analysis 
available. As non-swelling surface supports, on resin gel phase ' 3C NMR and JR 
analysis were not feasible and any destructive analysis e.g. cleavage followed by 
ESMS, required sacrificing an entire crown. 
In order to confirm the success of each step, sufficient crowns were withheld for 
ESMS and quantitative (p-nitophenol or Fm) analysis. The low loadings (1.8 
jtmole/g starting loading) of the crowns meant that analysis was very weak and mass 
spectroscopy signals were often difficult to see. 
Although it would appear from the, albeit weak, ESMS data and loading analyses 
that each supported derivative 106-109 was prepared, the lack of more convincing 
data precluded any further transformations from being examined. It is possible that 
the weak signals are a feature of the altered washing protocol recommended by the 
manufacturers. By washing with only MeOH and DCM, rather than a wider variety 
of solvents, it is possible that there is insufficient removal of the impurities and 
excess reagents, resulting in swamping of the target signals. Further examination of 
this supported system is clearly necessary before its scope can be properly explored. 
Provided the problem with analysis of the crowns can be overcome, these supports 
appear particularly promising for facilitating enzyme-catalysed reactions on 
supported oxazolone derivatives. It is also possible that employing such surface 
supports for the alkylation and dimerisation reactions described in section 4.2.3, 
might help overcome problems such as compatibility and functional site access for 
hindered bases. 
5.2 Other Applications 
The elegance of the resin-bound 5(41f)-oxazolone fragment is that its application is 
not merely limited to acting as a precursor for the preparation of the derivatives 
described. Its versatility can be reflected in the vast scope of reactions for which it is 
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potentially the basis. Figure 27 represents some of the many diverse transformations 
with marked potential for future investigation. 
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Figure 27 Potential of the resin-bound 5(4H)-oxazolone - references: (i) Michael addition 153 (ii) 
tamdem alkylation and translactonisatio& 54 (iii) dimerisation (4.2.3.2) (iv) enzyme-catalysed 
alcoholysis96 (v) enzyme-catalysed condensation 151,152  (vi) asymmetric reduction 68 (vii) ring 
transformation of Michael adduct 155 (viii) Diels-A1der 156 (ix) conjugate addition of Grignard 




6.1 General Experimental 
1 H and ' 3C NMR spectra were recorded on Bruker AC250, Bruker WH 360 or Varian 
UNITY INOVA 600 instruments. Chemical shifts (oH, O) of signals are reported in 
ppm, and coupling constants (J) in Hertz (Hz). Residual protic solvent present in the 
deuterated sample was used as internal standard in NMR spectra, e.g. CHC13 in 
CDC13 . When products were obtained as a mixture of diastereomers, "M" and "m" 
denote signals corresponding to the major and minor diastereomers respectively. 
Electron impact (El) nominal mass spectra were recorded on a Finnigan 4600 mass 
spectrometer. El high resolution and fast atom bombardment (FAB) accurate and 
nominal mass spectra were recorded on a Kratos MS50TC instrument. 
JR absorption spectroscopy was performed on a Perkin-Elmer FT-JR Paragon 1000 
spectrophotometer, and frequencies (v) measured in wave numbers (cm'). Samples 
were measured on disposable JR cards (Type 61 3M, polyethylene, 19 mm aperture), 
as thin films, KBr discs or Nujol mulls. Resin-bound samples were swollen in DCM 
and compressed between NaCl plates. 
Melting points were measured on a Gallenkamp melting point apparatus and are 
uncorrected. 
Optical rotations were performed on an AA-1000 polarimeter from Optical Activity 
Ltd (measurements being made at the sodium D-line). Concentrations are given in 
gIlOO ml and [a] ° are quoted in 10' deg cm' g'. 




Possible low energy conformations of 102 were explored using Insight IITm from 
Biosym with energy minimsations performed using a DiscoverTm forcefield 
(Biosym). 
Flash chromatography employed silica gel 60H (0.04-0.063 mm, 230-400 mesh) 
(Merck 9385) and analytical tic was carried out on Merck aluminium-backed plates 
coated with silica gel 60 F 2541 0.25 mm. Visualisation techniques include UV 
fluorescence (254 nm), and ammonium molybdate, ninhydrin and permanganate 
dips. 
All reactions with air- or moisture-sensitive reactants or solvents were carried out in 
oven- or flame-dried glassware under a positive pressure of dry argon. THF was 
distilled under argon from sodium, with benzophenone ketyl as indicator, and 
dichloromethane was distilled from calcium hydride shortly before use. Al! other 
solvents described as anhydrous have been purchased as "anhydrous-grade". Where 
DMF was required for reactions on solid phase or qualitative analytical tests, 
"peptide synthesis grade", purchased from Rathburns, was employed. Solvents and 
reagents used for quantitative resin analysis were "spectrophotometric grade", and 
the H20 and MeCN used for LC-MS and HPLC were "HPLC grade" and filtered 
prior to use. Allyl bromide was purified prior to use by distillation and 2,4,6-
collidine was distilled and stored over calcium oxide. All other reactants and 
solvents were "reagent-grade" and used as supplied unless otherwise stated. Where 
light petroleum has been stated in the text, petroleum ether (bp 40 - 65 °C) has been 
used. 
6.2 General Experimental - Solid Phase 
6.2.1 Nomenclature of Resin-Bound Compounds 
When naming resin-bound compounds, the resin has been considered to be the 
functional class name in accordance with JUPAC recommendations and the 
compound anchored to the resin is described using prefixes. Hence, 47 is called 4-
(hydroxymethyl)-phenoxyacetyl aminomethyl polystyrene. 
Experimental 
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Figure 28 Example of supported compound (47) 
When resin-bound amino acids and peptides are described, the non-IUPAC names 
valine, phenylalanine etc. have been employed for clarity. Also, the traditional 
method for naming peptides, on- or off-resin, which have been synthesised in the 
classical C-N direction, is from N terminus to C terminus. Therefore, in order to 
achieve consistent nomenclature for peptides cleaved from the resin, resin-bound 
peptides synthesised in the inverse (N-C) direction are, nevertheless, named 
according to this standard method. Thus, the peptide/peptidomimetic chain is 
systematically named (N-C) and included in the full compound name as a prefix to 
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Figure 29 Example of a polymer-supported inverse peptide analogue (69a) 
6.2.2 Resins/Crowns 
The resins employed were aminomethylated polystyrene resin purchased from 
Novabiochem (Nova) HL 38-75 jIm copoly-(styrene-1 % DVB) and Polymer 
Laboratories (PL) 75-150 copoly-(styrene-1 % DVB), or PL-Wang resin 75-150 tm 
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copoly-(styrene-1 % DVB). Preliminary studies were carried out on I-Series 
SynPhaseTm methylacrylic acidldimethylacrylamide graft polymer (MD) crowns, 
purchased from Chiron Technologies (CT). 
6.2.3 Solid Phase Reactions 
Solid phase reactions were carried out in either 3, 10 or 25 ml plastic isolute SPE 
filtration columns with top caps, luer tip caps and 20 pm porosity frits, purchased 
from Jones Chromatography and spun on a blood rotator to effect thorough mixing 
of the resin and reagents. Large scale reactions (>1.5 g resin) were carried out in 
standard glass round bottom flasks and a New Brunswick Scientific Gyrotory® 
water bath shaker was used to provide suitable agitation. In general, reactions were 
carried out using a minimum three-fold excess of reagents for polystyrene resins and 
a minimum ten-fold excess when reacting SynPhaseTM MD crowns. On the whole, 
reactions were allowed to proceed for >15 h before filtering and washing as 
described below. 
6.2.4 Washing Protocol 
Once the solid phase reaction was deemed complete, the polystyrene resin was 
filtered and washed according to the following procedure: THF (x 2); DMF (x 2); 
DMF/MeOH (1:1) (x 2); DMF (x 2); THF (x 2); DCM (x 2). Plastic pipettes were 
used to provide agitation during the washing steps in order to avoid loss of the 
polystyrene resin which sticks to glass. When using isolute tubes a VacMasterTM 10 
wash station was employed, otherwise a standard sinter funnel and water pump were 
used. The resin was then dried to constant weight under vacuum before analysing 
using the following methods (6.3 and 6.4). SynPhaseTM MD crowns were washed 
with MeOH (x 3) and DCM (x 1) before drying and analysing as above. 
Experimental 
6.3 On-Resin Analysis of Polymer-Supported Intermediates 
6.3.1 IR Spectroscopy 
Samples were prepared by taking a pre-washed and dried aliquot of resin (-5-10 
mg), swelling in DCM and pressing between a pair of NaCl plates. The broad C-Cl 
stretch from the DCM masks any diagnostic peaks below Vmax  -820 cm', but signals 
in the carbonyl region are generally very apparent. 
6.3.2 Gel Phase ' 3C NMR Spectroscopy 
Samples were prepared by loading dry resin into an NMR tube (- 1-1.5 cm depth) 
and adding CD2C12 dropwise until the resin had swollen fullyt.  Due to the broad 
nature of gel phase spectra, quaternary carbons are often too weak or broad to be 
observed clearly. Also, the polymer backbone itself gives two very broad peaks in 
the benzylic and aromatic regions of the spectrum, often obscuring any weaker 
signals. Therefore, where gel phase NMR data has been quoted in the experimental 
section, peaks have been assigned as far as possible, often with the aid of relevant 
solution spectra. Where atoms are not assigned, it is assumed that the corresponding 
peaks have either been obscured or are too weak to assign confidently. 
6.3.3 Qualitative Detection of Resin-Bound Free Amines 
6.3.3.1 Kaiser test 159 
A small sample of washed and dried resin (2 mg) was treated with two drops each 
of reagents (A), (B) and (C). The resin suspension was then heated (-400 °C) for 2-5 
min and any colour change noted. A dark blue/black colour indicated the presence of 
free amine, whereas a straw brown colour verified complete coupling. Due to the 
sensitivity of the test (5 tmole/g free amine) if a pale blue colour developed after 5 
min it was assumed that the reaction had reached virtual completion, nevertheless, 
the test was always used in conjunction with the TNBS test (6.3.3.2). 
Care must be taken to avoid any air bubbles or foreign bodies (as unable to filter) which may give 
rise to distortions in the NMR spectrum. 
Experimental 
Reagents: (A) ninhydrin (500 mg) in EtOH (10 ml); (B) phenol (80 g) in EtOH (20 
ml); (C) 0.001 M potassium cyanide (2ml) diluted to 100 ml with pyridine. 
6.3.3.2 TNBS test 160 
A small portion of washed and dried resin was treated with one drop each of 
solutions (C) and (D). Red polystyrene beads, viewed under a microscope, indicated 
the presence of free amine. 
Reagents: (C) 10 % DIPEA in DMF; (D) 1 % TNBS in DMF. 
6.3.4 Determination of Loading 
6.3.4.1 Fmoc/Fm analysis 
A minimum of two samples of dry resin (4-10 mg) were weighed directly into 10 ml 
volumetric flasks and made up to the volumetric level with a solution of 20 % 
piperidine in DMF. The samples were sonicated at room temperature for 4 h, before 
recording the UV spectrum of the supernatant between 280 and 320 nm. Where 
absorbances with a X max  >1 were measured, the sample was diluted with blank 20 % 
piperidine in DMF, until an absorbance of X max  <1 was achieved in accordance with 
the Beer-Lambert Law. 
The formula below was used to calculate the resin loading: 
mmoL'g = (A x v) / ( E x iO x wt) 
[A - absorbance @ 301 nm (max)  v - volume (ml); wt - weight of resin (mg); c - 
extinction coefficient of N-(9-fluorenylmethyl)piperidine 16 ' (E 301 nm = 7800 M 
cm')] 
6.3.4.2 p-Nitrophenol analysis 
One blank, three standards and two samples were prepared as follows: 
Blank 	DMF (1 ml) was added to 20 % piperidine in DMF (1 ml) and the 
solution stirred for 1 h. The solution was diluted to 10 ml with MeOH, 
200 t1 withdrawn and diluted to 5 ml with H20. 
W. 
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Standard 	p-nitrophenol (4-6 mg) was dissolved in DMF (2 ml) and 20 % 
piperidine in DMF (2 ml) added. The bright yellow solution was 
agitated for 1 h before being diluted to 25 ml with MeOH, 250 .il 
withdrawn and diluted to 10 ml with H20. 
Sample 	a sample of dry resin (4-6 mg) was suspended in DMF (1 ml) 
Addition of 20 % piperidine in DMF (1 ml) was followed by agitation 
for 1 h and the resultant bright yellow slurry diluted to 10 ml with 
MeOH, 200 tl withdrawn and diluted to 5 ml with H 20. 
Using the blank as a reference, the UV spectrum of each supernatant was recorded 
between 200 and 600 nm. The approximate resin loading was determined using the 
formula below: 
mmollg = [Asampie x WtStd x 1000]/[Wtsampie x AStd  x 4 x 139.1] 
[A - absorbance @ 400 nm; wt - weight of resinlp-nitrophenol (mg)] 
Due to the errors incurred from weighing small samples and carrying out repeated 
dilutions, the loadings obtained from both methods (6.3.4.1 & 6.3.4.2) are only 
considered to be accurate to ± 0.05 mmol/g and are merely intended to give an 
indication of the success of the reaction. In terms of starting loadings for reactions, 
although the loading of the resin to be derivatised was calculated where possible, in 
order to account for inconsistencies, reagents were often added with respect to the 
maximum loading (manufacturer). Where yields are quoted, however, the calculated 
loading of the precursor has been used to determine the theoretical maximum loading 
of the product (6.3.4.3). 
6.3.4.3 Calculation ofyields based on loading analysis 
When determining the yield of a solid phase reaction, the weight gain/loss during the 
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Scheme 37 Activation of PS- Wang (46) 
For instance during the activation of Wang resin 46 (Scheme 37), there is a net 
weight gain of 165.11 glmole functionality. Therefore the increase in weight of 1 g 
of starting material (0.9 mmol/g) after activation would be (0.9 x 10 x 165.11) = 
0.15 g. Therefore, the maximum possible loading of the activated resin can be 
calculated as (0.90 / 1.15) = 0.78 mmollg. The loading of 72 was determined to be 
0.90 mmol/g by p-nitrophenol analysis (6.3.4.2). The percentage yield was therefore 
calculated to be (0.90 I 0.78 x 100) = 100 %*,t  thus exemplifying the inaccuracy of 
the loading analysis method. Therefore, as with the loadings, yields are only included 
to give a rough indication of the reaction concerned, with corroborating evidence of 
yield and purity being obtained from gel phase ' 3C NMR and LC-MS analysis. 
6.4 Product Release and Subsequent Analysis 
6.4.1 General Procedure for Acidic Cleavage 
An aliquot of dry resin (-4-6 mg) was treated with a solution of TFA/DCMJH 20 
(9:10:1) (300 p.1) for 1 h. The resin was filtered using a glass pipette and cotton-
wool, washed with DCM and the filtrate and washings combined and concentrated. 




After cleavage (6.4.1.) the crude product was dissolved in a solution of MeCN/H 20 
(1:1) with 0.01 % TFA. An aliquot (100 - 500 p.1 depending on expected yield) was 
withdrawn and diluted to 1 ml with the original solution. Analysis by ES-MS was 
carried out on a MicromassTm Platform II spectrometer with MassLynx Version 2.3, 
Build 5 software. When required, LC-MS analysis was carried out using a WatersTm  
2690 Separations Module and a WatersTm 486 Tunable absorbance Detector 
measuring at 215 run. A Phenomenex Luna 3 p. C18(2) 50 x 1.00 mm column was 
used as the stationary phase eluting with H 20IMeCN at a flow rate of 0.1 ml min'. 
Retention times (Ri) are quoted in minutes. Two gradient elutions were employed 
(Tables 7 and 8): 
Time (mm) H20 MeCN 
0 80% 20% 
5 80% 20% 
25 40% 60% 
30 80% 20% 
40 80% 20% 
Table 8 LC-MS gradient A 
Time (mm) H20 MeCN 
0 95% 5% 
5 95% 5% 
35 5% 95%. 
40 5% 95% 
45 95% 5% 
60 95% 5% 
Table 9 LC-MS gradient B 
6.4.3 Semi-Preparative HPLC 
HPLC analysis was carried out on large-scale cleavage products, using a WatersTM 
600 Controller and Pump, a WatersTm 486 Tunable absorbance Detector measuring at 
214 nm and Millenium software. A Phenomenex Sphereclone 5 p. ODS(2) 250 x 10.0 
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mm colunm was used as the stationary phase eluting with a H 20/MeCN gradient 
(Table 9) at a flow rate of 5 ml min- '. Retention times (R 1) are quoted in minutes. 
Time (mm) H20 MeCN 
0 30% 70% 
2 30% 70% 
12 10% 90% 
13 10% 90% 
13.5 30% 70% 
15 30% 70% 
Table 10 HPLC gradient 
6.5 Synthesis of Resin-Bound HMPA Linker (PS-HMPA) (47) 
6.5.1 Methyl-4-(hydroxymethyl) phenoxyacetate (48) 
101,~OH 
Anhydrous potassium carbonate (5.00 g, 0.04 mole) and sodium iodide (1.20 g, 8.0 
mmol) were suspended in anhydrous DMF (10 ml). To this solution was added a 
solution of 4-hydroxybenzyl alcohol (5.00 g, 0.04 mmol) in DMF (30 ml), dropwise 
(exothermic), with stirring. Methyl bromoacetate (4.25 ml, 0.05 mmol) was added 
dropwise and the suspension left to stir under an inert atmosphere (>15 h). The 
reaction was quenched with H 20 (100 ml) and saturated ammonium chloride (100 
ml). The product was taken up with chloroform (3 x 200 ml) and the combined 
extracts washed alternately with saturated sodium thiosulfate (2 x 400 ml), H20(2 x 
400 ml) and brine (2 x 400 ml). After drying (Na 2SO4), the solvent was removed 
under reduced pressure to yield the crude product as a yellow oil. Purification by 
column chromatography, eluting with EtOAc/light petroleum (2:3), furnished the 
title compound as a white solid (5.95 g, 76 %). 
Rf (EtOAc/light petroleum, 1:2) 0.19; Mp 46-47 °C; (Found: C, 61.55; H, 6.13; 
C 10H 1204 requires C, 61.22; H, 6.16); Vmax  (thin film)/cm' 3252 (OH), 1770 (C=O), 
1614, 1587 & 1515 (aromatic CC), 842, 820 or 810 (p-disubstituted Ar-H); 8 H (250 
102 
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MHz, CDC1 3) 2.04 (1H, br s, OH), 3.77 (3H, s, OCH3), 4.57 (2H, s, CH20H), 4.60 
(2H, s, COCH20), 6.82 (2H, d, J 9.0, 2 x m-ArHCH20H), 7.26 (2H, d, J 9.0, 2 x o-
ArHCH20H); & (63 MHz, CDC1 3) 52.1 (OCH3), 64.6 (CH20H), 65.1 (COCH20), 
114.4 (2 x m-ArHCH 20H), 128.5 (2 x o-ArHCH20H), 134.2 (ArCH20H), 157.1 
(ArOCH2), 169.3 (COOCH3); Found (FAB) W 196.07369, C 10H 1204 requires 
196.07356. 
6.5.2 4-(Hydroxymethyl)-phenoxyacetic acid 49 
OH 
To a solution of ester 48 (2.00 g, 10.20 mmol) in THF (150 ml), was added a 4 M 
solution of lithium hydroxide monohydrate (26 ml, 0.10 mole) and the resulting 
solution stirred at room temperature until tic analysis (EtOAc/light petroleum, 1:2) 
indicated disappearance of starting material (30 mm). The solution was acidified by 
addition of 2 M HC1 and the product extracted with EtOAc (3 x 300 ml). The 
combined organic extracts were washed with brine (2 x 300 ml), dried (Na 2 SO4) and 
concentrated. The crude solid was recrystallised from minimum boiling EtOAc, to 
furnish the title compound as white crystals (0.77 g, 41 %). 
Mp 110-111°C, Lit. 116  110.5-112°C; (Found: C, 59.60; H, 5.56; C9H, 004 requires C, 
59.34; H, 5.53); Vmax (KBr)/cm' 3539 & 3379br (alcohol & acid OH), 1718 (C0), 
1610, 1588 & 1514 (aromatic C=C), 856, 841 or 825 (p-disubstituted Ar-H); oH  (250 
MHz, CD30D) 4.62 (2H, s, CH20D), 4.73 (2H, s, CH2OAr), 7.00 (2H, d, J 9.0, 2 x 
m-ArHCH 20D), 7.37 (2H, d, J 9.0, 2 x o-ArHCH20D); Oc  (63 MHz, CD30D) 62.9 
(CH20D), 64.0 (COCH 20), 113.6 (2 x m-ArHCH 20D), 127.7 (2 x o-ArHCH 20D), 
133.7 (ArCH 20D), 156.9 (ArOCH 2), 170.8 (CH2COOD); Found (FAB) M 
182.05775, C9H 1004 requires 182.05791. 
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6.5.3 4- (4'-(Hydroxymethyl)-phenoxyacetoxymethyl] -phenoxyacetyl 
aminomethyl polystyrene 50 
0 
jo"'~ 	IC,~ t0H 
0 
Typical procedure" - a solution of 4-(hydroxymethyl)-phenoxyacetic acid (49) 
(1.64 g, 9.0 mmol), HOBt (1.22 g, 9.0 mmol) and DIC (1.41 ml, 9.0 mmol) in 
DCM/DMF (1:1, 40 ml) was added to a suspension of aminomethylated polystyrene 
resin (1.0 no1/g - 4.50 g, 4.5 mmol) in DCM (100 ml). The reaction was 
agitated at room temperature (>15 hours). A small sample (20 mg) of resin was 
withdrawn and washed with EtOH (x 3), dried and analysed for the presence of free 
amine using both the Kaiser and TNBS tests (6.3.3.1 & 6.3.3.2). Upon observation of 
a negative resultt,  the full resin sample was filtered, washed according to standard 
protocol and dried to a constant weight under vaccuum. 
Vmax  (DCM)/cm' 3601 & 3428 (OH & NH), 1757 (ester C=O), 1679 (amide I C=O), 
1612, 1602 (aromatic C=C), 1512 (amide II NH), 1493 (aromatic C=C), 829 (p -
disubstituted Ar-H); ö (63 MHz, CD 2C12, gel) 42.9 (CH 2NH), 64.5 (CH20H), 65.4 
(CH2000), 66.7 (OCOCH 20), 67.6 (NHCOCH20), 114.6. & 114.7 (2 x m-
ArHCH 20), 128.2 (ArCH2000 obscured by broad resin signal), 128.6 (2 x o-
ArHCH 20H), 130.4 (2 x o-ArHCH 2000), 134.9 (ArCH 20H), 157.3 & 158.2 (2 x 
ArOCH 2), 168.9(2 x COCH20). 
6.5.4 4-(Hydroxymethyl)-phenoxyacetyl aminomethyl polystyrene 47 
Typical procedure - resin-bound ester (50) (assume : ~ 1.0 mmol/g - 6.22 g, :!~ 6.22 
mmol) was suspended in DMF (60 ml). Hydrazine monohydrate (15.1 ml, 0.31 




mole) was added to the slurry and the reaction mixture agitated at room temperature 
(>15 hours). A small portion (20 mg) of resin was withdrawn, washed: THF (x 2); 
DMF(x 2); DMF/MeOH (1:1) (x 2); DMF/H 20 (1:1) (x 2); DMF/MeOH (1:1) (x 2); 
DMF(x 2); THF (x2); DCM (x 2); and analysed by IR. Disappearance of the strong 
ester stretch (Vm 1757 cm') indicated complete hydrolysis. After filtration the full 
resin sample was washed as above and dried to constant weight. 
Vmax  (DCM)/cm' 3603 & 3427 (OH), 1679 (amide I C=O), 1602br (aromatic C=C), 
1532 (amide II NH), 1510 (aromatic C=C), 830 (p-disubstituted Ar-H); $ (63 MHz, 
CD2C12, gel) 42.7 (CH2NH), 64.3 (CH20H), 67.6 (NHCOCH20), 114.7 (2 x m-
ArHCH 20), 128.7 (2 x o-ArHCH 20H), 135.5 (ArCH 20H), 156.7 (ArOCH 2), 168.2 
(COCH2O). 
6.6 Preparation of Resin-Bound 5(411)-oxazolones 55a-b Using Free 
Amino Acids 
6.6.1 General Procedure for Activation of Linkers 47" & 46 
A solution of p-nitrophenyl chloroformate (3 eq) in dry DCM, was added to a 
suspension of the resin-bound linker (1 eq) in dry DCM. Anhydrous pyridine (3 eq) 
was added and the reaction agitated under an atmosphere of argon (>15 h). An 
aliquot (-20 mg) of resin was withdrawn, washed according to the standard protocol, 
dried and analysed by JR. Upon observation of a strong carbonate stretch (Vmax  —1767 
cm') the entire sample was filtered and washed thoroughly in the usual manner. 
6.6.2 4-[Hydroxymethyl-(4'-nitrophenylcarbonate)] -phenoxyacetyl 




The general procedure (6.6.1) detailed above, was followed using p-nitrophenyl 
chloroformate (2.78 g, 13.8 mmol) in DCM (40 ml), PS-HMPA (47) (assume ! ~ 1.0 
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mmollg - 4.6 g, :~4.6 mmol) in DCM (20 ml) and anhydrous pyridine (1.21 ml, 13.8 
mmol). A strong carbonate stretch (Vmax  1767 cm- ') present in the JR spectrum of the 
small aliquot of resin indicated success and the entire sample was filtered and 
washed thoroughly. Gel phase ' 3C NMR indicated complete conversion to the 
desired resin-bound carbonate (53). 
Loading 1.0 mmol/g (p-nitro), 100 %*; Vmax  (DCM)/cm' 3430 (NH), 1767 
(carbonate C=O), 1681 (amide I C=O), 1596 (aromatic C=C), 1529 (asymmetric 
NO2), 1513 (amide II NH), 1493 (aromatic C=C), 1349 (symmetric NO 2), 864 (p-
disubstituted p-nitro Ar-H), 834 (p-disubstituted Ar-H); ö (63 MHz, CDC1 3 , gel) 
42.5 (CH2NH), 67.2 (CH20A0, 70.3 (CH2000), 114.7 (2 x m-ArHCH 20), 121.5 (2 
x m-ArHNO 2), 125.1 (2 x o-ArHNO 2), 130.6 (2 x o-ArHCH 20), 145.1 (ArNO 2-
obscured by broad polymer peak), 152.2 (ArOCO), 155.2 (ArOCH 2), 157.5 (OCOO), 
167.4 (NHCO). 
6.6.3 4(NaMethoxycarbonylvalylphenyla1anine)phenoxyacetyl  aminomethyl 
polystyrene 54a - via direct dipeptide coupling 
oV 0 
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Valinyiphenylalanine (250 mg, 0.95 mmol) was dissolved in DMF (10 ml) using 
BSA (0.59 ml, 2.40 mmol) and sonication (:!~ 60 °C). 107  This solution was added to 
activated resin (53) (-1.0 mmollg - 240 mg, —0.24 mmol) followed by a solution of 
DMAP (59 mg, 0.48 mmol) in DMF (0.5 ml). The resin suspension was spun at 
room temperature (>15 h). The resin was filtered and washed according to the 
standard protocol and dried under vacuum. JR analysis indicated successful coupling 
due to the disappearance of the distinctive carbonate stretch (Vmax  1767cm- '). Gel 
phase ' 3C NMR analysis gave a very broad spectrum, which proved difficult to 
interpret but indicated that the desired product was indeed present but impure. 
Vmax  (DCM)/cm' 3425 & 3321 (2° amide & urethane NH), 1682br (urethane, acid & 
2 x amide I CO), 1602br (aromatic C=C), 1504br (2 x amide II NH & aromatic 
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C=C), 830 (p-disubstituted Ar-H); & (63 MHz, CD 2C121  gel) 17.9 (CH(C4H3CBH3)), 
19.2 ((CH(CAH3 CBH3)), 31.1 (CH(CH3)2), 40.7 (CH2Ph obscured by broad polymer 
signal), 53.6 (CHCH2Ph obscured by solvent), -61br (CHCH(CH 3)2), 64.3 
(unknown), 67.5br (COCH20 & CH2000NH), 114.7 (2 x m-ArHCH20)1  128.2br (all 
other aromatics obscured by broad polymer signal); Cleavage 9:10:1 
TFA/DCMIH20: m/z (ES-MS) 265 (MW), 287 (MNa). 
6.6.4 (1'S, 4' 'RS)-4- IN-Methoxycarbonyl-2'-methyl-1 '-(4' '-benzyl-5' '-oxo-4' ',5' '-
dihydro-oxazol-2' '-yl)-aminopropyl] -phenoxyacetyl aminomethyl polystyrene 
55a - derived from dipeptide coupling 
Resin-bound dipeptide (54a) (assume :! ~ 1 mmol/g - 164 mg, :!~ 0.16 mmol) was 
allowed to swell in DCM (8 ml), before addition of EDCI (92 mg, 0.48 mmol). The 
resulting suspension was spun at room temperature (15 h). The resin was filtered and 
washed according to the standard protocol, before drying under vacuum. Analysis by 
IR confirmed the presence of the desired oxazolone (Vmax  1 824cm'). Gel phase 13 C 
NMR analysis indicated the title compound was present as a mixture of 
diastereomers, but extra peaks and the general broad quality of the spectrum 
suggested that the product was not pure. 
Vmax  (DCM)/cm' 3427 (2° amide & urethane NH), 1825 (oxazolone C=O), 1722 
(urethane C=O), 1680 (amide I C=O), 1602 (aromatic C=C), 1510 (amide II NH), 
1494 (aromatic C=C), 828 (p-disubstituted Ar-H); o (63 MHz, CD2C12, gel) 16.9 & 
17.5 (CH(C4H3CBH3)),  18.8 & 19.2 ((CH(CAH3CBH3)),  30.6 (2 x CH(CH3)2), 36.7 & 
36.8 (2 x CH 2Ph), 55.1 & 55.5 (2 x CHCH2Ph), 64.3 (unknown), 65.7 & 65.8 (2 x 
CHCH(CH3)2), 66.7 (COCH 20), 67.2 & 67.6 (2 x CH2000NH), 114.7 (2 x m-
ArHCH20), 127.4 (ArH Phe), 128.6 (2 x ArH Phe), 129.8 (2 x ArH Phe), 135.3 (ipso- 
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C Phe); Cleavaget  9:10:1 TFA/DCMIH20: m/z (ES-MS) 247 (MW), 265 (MW + 
H20), 287 (MNa + H20). 





L-Valine (1.87 g, 16 mmol) was dissolved in DMF (115 ml) with the help of BSA 
(9.89 ml, 40 mmol) and sonication at elevated temperature (:! ~ 60 1C).107  After adding 
activated resin 53 (-'1.0 mmol/g - 4.0 g, -4.0 mmol) along with a solution of DMAP 
(0.98 g, 8.0 mmol) in DMF (5 ml), the suspension was agitated at room temperature 
(>15 h). A small sample of resin was withdrawn from the bulk reaction, washed 
according to standard protocol, dried and analysed by JR. Disappearance of the 
distinctive carbonate stretch (Vmax  1767cm') indicated successful coupling, allowing 
the main resin sample to be filtered and washed accordingly. After drying, analysis 
by JR, gel phase ' 3C NMR and after cleavage, ES-MS indicated the presence of the 
desired product. However, the poor quality of the spectra obtained implied that it was 
not pure. 
Vmax  (DCM)/cm' 3424 & 3329 (2° amide & urethane NH), 173 lbr (urethane & acid 
C0), 1673br (amide I C=O), 1602 (aromatic C=C), 1504br (2 x amide II NH & 
aromatic C=C), 827 (p-disubstituted Ar-H); Ei (63 MHz, CDC1 31  gel) 17.5 or 17.9 
(CH(C4H3CBH3)) , 19.3  ((CH(CAH3CBH3)),  31.2 (CH(CH 3)2), 59.8br (CHCH(CH3)2), 
64.2 (unknown), 66.6 (COCH 20), 67.5 (CH2000NH), 114.7 (2 x m-ArHCH 20), 
134.2 (2 x o-ArHCH 20), 156.8br (OCONH), 168.5br (NHCOCH 20), 174.9br 
(COOH); Cleavage 9:10:1 TFA/DCMIH 20: m/z (ES-MS) 118 (MW). 
treatment with TFA results in almost complete hydrolysis of the 5(4H)-oxazolone 
W. 
Experimental 
6.6.6 4- [N'-Methoxycarbony1valyloxycarboxy-4 '-(nitrophenoxy)] - 




A solution of p-nitrophenyl chloroformate (1.08 g, 5.37 mmol) in anhydrous DCM 
(18 ml), was added to a suspension of 56 (assume : ~ 1.0 mmol/g - 1.79 g, :!~ 1.79 
mmol) in dry DCM (6 ml). Anhydrous pyridine (0.43 ml, 5.37 mmol) was added 
slowly (exothermic) and the reaction agitated at room temperature, under argon (>15 
h). An aliquot of resin was removed and washed according to the standard protocol. 
Analysis, by IR, of the dried sample indicated the presence of a nitro group and 
strong carbonyl stretches, accordingly the bulk reaction was drained, washed and 
dried to constant weight. Analysis by gel phase ' 3C NMR resulted in a broad 
spectrum, which proved difficult to interpret, however, diagnostic peaks have been 
selected and the proposed assignments detailed below. 
Loading 0.71 mmol/g (p-nitro), 82%; Vmax  (DCM)/cm' 3429 (2° amide & urethane 
NH), 1767 & 1723 (mixed anhydride of carbonic acid & urethane C=O), 1681 
(amide I C=O), 1614 & 1602 (aromatic C=C), 1524 (asymmetric NO 2), 1513 (amide 
II NH), 1493 (aromatic C=C), 1348 (symmetric NO 2), 864 (p-disubstituted p-nitro 
Ar-H), 832 (p-disubstituted Ar-H); o (63 MHz, CDC13, gel) 17.5 & 17.8 (2 x 
CH(CAH3CBH3)) ,  18.8 & 19.1 (2 x CH(CAH3CBH3)),  31.Obr (CH(CH 3)2), 42.6 
(CH2NH), 46.1 (unknown), 55.6, 59.7 or 60.5 (CHCH(CH 3 )2), 66.7 (unknown), 67.5 
(COCH20), 70.6 (CH2000NH), 114.8 (2 x m-ArHCH 20), 116.0 & 122.0 
(unknown), 122.5 (2 x m-ArHNO 2), 125.3 (2 x ArHNO 2), 130.1 (2 x o-ArHCH 20), 
141.9br (ArNO 2); Cleavage 9:10:1 TFA/DCM/H 20: m/z (ES-MS) 239 (MW-0O2). 
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6.6.7 4(NaMethoxycarbonylva1y1phenyalanine)phenoxyacety1 aminomethyl 
polystyrene 54b - via stepwise coupling 
00 
 
OAN N OH 
H 
N -Jr'O ji:~r 
L-Phenylalanine (344 mg, 2.08 mmol) was dissolved in DMF (10 ml), with the help 
of BSA (1.29 ml, 5.20 mmol) and sonication (3 h). 107  PS-HMPA-Val (56) (-0.6 
mmol/g - 860 mg, —0.52 mmol) was allowed to swell in this solution before addition 
of DMAP (127 mg, 1.04 mmol) and the resulting suspension was shaken at room 
temperature (>15 h) . The yellow reaction solution was drained off and the resin 
washed according to the standard protocol. After drying, analysis by gel phase ' 3C 
NMR, IR and, after cleavage, ES-MS did indicate the presence of the title 
compound. However, the quality of spectra obtained suggested that 54b was present 
as the major product in a mixture of several by products leading to some difficulties 
in interpretation and assignment. ' 3C NMR peaks have been assigned as far as 
possible. 
Vmax  (DCM)Icm t 3426 & 3334 (2° amide & urethane NH), 168 lbr (urethane, acid & 
2 x amide I C=O), 1614 & 1602 (aromatic C=C), 1504br (2 x amide II NH & 
aromatic C=C), 823 (p-disubstituted Ar-H); ö (63 MHz, CD2C12, gel) 17.9 
(CH(C4H3 CBH3)) , 19.3  ((CH(CAH3CBH3)),  31.2 (CH(CH3)2), 40.7 (CH2Ph partially 
obscured by broad polymer signal), 53.6 (CHCH 2Ph obscured by solvent), 60.7br 
(CHCH(CH3)2), 64.3 (unknown), 66.6 (COCEI20), 67.6 (CH2000NH), 114.8 (2 x m-
ArHCH20), 128.5 & 129.7 (5 x ArH Phe obscured by broad polymer signal), 134.2 
(2 x o-ArHCH 20), 156.4br (OCONH), 174.4br (COOH); Cleavage 9:10:1 
TFAIDCMIH20: m/z (ES-MS) 265 (MW), 287 (MNa). 
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6.6.8 (1'S, 4"RS)-4-[N-Methoxycarbonyl-1 '-(4' '-benzyl-S' '-oxo-4' ',5"-dihydro-
oxazol-2' '-yl)-2 '-methyl-aminopropylJ-phenoxyacetyl aminomethyl polystyrene 
55b - derived from stepwise coupled dipeptide 




PS-HMPA-Val-Phe (54b) (assume : ~ 0.6 mmol/g - 0.54 g, :~ 0.33 mmol) was allowed 
to swell in DCM (4 ml), before addition of EDCI (0.19 g, 0.99 mmol). The reaction 
was spun at room temperature (>15 h). A small sample of resin was withdrawn, 
washed according to standard lab protocol and dried. Analysis by JR showed a 
stretch at Vmax  1824cm', indicative of the 5(411)-oxazolone carbonyl group. The 
remaining resin was filtered, washed according to general procedure and dried. 
Subsequent analysis indicated that the desired product had indeed been formed, 
however, ' 3C NMR spectral data was of poor quality due to the impurity of the final 
product and was too broad to derive any meaningful data. 
Vmax  (DCM)/cm' 3427 (2° amide & urethane NH), 1824 (oxazolone C=O), 1716 
(urethane C=O), 1682 (amide I C=O), 1602 (aromatic C=C), 1530 & 1511 (2 x 
amide II NH), 1494 (aromatic C=C), 827 (p-disubstituted Ar-H); Cleavaget  9:10:1 
TFA/DCMIH20: m/z (ES-MS) 265 (MH + H20). 
6.6.9 General procedure for BSA-assisted coupling of free amino acids 58a-d 1 °7 
Unprotected L-amino acidldipeptide (4 eci) was dissolved in DMF (4 ml), with the 
help of BSA (10 eq) and sonication (:! ~60°C). PS-HMPA-Val (56) (- 0.7 mmollg, 1 
eq) was allowed to swell in this solution before addition of a solution of DMAP (4 
eq) in DMF (1 ml). The reaction was spun at room temperature (>15 h), before being 
filtered and washed according to standard protocol. 
treatment with TFA results in almost complete hydrolysis of the 5(4H)-oxazolone 
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6.6.10 4(NaMethoxycarbonylva1y1valine)phenoxyacety1 	aminomethyl 
polystyrene 58a 
0 	 0 
N 
The general procedure outlined above (6.6.9) with L-valine (66 mg, 0.56 mmol) and 
a further portion of DMF (1 ml) to aid dissolution. 
Vmax (DCM)/cm' 3427 & 3316 (2 x amide & urethane NH), 1682br & 1652br 
(urethane, acid & 2 x amide I C=O), 1 602br (aromatic C=C), 1 504br (2 x amide II & 
aromatic C=C); Cleavage 9:10:1 TFAJDCM/H 20: m/z (ES-MS) 217 (MW); other 
products tabulated in results and discussion (Table 1). 
6.6.11 4(NaMethoxycarbony1va1y1pheny1alanine)phenoxyacetyl aminomethyl 
polystyrene 58b 
r0 01 
The general procedure detailed previously (6.6.9) with L-phenylalanine (93 mg, 0.56 
mmol). 
Vmax (DCM)/cm' 3426 & 3317 (2 x amide & urethane NH), 1682br (urethane, acid & 
2 x amide I C=O), 1602br (aromatic C=C), 1493br (2 x amide II & aromatic C=C); 
Cleavage 9:10:1 TFAIDCIVI/H 20: m/z (ES-MS) 265 (MW); other products tabulated 
in results and discussion (Table 1). 
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The general procedure outlined previously (6.6.9) with L-leucine (37 mg, 0.28 
mmol). 
Vmax  (DCM)/cm' 3427 & 3316 (2 x amide & urethane NH), -'1680br & 1652br 
(urethane, acid & 2 x amide I C=O), 1602br (aromatic C=C), 1504br (2 x amide II & 
aromatic C=C); Cleavage 9:10:1 TFA!DCMIH 20: m/z (ES-MS) 231 (MW); other 
products tabulated in results and discussion (Table 1). 
6.6.13 4(NaMethoxycarbony1valy1serine)phenoxyacetyl 	aminomethyl 
polystyrene 58d 
00 
OANNOH~(r - H ° 
	
OH 
The general procedure outlined above (6.6.9) with L-serine (29 mg, 0.28 mmol). 
Vmax  (DCM)/cm' 3427 & 3317br (2 x amide & urethane NH & OH), 1682br & 
1651br (urethane, acid & 2 x amide I C=O), 1603br (aromatic C=C), -4500br (2 x 
amide II & aromatic C=C); Cleavage 9:10:1 TFAIDCM/H 20: m/z (ES-MS) 205 




aminomethyl polystyrene 58e 
0 	 0 
OAN N N OH 
( 	H 	ii 	 H 	 H 
0 	 0 
The general procedure detailed previously (6.6.9) with valinylphenylalanine (71 mg, 
0.27 mmol). 
Vmax (DCM)/cm' 3426 & 3316 (3 x 2° amide & urethane NH), -'1680br & 1651 br 
(urethane, acid & 3 x amide I C0), 1602br (aromatic C=C), 1504br (3 x amide II & 
aromatic C=C); Cleavage 9:10:1 TFA/DCMIH 20: m/z (ES-MS) 364 (MH); other 
products tabulated in results and discussion (Table 1). 
6.7 Preparation of Building Blocks for Inverse Peptide Synthesis 
using OFm Ester Methodology 
6.7.1 General procedure for OFm ester protection of Boc-amino acid 
derivatives' 2 ' 
Boc-amino acid derivative (1 eq), 9-fluorenylmethanol (2 eq) and catalytic DMAP (1 
%) were dissolved in anhydrous DCM (3-5 ml!mmol) and cooled (iceIH 20 bath). 
DIC (2 eq) was added dropwise, with stifling to the cooled solution. The reaction 
was continued until complete conversion of starting amino acid, as indicated by tic. 
The white urea precipitate was then filtered off and washed with DCM. The filtrate 
and washings were combined and washed consecutively with H 20 (x 2), saturated 
sodium bicarbonate (x 2), and 10 % citric acid (x 2), then alternately with H 20 (x 2) 
and brine (x 2). The organic layer was separated, dried (Na 2SO4), filtered and 
concentrated. The crude product was then carried straight through to the TSA salt 
(65a-e) unless otherwise stated. 
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The general procedure outlined above (6.7.1) was followed using Boc-phenylalanine 
(2.50 g, 11.5 mmol), 9-fluorenylmethanol (4.51 g, 23 mmol), DMAP (12 mg, 0.1 
mmol), DCM (40 ml) and DIC (3.60 ml, 23 mmol). The crude product was purified 
by column chromatography, eluting with hexane/EtOAc (5:1). Recrystallisation of 
the combined fractions with hot hexane/EtOAc (5:1) furnished the title compound as 
white crystals (3.05 g, 60%). 
Rf (Hexane:EtOAc, 5:1) 0.18; Mp 126-127 °C, Lit. 162 126-127°C; (Found: C, 76.01; 
H, 6.50; N, 3.24; C 28H29N04 requires C, 75.82; H, 6.59; N, 3.16); [a]21  -6 (c 1.00, 
CHC13), Lit.125 [a]21D  -6 (c 0.84, CHC1 3); V max (thin film)/cm' 3364br (NH), 1742 
(ester C=O), 1712 (urethane C=O), 1605 (aromatic C=C), 1498br (amide II & 
aromatic C=C), 758 & 701 (monosubstituted Ar-H), 740 (o-disubstituted Ar-H); oH 
(250 MHz, CDC1 3) 1.46 (9H, s, C(CH3)3), 3.02 (1H, dd, J 14.0, 6.5, CHCHA HBPh), 
3.10 (1H, dd, J 14.0, 6.5, CHCHAHBPh), 4.16 (1H, t, J7.0, OCH2CH), 4.44 (2H, d, J 
7.0, OCH2CH), 4.70 (1H, br dt, J 8.0, 6.5, NHCHCH 2Ph), 5.06 (1H, br d, J 8.5, 
NHCHCH2), 7.12-7.15 (2H, m, An]), 7.21-7.36 (5H, m, ArH), 7.43 (2H, t, J 7.5, 
An]), 7.53-7.58 (2H, in, An]), 7.78 (2H, d, J 7.5, An]); O (63 MHz, CDC1 3) 28.1 
(C(CH 3)3), 38.1 (CHCH 2Ph), 46.5 (OCH 2 CH), 54.3 (CHCH 2Ph), 66.9 (OCH 2CH), 
79.8 (OC(CH3)3)
1 
 119.8 (2 x ArH OFm), 124.8 (ArH OFm), 124.9 (ArH OFm), 126.9 
(ArH Phe), 127.0(2 xArH OFm), 127.7(2 xArH OFm), 128.4(2 xArH Phe), 129.1 
(2 x ArH Phe), 135.8 (ipso-C Phe), 141.1 (2 x C OFm), 143.2 (C OFm), 143.3 (C 





Improved yield, over two steps, when the general procedure outlined above (6.7.1) 
with Boc-phenylalanine (6.10 g, 23 mmol), 9-fluorenylmethanol (9.03 g, 46 mmol), 
DMAP (24 mg, 0.2 mmol), DCM (80 ml) and DIC (7.20 ml, 46 mmol), was 
followed and the crude product deprotected and carried through to the TSA salt (65a) 
without any further purification. 




The general procedure outlined above (6.7.1) was followed with Boc-valine (5.0 g, 
23 mmol), 9-fluorenylmethanol (9.03 g, 46 mmol), DMAP (24 mg, 0.2 mmol), DCM 
(80 ml) and DIC (7.20 ml, 46 mrnol), to furnish the title compound as a yellow/white 
solid. The crude product was deprotected and carried through to the TSA salt (65b) 
without any further purification. 
6.7.4 9-Fluorenylmethyl Na(tertbutoxycarbony1)g1ycinate 64c 
H 7 O N 
0 
The general procedure outlined above (6.7.1.) with Boc-glycine (4.03 g, 23 mmol), 
9-fluorenylmethanol (9.03 g, 46 mmol), DMAP (24 mg, 0.2 mmol), DCM (80 ml) 
and DIC (7.20 ml, 46 mmol), was followed to furnish the crude title compound as a 
yellow/white solid. The crude product was deprotected and carried through to the 
TSA salt (65c) without any further purification. 
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The general procedure outlined above (6.7.1) was followed with Boc-leucine (2.03 g, 
8.7 mmol), 9-fluorenylmethanol (3.41 g, 17.4 mmol), DMAP (10 mg, 0.01 mmol), 
and DIC (2.73 ml, 17.4 mmol), to furnish the crude title compound which was 
deprotected and carried through to the TSA salt (65d) (without any further 
purification. 
6.7.6 9-Fluorenylmethyl Na(tertbutoxycarbonyl)alaninate4 W 64e 
0 I 
The general procedure outlined above (6.7.1) was followed with Boc-alanine (1.97 g, 
10.4 mmol), 9-fluorenylmethanol (4.08 g, 20.8 mmol), DMAP (12 mg, 0.10 mmol), 
and DIC (3.25 ml, 20.8 mmol), to furnish the crude title compound which was 
deprotected and carried through to the TSA salt (65e) without any further 
purification. 
6.7.7 General procedure for preparation of ammonium salts of amino acid 9-
fluorenylmethyl ester tosylates 125 
The crude, or otherwise, Boc-amino acid fluorenylmethyl ester (1 eq) was treated 
with TFA (1-4 ml/mmol) with stirring for 15-20 mi p-Toluene sulfonic acid 
(TSA) (1.15 eq) was added along with, where necessary, extra TFA to aid 
dissolution. After stirring for a further 5 mm, the TFA was removed under reduced 
pressure and the resulting oil triturated with copious ether to yield the desired salt. 
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6.7.8 9-Fluorenylmethyl Na(tosy1ate)pheny1a1aninate  65a 




The general procedure outlined above (6.7.7) was followed using purified Boc-Phe-
OFm (64a) (2.92 g, 6.58 mmol), TFA (25 ml) and TSA (1.44 g, 7.57 mmol), to 
afford the title compound as a white solid (3.25 g, 96 %). 
6.7.8.2 
The general procedure outlined above (6.7.7) was followed using crude Boc-Phe-
OFm (64a) (23 mmol), TFA (25 ml) and TSA (5.03 g, 26.45 mmol), to afford the 
title compound as a white solid (10.85 g, 91 % over two steps). 
Mp 199-201 °C, Lit. 125 210-212'C; (Found: C, 69.53; H, 5.67; N, 2.81; C 30H29N05 S 
requires C, 69.88; H, 5.67; N, 2.72); [a]20  -41 (c 1.00, MeOH); Vmax  (KBr)/cm' 1740 
(ester C=O), 1609br (aromatic C=C), 1209br & 1036 (SO 3 ), 814 (p-disubstituted Ar-
H), 759, 740, 699, & 681 (mono- & o-di-substituted Ar-H); 8H  (250 MHz, DMSO d6) 
2.27 (3H, s, CH3Ar), 2.97c  (2H, m, CHCHAHBPh), 4.14 (1H, bt, J 6.5, OCH2CII), 
4.43-4.41 (2H, m, OCHA HBCH & CHCH2Ph), 4.59 (1H, dd, J 10.5, 6.0, 
OCHAHBCH), 7.09-7.16 (4H, m, An]), 7.21-7.63 (11H, m, An]), 7.86-7.90 (2H, m, 
ArH OFm), 8.51 (3H, bs, NH3 ); 6 (63 MHz, DMSO d 6  ) 20.9 (CH 3Ar), 36.0 
(CHCH2Ph), 46.1 (OCH2 CH), 53.3 (CHCH2Ph), 67.1 (OCH2CH), 120.3 (2 x ArH 
OFm), 125.2 (ArH OFm), 125.4 (ArH OFm), 125.7(2 xArH TSA), 127.3 (ArH Phe), 
127.4 (ArH OFm), 127.5 (ArH OFm), 128.0 (2 x ArH OFm), 128.3 (2 x ArH TSA), 
128.8 (2 x ArH Phe), 129.5 (2 x ArH Phe), 134.6 (ipso-C Phe), 138.2 (ArCH 3), 140.9 
(2 x C OFm), 143.2 (C4 OFm), 143.4 (C OFm), 145.3 (ArSO 3 ), 169.3 (COOCH 2); 
Found (FAB) MH 344.16555, C 23H22NO2 requires 344.16505. 
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6.7.9 9-Fluorenylmethyl Na(tosy1ate)va1inate 65b 
rN 
H3N 
The general procedure outlined above (6.7.7) was followed using crude Boc-Val-
OFm (64b) (-23 mmol), TFA (25 ml) and TSA (5.03 g, 26.45 mmol), to afford the 
title compound as a white solid (9.40 g, 87 % over two steps). 
Mp 172-174°C, Lit. 12 ' 179-180°C; [a]21  -14 (c 1.00, MeOH); Vmax  (KBr)/cm' 3447 
(NH), 1749 (ester C=O), 1617br (aromatic C=C), 1187br & 1036 (SO 3 -), 1011, 813 
(p-disubstituted Ar-H), 755, 741, 683, & 676 (mono- & o-di-substituted Ar-H); 8H 
(250 MHz, DMSO d 6) 0.55 (3H, d, J 7.0, CH(CAH3CBH3)),  0.63 (3H, d, J 7.0, 
CH(CAH3CBH3)) ,  1.80-1.88 (1H, m, CH(CH3)2), 2.27 (3H, s, CH3Ar), 3.75 (1H, bs, 
CHCH(CH3)2), 4.32 (1H, t,J5.0, OCH2CH), 4.60 (1H, dd,J 11.0, 5.0, OCHA HB CH), 
4.94(1H, dd,J 11.0, 5.0, OCHAHBCH), 7.12 (2H, d',J-8, ArHTSA), 7.29-7.45 (4H, 
m, ArH OFm), 7.50 (2H, dl ,  J —8, ArH TSA), 7.67-7.74 (2H, m, ArH OFm), 7.88 
(2H, ddd, J 6.5, 2.5, 1.0, ArH OFm), 8.29 (3H, bs, NH3 ); ö c (63 MHz, DMSO d6) 
17.1 (CH(CAH3CBH3)),  17.9 (CH(CAH3CBH3)),  20.9 (CH3Ar), 29.2 (CHCH(CH 3)2), 
46.4 (OCH2CH), 57.2 (CHCH(CH 3)2), 66.4 (OCH 2CH), 120.3 (2 x ArH OFm), 125.0 
(ArH OFm), 125.1 (ArH OFm), 125.7 (2 x ArH TSA), 127.3 (2 x ArH OFm), 127.9 
(2 x ArH OFm), 128.3 (2 x ArH TSA), 138.1 (ArCH 3), 141.1 (C4 OFm), 141.2 (C 
OFm), 143.4 (C OFm), 143.6 (C OFm), 145.4 (Ar50 3 ), 169.1 (COO); Found 
(FAB) MH 296.16375, C, 9H22NO2 requires 296.16505. 
6.7.10 9-Fluorenylmethyl N'-(tosy1ate)-g1ycinate 65c 




The general procedure outlined above (6.7.7) was followed using crude Boc-Gly-
OFm (64c) (-23 mmol), TFA (25 ml) and TSA (5.03 g, 26.45 mmol), to afford the 
title compound as a white solid (9.35 g, 96 % over two steps). 
Mp 147-150 °C; Vm , (KBr)/cm' 1760 (ester C=O), 1597br (aromatic C=C), 1216, 
1183 & 1033 (SO 3 -), 822 (p-disubstituted Ar-H), 759 & 744 (o-disubstituted Ar-H); 
5H (250 MHz, DMSO d 6 ) 2.26 (3H, s, CH3Ar), 3.92 (2H, bs, CH2COO), 4.29 (1H, t, J 
7.0, OCH2CH), 4.49 (1H, d, J 7.0, OCH2CH), 7.11 (2H, d', J -8, ArH TSA), 7.31-
7.46 (4H, m, ArH OFm), 7.53 (2H, d', J -8, ArH TSA), 7.71 (2H, br d, J 7.5, ArH 
OFm), 7.90 (2H, br d, J 7.0, ArH OFm); 8.32 (3H, bs, NH3'); O (63 MHz, DMSO 
d 6 ) 20.9 (CH3Ar), 39.9 (CH2COO), 46.1 (OCH2 CH), 67.0 (OCH 2CH), 120.4(2 xArH 
OFm), 125.4 (2 x ArH OFm), 125.7 (2 x ArH TSA), 127.4 (2 x ArH OFm), 128.0 (2 
x ArH OFm), 128.3 (2 x ArH ISA), 138.1 (ArCH 3), 140.9 (2 x C4 OFm), 143.4 (2 x 
C4 OFm), 145.3 (ArSO 3 ), 168.0 (COO); Found (FAB) MH 254.11848, C 16H16NO2 
requires 254.11810. 
6.7.11 9-Fluorenylmethyl 	 65d 
—--S? H3N 
~T 
The general procedure outlined above (6.7.7) was followed using crude Boc-Leu-
OFm (64d) (-8.7 mmol), TFA (20 ml) and TSA (2.15 g, 11.3 mmol), to afford the 
title compound as an off-white solid (3.25 g, 78 % over two steps). 
Mp 195-196°C (decomposes), Lit.  121 206-208°C; (Found: C, 67.25; H, 6.39; N, 2.79; 
C27H31N05 S requires C, 67.34; H, 6.49; N, 2.91); Vmax (KBr)/cm' 1750 (ester C=O), 
1224, 1189 & 1038 (SO3-), 814 (p-disubstituted Ar-H), 758 & 733 (o-disubstituted 
Ar-H); OH  (250 MHz, DMSO d6) 0.53 (3H, d, J 5.0, CH(CAH3CBH3)) ,  0.61 (3H, d, J 
5.0, CH(CAH3CBH3)),  1.08-1.31 (3H, m, CH2CH(CH3)2), 2.27 (3H, s, CH3Ar), 3.59-
3.84 (1H, m, obscured by H 2O in DMSO, CHCH2CH(CH3)2), 4.31 (1H, bs, 
OCH2CII), 4.62 (1H, dd, J 11.0, 4.5 OCHA HBCH), 4.95 (1H, dd, J 11.0, 4.5, 
OCHAHBCH), 7.12 (2H, br d, J 8.0, ArH ISA), 7.29-7.44 (4H, m, AsH OFm), 7.50 
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(2H, br d, J 8.0, ArH TSA), 7.65 (1H, br d, J 7.0, ArH OFm), 7.71 (1H, br d, J 7.0, 
ArH OFm), 7.88 (2H, br d, J 7.5, ArH OFm); 8.25 (3H, bs, NH3 ); 8 (63 MHz, 
DMSO d 6  ) 20.9 (CH 3Ar), 21.6 (CH(C4H 3CBH3)) , 22.3 (CH(CAH3 CBH3)) ,  23.4 
(CH(CH3)2), 39.1 (CH2CH(CH3)2), 46.5 (OCH2 CH), 50.5 (CHCH 2CH(CH 3)2), 66.3 
(OCH2CH), 120.3 (2 x ArH OFm), 124.9 (2 x ArH OFm), 125.6 (2 x ArH TSA), 
127.2 (ArH OFm), 127.3 (ArH OFm), 127.9 (2 x ArH OFm), 128.3 (2 x ArH TSA), 
138.1 (ArCH 3) 141.1 (C OFm), 141.2 (C OFm), 143.4 (C OFm), 143.6 (C OFm), 
145.4 (ArS0 3 ), 170.2 (COO); Found (FAB) MH 482.20052, C 27H32N05 S requires 
482.20012. 
6.7.12 9-Fluorenylmethyl N(tosy1ate)a1aninateA W 65e 
——so? H3JI12 
The general procedure outlined above (6.7.7) was followed using crude Boc-Ala-
OFm (64e) (--10.4 mmol), TFA (20 ml) and TSA (3.67 g, 19.32 mmol), to afford the 
title compound as a buff solid (4.56 g, 99 % over two steps). 
Mp 186-191°C (decomposes), Lit. 121  198-199°C; V max (KBr)/cm' 1751 (ester C=O), 
1214, 1163 & 1033 (SO 3 ), 817 (p-disubstituted Ar-H), 767 & 742 (o-disubstituted 
Ar-H); 8H  (250 MHz, DMSO d6) 1.14 (3H, d, J 7.0, CHCH3), 2.27 (3H, s, CH3Ar), 
4.05' (1H, m, CHCH3), 4.31 (1H, t, J 6.0, OCH2CI]), 4.50 (1H, dd, J 10.5, 6.0, 
OCHA HB CH), 4.73 (1H, dd, J 10.5, 6.0, OCHAHBCH), 7.12 (2H, dd, J 8.5, 0.5, ArH 
TSA), 7.30-7.45 (4H, m, ArH OFm), 7.52 (2H, d', J -8, ArH TSA), 7.65-7.72 (2H, 
m, ArH OFm), 7.90 (2H, br d, J 7.5, ArH OFm), 8.33 (3H, bs, NH3 ); ö (63 MHz, 
DMSO d6) 15.6 (CHCH 3), 20.9 (CH3Ar), 46.4 (OCH 2 CH), 48.0 (CHCH 3), 66.7 
(OCH2CH), 120.3 (2 x ArH OFm), 125.2 (2 x ArH OFm), 125.7 (2 x ArH TSA), 
127.4 (2 x ArH OFm), 128.0 (2 x ArH OFm), 128.3 (2 x ArH TSA), 138.2 (ArCH 3), 
141.0 (2 x C OFm), 143.3 (C OFm), 143.6 (C OFm), 145.3 (ArSO 3 ), 170.2 
(COO); Found (FAB) MH 268.133 16, C 17H 18NO2 requires 268.13375. 
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6.7.13 Potassium oxy-(benzotriazol-1-yl) (KOBt) 67 
BO: N 
C 
D 	0 	K 
Typical procedure - HOBt hydrate (:515% H 20) (12.69 g, 0.08 mole) was dissolved 
in absolute EtOH (750 ml). Potassium hydroxide pellets (4.48 g, 0.08 mmol) were 
added and stirring continued until complete dissolution was observed (--20 mm). The 
solvent was removed in vacuo to afford the title compound as a white solid (13.54 g, 
98 % yield). 
(Found: C, 42.02; H, 2.39; N, 24.56; C 6H4N20K requires C, 41.60; H, 2.33; N, 
24.26); Vmax  (KBr)/cm' 3056 (C-H Ar), 1611 (C=C Ar), 1449 (N-N), 1403 & 1383 
(N=N), 784, 762 & 725 (o-disubstituted Ar-H); 6 H  (250 MHz, DMSO d 
6  ) 7.01c  (2H, 
m, 2 x ArH B & C), 755C  (2H, m, 2 x ArH A & D); 6 (63 MHz, DMSO d 6) 112.2, 
117.9, 121.0 & 122.2 (4 x ArH), 127.3 & 143.0 (2 x ArH); Found (FAB) MH 
174.00670, C6H5N30K requires 174.00679. 
6.7.14 General procedure for exchange of amino acid TSA salts to HOBt salts 
KOBt (67) was dissolved in absolute methanol and added slowly to an equimolar 
solution of the ammonium salt of the-amino acid fluorenylmethyl ester tosylate, 
dissolved in absolute methanol. Precipitation of the potassium tosylate salt was 
facilitated by addition of diethyl ether. The salt was filtered and washed with ether, 
and the filtrate and washings combined and concentrated to dryness. When possible, 
trituration with copious ether furnished the desired HOBt salt which was filtered and 
dried, otherwise the crude product was used without any further purification. 
6.7.15 9-Fluorenylmethyl Na oxy (benzotriazo11 '-yl)-phenylalaninate 66a 
The general procedure outlined above (6.7.14) was followed using TSA-Phe-OFm 
(65a) (2.06 g, 4.0 mmol) and KOBt (0.69 g, 4.0 mmol) in methanol (80 ml). 
Trituration with copious ether furnished the desired salt as a chalky white solid (1.64 
g, 86 %). 
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6.7.16 9-Fluorenylmethyl Naoxy(benzotriazol1  '-yl)-valinate 66b 
The general procedure outlined above (6 .7.14) was followed using TSA-Val-OFm 
(0.5 g, 1.07 mmol) and KOBt (0.18 g, 1.07 mmol) in methanol (20 ml). 
Trituration with copious ether furnished the desired salt as a chalky white solid (0.26 
g, 56 %). 
6.7.17 9-Fluorenylmethyl Naoxy(benzotriazol_1  '-yl)-glycinate 66c 
The general procedure outlined above (6.7.14) was followed using TSA-Gly-OFm 
(1.70 g, 4.0 mmol) and KOBt (0.69 g, 4.0 mmol) in methanol (100 ml). 
Attempted trituration with copious ether lead to a sticky gum. On standing in ether 
the gum became more brittle and some solid salt was isolated, but in general the salt 
was freshly prepared and used directly, without trituration, as a solution in DMF. 
6.7.18 9-Fluorenylmethyl Naoxy(benzotriazo1_1  '-yl)-leucinate 66d 
The general procedure outlined above (6.7.14) was followed using a suspension of 
TSA-Leu-OFm (65d) (450 mg, 1.0 mmol) in methanol (65 ml) and KOBt (173 mg, 
1.0 mmol). After filtration of the potassium salt, concentration, followed by 
attempted trituration and standing in ether furnished an insoluble white solid (66 mg, 
17 %). It was concluded that this was not an efficient method for the preparation of 
this particular salt and an in situ exchange was attempted instead (6.8.13). 
6.8 Solid Phase Inverse Peptide Synthesis using Fm Ester 
Methodology 
6.8.1 General procedure for coupling of first amino acid 
Resin-bound activated carbonate (1 eq) was swollen in DMF before addition of a 
solution of the ammonium salt of the amino acid fluorenylmethyl ester tosylate (3 
eq) in DMF. A catalytic portion of DMAP (-1-10 %) was added to the resin slurry, 
along with NMM (3 eq). The reaction was spun at room temperature for >15 h 




aminomethyl polystyrene 68a 
The general procedure outlined above (6.8.1) was followed using resin-bound 
carbonate (53) (assume !! ~0.9 mmol/g- 0.60 g, 0.54 mmol) in DMF (4 ml), with TSA-
Val-OFm (65b) (0.76 g, 1.62 mmol) in DMF (6 ml), catalytic DMAP and NMM 
(178 p1, 1.62 mmol). Analysis indicated successful coupling to furnish the title 
compound. 
0.58 mmol/g (Fm), 95 %; Vmax (DCM)/cm' 3429 (NH), 1721 (ester & urethane 
C=O), 1677 (amide I C=O), 1602br (aromatic C=C), 1510 (amide II & urethane 
NH), 1493 (aromatic C=C); Ei (63 MHz, CD2C121  gel) 17.4 (CH(CAH3CBH3)),  19.0 
(CH(CAH3 CBH3)) ,  31.1 (CH(CH3)2), 42.8 (CH2NH), 47.0 (OCH2CH), 59.4 
(CHCH(CH3)2), 66.5 (CH2000NH), 66.8 (OGEI2CH), 67.6 (CH 2OAr), 114.8 (2 x m-
ArHCH20), 120.1 (2 x ArH OFm), 125.1 (2 x ArH OFm), 127.3 (2 x ArH OFm), 
127.9 (2 x ArH OFm), 130.1 (2 x o-ArHCH 20), 141.4 (2 x C OFm), 143.7 (2 x C 
OFm), 156.3 & 157.3 (ArOCH 2 & OCONH), 172.1 (COOCH2); Cleavage 9:10:1 
TFAIDCM/H20: LCMSA  R1 18.6 mm; m/z (ES-MS) 296 (MW). 
6.8.3 General procedure for coupling of second or subsequent amino acid 
Resin-bound amino acid fluorenylmethyl ester (1 eci) was deprotected with 20 % 
piperidine in DMF (3 x 10 ml/300 mg resin; 15 min ea), washed (DMF x 3) and 
neutralised with 3 % acetic acid in DCM (4 x 12 m11300 mg resin; 5 min ea). After 
washing (DMF x 3) the resin was treated with a solution of TBTU (8 eq) and NMM 
(8 eci) in DMF (15 ml/300 mg resin) for ~40 mm. The activated resin was filtered 
and washed (DMF x 3), before finally swelling in a solution of the HOBt ammonium 
salt of the amino acid fluorenylmethyl ester (6 eq) in DMF (15 m11300 mg resin). 
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The suspension was spun at ambient temperature (>15 h) before filtering, washing 
according to the standard protocol, and drying under vacuum. 
6.8.4 
phenoxyacetyl aminomethyl polystyrene 69a 
t--'& H 	H)(r 0" cir 
The general procedure outlined above (6.8.3) was followed using PS-HMPA-Val-
OFm (68a) (assume :0.9 mmol/g, 450 mg, 0.41 mmol), TBTU (1.04 g, 3.24 mmol), 
NMM (0.36 ml, 3.24 mmol) and HOBt-Phe-OFm (66a). Analysis of the isolated 
resin confirmed the presence of the title compound as a single diastereomer. 
0.57 mmol/g (Fm), 100 %*; Vmax  (DCM)/cm' 3426 & 3325br (2° amide & urethane 
NH), 1722br (ester & urethane C=O), 1674 (amide I C=O), 1602 (aromatic C=C), 
1514br (amide II & urethane NH), 1494 (aromatic C=C); ö (63 MHz, CD 2C12, gel) 
17.7 (CH(CAH 3CBH3)) ,  19.2 (CH(CAH3CBH3)),  31.2 (CH(CH3)2), 38.0 (CHCH2Ph), 
46.9 (OCH2CH), 53.6 (CHCH2Ph), 60.5 (CHCH(CH 3)2), 66.6 (CH2000NH), 67.3br 
(OCH2CH & CH2OAr), 114.8 (2 x m-ArHCH 20), 120.2 (2 x ArH OFm), 125.2 (2 x 
ArH OFm), 127.4(2 xArH OFm), 128.1 (2 xArH OFm), 128.7(2 xArH Phe), 129.5 
(2 x ArH Phe), 130.0 (2 x o-ArHCH 20), 136.2 (ipso-C Phe), 141.5 (2 x C'4 OFm), 
143.8 (2 x C OFm); Cleavage 9:10:1 TFA/DCM/H 20: LCMSA  R 20.4 mm (single 
diastereomer); m/z (ES-MS) 443 (MW), 465 (MINa). 
6.8.5 4-(Na-methoxycarbony1valylglycyIoxymethy1fluorenyl9?yl) 









The general procedure outlined above (6.8.3) was followed using resin-bound 
HMPA-Val-OFm (68a) (:~0.3 mmollg - 300 mg, 0.09 mmol), TBTU (231 mg, 0.72 
mmol), NMM (79 j.tl, 0.72 mmol) and a partial suspensiont  of HOBt-Gly-OFm (66c) 
(210 mg, 0.54 mmol) in DMF (15 ml). Analysis confirmed successful coupling of 
the glycine salt to furnish the title compound. 
Vmax (DCM)/cm' 3427 & 3332br (2° amide & urethane NH), 1748 (ester C=O) 1716 
(urethane C=O), 1 674br (2 x amide I C=O), 1602 (aromatic C=C), 151 2br (2 x amide 
II & urethane NH), 1494 (aromatic C=C); 6 (63 MHz, CDC1 3, gel) 18.3 
(CH(CAH3CBH3)), 19.9 (CH(CAH3CBH3)), 31.9 (CH(CH 3)2), 41.9 (NHCH 2CO), 47.3 
(OCH2CH), 60.7 (CHCH(CH3)2), 66.8 (CH2000NH), 67.7 (OCH2CH & CH20Ar), 
114.7 (2 x m-ArHCH 20), 120.2 (2 x ArH OFm), 125.2 (2 x ArH OFm), 127.4 (2 x 
ArH OFm), 128.0 (2 x ArH OFm), 130.0 (2 x o-ArHCH 20), 141.4 (2 x C4 OFm), 
143.8 (2 x C4 OFm), 156.6 & 156.7 (ArOCH2 & OCONH), 167.9 & 169.9 (2 x 
CONH), 172.0 (CH2 COO); Cleavage 9:10:1 TFA/DCMIH 20: LCMSA R 19.6 mm; 
m/z (ES-MS) 353 (MW). 
6.8.6 4(NaMethoxycarbonylvaly1glycylpheny1alanyloxymethylfluorenyl9t y1) 
phenoxyacetyl aminomethyl polystyrene 70 
0 
0 	 - 
N 
0 N 
)H 	 H 
The general procedure outlined above (6.8.3) was followed using PS-HMPA-Val-
Gly-OFm (69b) (-0.6 mmol/g - 215 mg, 0.13 mmol), TBTU (331 mg, 1.03 mmol), 
NMM (1.13 ml, 1.03 mmol) and a solution of HOBt-Phe-OFm (66a) (368 mg, 0.77 
mmol) in DMF (10 ml). Analysis confirmed successful coupling to furnish the 
desired resin-bound tripeptide (70) as a single diastereomer. 
Vmax (DCM)/cm' 3426 & 3325br (3 x 2° amide & urethane NH), 1715br (ester & 
urethane C0), 1682br (3 x amide I CO), 1602br (aromatic C=C), 1504br (3 x 
poor solubility leading to incomplete dissolution 
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amide II & urethane NH), 1494 (aromatic C=C); ö (63 MHz, CD 2C121  gel) 17.8 
(CH(C4H 3CBH3)) , 19.3  (CH(CAH3CBH3)),  31.3 (CH(CH3)2), 37.8 (CHCH 2Ph), 40.6 
(NHCH2CO partially obscured by broad polymer backbone), 46.8 (OCH 2CH), 53.8 
(CHCH2Ph), 60.4 (CHCH(CH 3)2), 66.5 (OCH2CH & CH2000NH), 67.2 (CH20A01 
114.8 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 125.2 (2 x ArH OFm), 127.4 (2 x 
ArH OFm), 128.0 (2 x ArH OFm), 128.6 (2 x ArH Phe), 129.4 (2 x ArH Phe & 2 x o-
ArHCH20), 136.3 (ipso-C Phe), 141.4 (2 x C OFm), 143.8(2 x C OFm); Cleavage 
9:10:1 TFAIDCM/H20: LCMSA  R1 24.0 mm (single diastereomer); m/z (ES-MS) 
500 (MW), 522 (MNa). 
6.8.7 9-Fluorenylmethyl valylglycyiphenylalaninate 71 
H2N N N 
PS-HMPA-Val-Gly-Phe-OFm (70) (50 mg) was treated with a solution of 
TFA/DCM/H20 (9:10:1) (5 ml) for 2 h. The resin was washed (DCM x 3) and the 
filtrate and washings combined and concentrated to give crude 71 (11 mg). The 
sample was purified by semi-preparatory HPLC, but during the purification 
procedure became contaminated with copper sulfate leading to paramagnetic 
distortion in the 'H NMR spectrum. All remaining 70 (-70 mg) was cleaved under 
identical conditions and the crude product obtained (-47 mg) was purified in the 
- same manner and the isolated tripeptide (7 mg) successfully analysed by 'H NMR. 
ö, (600 MHz, CD 30D) 1.21 (3H, d, J 6.84, CH(CAH3CBH3)),  1.22 (3H, d, J 6.84, 
CH(CAH 3CBH3)) ,  2.33-2.36 (1H, m, CH(CH3)2), 3.00 (1H, dd, J 13.89, 8.66, 
CHA HBPh), 3.12 (1H, dd, J 13.89, 5.77, CHCHAHBPh), 3.81 (1H, d, J 5.98 
CHCH(CH0 2), 4.03 (1H, d, J 16.78, NHCHA HBCO), 4.15 (1H, d, J 16.78, 
NHCHAHBCO), 4.37 (1H, br t, J 6.20, OCH2CH), 4.62 (1H, dd, J 10.79, 6.30, 
OCHA HBCH), 4.72 (1H, dd, J 10.79, 6.30, OCHAHBCH), 4.82 (1H, dd, J 8.55, 5.77, 
CHCH2Ph), 7.31 (2H, br d, J7.16, ArHPhe), 7.38c  (1H, m, ArHPhe), 7.43-7.46 (2H, 
m, ArHPhe), 7.50-7.54 (2H, m, ArHOFm), 7.57-7.61 (2H, m, ArHOFm), 7.76 (1H, 
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d, J 7.37, ArH OFm), 7.80 (1H, d, J 7.48, ArH OFm), 8.00' (2H, overlapping 
doublets, ArH OFm); 3 (63 MHz, CD 30D) 15.9 (CH(CH3CBHMI  16.9 
(CH(CAH3 CBH3)), 29.3 (CH(CH3)2), 36.1 (CHCI-I 2Ph), 41.6 (NHCH 20), -46 
(OCH2CH masked by strong solvent signal), 53.3 (CHCH 2Ph), 57.6 (CHCH(CH 3)2), 
66.0 (OCH 2CH), 119.1 (2 xArH OFm), 124.1 & 124.2(2 xArHOFm), 125.3, 126.4, 
127.0. 127.7 & 128.3(4 xArH OFm & 5 xArH Phe), 135.5 (ipso-C Phe), 141.0(2 x 
C OFm), 142.2 (2 x C OFm); m/z (ES-MS) 500 (MW), 522 (MNa). 
6.8.8 Continuation of Fm ester mediated solid phase inverse peptide synthesis 
using 4-(hydroxymethyl)-phenoxymethyl polystyrene (Wang Resin) 




The general procedure previously described (6.6.1) was followed using PS-Wang 
(0.9 mmo1/gIL,  6.0 g, 5.4 mmol) in DCM (20 ml), p-nitrophenyl chioroformate 
(3.27g, 16.2 mmol) in DCM (60 ml) and anhydrous pyridine (1.31 ml. 16.2 mmol). 
A strong carbonate stretch (Vmax  1766 cm') present in the JR spectrum of the aliquot 
of resin indicated success and the entire sample was filtered and washed thoroughly. 
Gel phase ' 3C NMR indicated complete conversion to the desired resin-bound 
carbonate (72). 
0.91 mmol/g (p-nitro), 100 %*; Vmax  (CH2CL2)/cm1 1766 (carbonate C=O), 1602, 
1584 (aromatic C=C), 1528 (asymmetric NO 2), 1493 (aromatic C=C), 1349 
(symmetric NO 2), 864 (p-disubstituted Ar-H); o (63 MHz, CD2C12 , gel) 70.2 
(CH20Ar), 71.0 (CH2000), 115.0(2 x m-ArHCH 20), 122.0(2 x m-ArHNO 2), 125.4 
(2 x o-ArHNO 2), 130.8 (2 x o-ArHCH 20), 145.5 (ArNO2-obscured by broad polymer 









The general procedure previously described (6.8.1) was followed using resin-bound 
carbonate (72) (assume :! ~0.90 mmol/g - 1.26 g, :!~ 1.13 mmol) in DMF (5 ml), with 
TSA-Val-OFm (65b) (1.59 g, 3.40 mmol) in DMF (10 ml), catalytic DMAP (1.5 mg, 
0.01 mmol) and NMM (0.37 ml, 3.40 mmol). Analysis indicated successful coupling 
to furnish the title compound. 
0.63 mmollg (Fm), 79 %; Vmax  (CH2C12)/cm' 3433 (NH), 1723br (ester & urethane 
C=O), 1602 & 1585 (aromatic C=C), 1514 (amide II urethane), 1494 (aromatic 
CC); ö (63 MHz, CD 2C12, gel) 17.3 (CH(CAH3CBHMI  19.0  (CH(CAH3CBH3)),  31.2 
(CH(CH3)2), 47.0 (OCH2CH), 59.3 (CHCH(CH3)2), 66.8br (OCH2CH & 
CH2000NH), 70.1 (CH20Ar), 114.8 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 
125.1 (2 x ArH OFm), 127.3 (2 x ArH OFm), 128.0 (2 x ArH OFm), 130.0 (2 x o-
ArHCH20), 141.5 (2 x C4 OFm), 143.8 (2 x C" OFm), 156.4 (OCONH), 172.1 





The general procedure previously described (6.8.1.) was followed using activated 
Wang resin (72) (assume : ~0.9 mmol/g - 240 mg, :!~0.22 mmol), TSA-Ala-OFm (65e) 
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(0.29 g, 0.66 mmol), catalytic DMAP (1 %) and NMM (73 .tl, 0.66 mmol). Analysis 
indicated successful coupling to furnish the title compound. 
0.64 mmollg (Fm), 82 %; Vm  (CH2C12) 3434 (NH), 1716br (ester & urethane C=O), 
1602 & 1584 (aromatic C=C), 1514 (amide II N -H), 1494 (aromatic C=C); ö (63 
MHz, CD2 C12, gel) 18.3 (CHCH 3), 47.0 (OCH 2CH), 49.9 (CHCH), 67.0 (OCH 2CH 
& CH2000NH), 70.1 (CH2OAr), 114.7 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 
125.2 (2 x ArH OFm), 127.3 (2 x ArH OFm), 128.0 (2 x ArH OFm), 130.0 (2 x o-
ArHCH20 Phe), 141.5 (2 x C 4 OFm), 143.6 (2 x C4 OFm); Cleavage 9:10:1 
TFAIDCM/H20: LCMSA  R1 4.4 mm; m/z (ES-MS) 268 (MW). 
6.8.12 
phenoxymethyl polystyrene 74a 
OAN NJ O I 
The general procedure outlined above (6.8.3) was followed using PS-Wang-Va!-
OFm (73a) (assume :!~0.9 mmollg - 750 mg, 0.68 mmol), TBTU (1.73 g, 5.4 mmol), 
NMM (0.59 ml, 5.4 mmol) and a solution of HOBt-Phe-OFm (66a) (1.94 mg, 4.05 
mmol) in DMF (15 ml). Analysis confirmed successful coupling of the 
phenylalanine ester to furnish the title compound as a single diastereomer. 
0.57 mmollg, 98 % (Fm); Vmax  (CH2C12)/cm' 3422 & 3323br (2° amide & urethane 
NH), 1723br (ester & urethane C=O), 1681 (amide I C=O), 1602 & 1584 (aromatic 
CC), 1514br (amide II & urethane NH), 1494 (aromatic C=C); E, (63 MHz, 
CD2C12, gel) 17.8 (CH(C4H3CBHMI  19.3 (CH(CAH3CBH3)),  31.3 (CH(CH3)2), 38.1 
(CHCH2Ph), 47.0 (OCH2CH), 53.6 (CHCH2Ph), 60.5 (CHCH(CH 3 )2), 67.4br 
(OCH2CH & CH2000NH), 70.2 (CH20Ar), 114.9 (2 x m-ArHCH 20), 120.3 (2 x 
ArH OFm), 125.3 (2 x ArH OFm), 127.5 (2 x ArH OFm), 128.1 (2 x ArH OFm), 
128.8 (2 x ArH Phe), 129.6 (2 x ArH Phe), 130.1 (2 x o-ArHCH 20), 136.2 (ipso-C 
Phe), 141.6 (2 x C OFm), 143.8 (2 x C OFm); Cleavage 9:10:1 TFAJDCM/H 20: 




phenoxymethyl polystyrene 74b 




2'.... ....--L'. 	N o  0 N Y 0 H 	II j~'~ 0 	
\/ 
The general procedure outlined above (6.8.3) was followed using PS-Wang-Ala-
OFm (73b) (assume :0.9 mmollg - 200 mg, 0.18 mmol), TBTU (462 mg, 1.44 
mmol) and NMM (0.16 ml, 1.44 mmol). Since exchanging to the HOBt salt in the 
case of TSA-Leu-OFm had not been successful, an in situ exchange was attempted. 
Therefore, the activated resin was added to a solution of TSA-Leu-OFm (65d) (486 
mg, 1.08 mmol), HOBt hydrate (:!~ 15% H20) (286 mg, 1.80 mmol w.r.t. HOBt) and 
DMAP (22 mg, 0.18 mmol) in DMF (12 ml). Analysis confirmed that coupling of 
the leucine salt to furnish the title compound as a single diastereomer had taken place 
but that the resulting product was not pure. 
0.18 mmol/g (Fm), 30 % Vmax  (CH2C12) 3423 (NH), 1715br (ester & urethane C=O), 
1645 (amide II), 1602 (aromatic C=C), 1513 (amide II urethane NH), 1493 (aromatic 
C=C); ö (63 MHz, CD 2C12, gel) 18.5 (CHCH3), 21.8 (CH(C4H3CBH3)),  22.7 
(CH(CAH3CBH3)), 24.8 (CH(CH3)200.6 (CH2CH(CH3)2 obscured by broad polymer 
signal), 47.0 (OCH 2 CH), 49.7 (CHCH 3), 50.9 (CHCH2CH(CH3)2) 66.7 (OCH2CH & 
CH2000NH), 70.1 (CH 2OAr), 114.7 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 
125.1 (2 x ArH OFm), 127.3 (2 x ArH OFm), 127.9 (2 x ArH OFm), 129.9 (2 x o-
ArHCH20); Cleavage 9:10:1 TFAIDCMIH 20: LCMSA R 18.1 mm (single 
diastereomer); m/z (ES-MS) 381 (MW), 403 (MNa). 
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6.9 Preparation of Library Building Blocks 
6.9.1 91-Fluorenylmethyl Na(tertbutoxycarbony1)_2_methy1a1aninate  76a 
The general procedure outlined above (6.7.1) was followed with Boc-2-
methylalanine (0.5 ig, 2.5 mmol), 9-fluorenylmethanol (0.98 g, 5.0 mmol), DMAP (4 
mg, 0.03 mmol), DCM (10 ml) and DIC (0.78 ml, 5.0 mmol), to furnish the crude 
title compound as a yellow/white crumbly solid. The crude product was deprotected 
and carried through to the TSA salt (77a) without any further purification. 









The general procedure outlined above (6.7.1) was followed with cis-2-(tert- 
butoxycarbonylamino)-1-cyclopentanoic acid (0.23g, 1.0 mmol), 9-
fluorenylmethanol (0.39 g, 2.0 mmol), DMAP (2 mg, 0.01 nimol), DCM (5 ml) and 
DIC (0.31 ml, 2.0 mmol), to furnish the crude title compound as a yellow/white 
solid. The crude product was deprotected and carried through to the TSA salt (77b) 




6.9.3 9-Fluorenylmethyl 	 76c 
0 	0 	rN 
0A 
The general procedure outlined above (6.7.1) was followed with Boc--alanine (5.0 
g, 23 mmol), 9-fluorenylmethanol (9.03 g, 46 mmol), DMAP (24 mg, 0.2 mmol), 
DCM (80 ml) and DIC (7.20 ml, 46 mmol), to furnish the crude title compound as a 
yellow/white oily solid. The crude product was deprotected and carried through to 
the TSA salt (77c) without any further purification. 





The general procedure outlined above (6.7.1) was followed using Boc-anthranilic 
acid (0.95 g, 4.0 mmol), 9-fluorenylmethanol (1.57 g, 8.0 mmol), DMAP (5 mg, 0.04 
mmol), DCM (20 ml) and DIC (1.25 ml, 8.0 mniol). The crude product was purified 
by column chromatography, eluting with light petroleumlEtOAc (9:1) to furnish the 
title compound as a white solid (60 mg, 15%). 
Rf(Hexane:EtOAc. 9:1) 0.27; Vmax  (thin film)/cm' 3318 (NH), 2972 (aromatic C-H), 
1732 (ester C=O), 1694 (urethane (C=O), 1603 & 1588 (aromatic C=C), 1524br 
(amide II & aromatic C=C), 754 & 741 (o-disubstituted Ar-H); oH  (250 MHz, 
CDC1 3) 1.52 (9H, s, C(CH3)3), 4.38 (1H, t, J 7.0, OCH2CII), 4.60 (2H, d, J 7.0, 
OCH2CH), 7.05 (1H, ddd, J 8.0, 7.5, 1.0, ArH Abz), 7.32 (2H, dt, J 7.5, 1.5, ArH 
OFm), 7.42 (2H, ddt, J7.5, 1.5, 0.5, ArHOFm), 7•54C  (2H, m, ArHAbz), 7.63' (2H, 
m, ArHOFm), 7.79 (2H, d',J - 7.5, ArHOFm), 8.05 (1H, ddd,J8.0, 1.5, 0.5,ArH 
Abz), 8.47 (1H, dd, J 8.5, 1.0, ArH Abz); E (63 MHz, CDC1 3) 28.2 (C(CH3)3), 46.7 
(OCH2 GH), 67.1 (OCH2CH), 80.5 (OC(CH3)3), 114.1 (ArCOO), 118.8 (ArH Abz), 
120.0 (2 x ArH OFm), 121.2 (ArH Abz), 124.9 (2 x ArH OFm), 127.1 (2 x ArH 
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OFm), 127.8 (2 x ArH OFm), 130.6 (ArH Abz), 134.6 (ArH Abz), 141.2 (2 x C4 
OFm), 142.4 (ArNH), 143.5 (2 x C4 OFm), 167.9 (COO); Found (FAB) MH 
416.18495, C26H26N04 requires 416.18618. 
6.9.5 9'-Fluorenylmethyl Nz(tosy1ate)2methy1a1aninate  77a 
—-- so? H3 	
0 
The general procedure (6.7.7) was followed using crude Boc-Aib-OFm (76a) (-P2.5 
mmol), TFA (10 ml) and TSA (548 mg, 2.88 mmol), to afford the title compound as 
an off-white solid (664 mg, 56 % over two steps). 
Mp 217-220 °C (decomposes); Vmax  (KBr)/cm' 1746 (ester CO), 1192, 1174 & 
1037 (S0 3 ), 815 (p-disubstituted Ar-H), 764 & 742 (o-disubstituted Ar-H); 8H  (250 
MHz, DMSO d6) 1.24 (6H, s, C(CH3)2), 2.27 (3H, s, CH3Ar), 4.33 (1H, t, J 5.5, 
OCH2CH), 4.63 (2H, d, J 5.5, OCH2CH), 7.12 (2H, d, J 8.0, ArH TSA), 7.26-7.45 
(4H, m, ArH OFm), 7.52 (2H, d, J 8.0, ArH TSA), 7.68 (2H, d, J 7.5, ArH OFm), 
7.89 (2H, d', J -7, ArH OFm), 8.43 (3H, bs, NH3 ); ö (63 MHz, DMSO d 6  ) 20.9 
(cFI3Ar), 23.2 (C(CH3)2), 46.4 (OCH2 CH), 56.0 (C(CH 3)2), 67.1 (OCH2CH), 120.3 (2 
x ArH OFm), 125.1 (2 x ArH OFm), 125.6 (2 x ArH TSA), 127.4 (2 x ArH OFm), 
128.0 (2 x ArH OFm), 128.3 (2 x ArH TSA), 138.1 (ArCH 3), 141.0 (2 x C4 OFm), 
143.4 (2 x C4 OFm), 145.3 (ArSO 3 ), 171.6 (COO); Found (FAB) MH 282.15011, 
C 18H20NO2 requires 282.14940. 








The general procedure (6.7.7) was followed using crude Boc-Acp-OFm (76b) (-4.0 
mmol), TFA (5 ml) and TSA (219 mg, 1.15 mmol). Unfortunately several attempts at 
trituration with ether were unsuccessful leading only to gums. The crude product 
was, therefore, taken straight through to the HOBt salt (78b) where it was hoped 
trituration would prove more successful. 
6.9.7 9-Fluorenylmethyl N'-(tosy1ate)--a1aninate 77c 
0 	rN 
-D--- ® ® II SO3 H3N -'O a 
The general procedure (6.7.7) was followed using crude Boc-13-Ala-OFm (76c) (-21 
mmol), TFA (50 ml) and TSA (4.59 g, 24.15 mmol). Solubility of the crude ester 
proved a real problem, so the reaction was carried out as a suspension. Concentration 
and trituration, did, however, furnish the title compound as a pale yellow solid (8.00 
g, 87 % over two steps), of very poor solubility. 
Mp 158-160 °C; (Found: C, 65.87; H, 5.77; N, 3.05; C 24H25N05 S requires C, 65.59; 
H, 5.73; N, 3.19); Vmax  (KBr)/cm' 1736 (ester C=O), 1223, 1185 & 1036 (S0 3 ), 814 
(p-disubstituted Ar-H), 760 & 741 (o-disubstituted Ar-H); oH (250 MHz, suspension 
in DMSO d 6  ) 2.27 (3H, s, CH3Ar), 2.71 (2H, t, J 7.0, COCH2CH2), 3.01' (2H, m, 
COCH2CH2), 4.29 (1H, t, J6.5, OCH2CH), 4.42 (2H, d, J6.5, OCH2CH), 7.13 (2H, 
dd, J 8.5, 0.5, ArH TSA), 7.34 (2H, dt, J 7.5, 1.5, ArH OFm), 7.40-7.46 (2H, m, ArH 
OFm), 7.53 (2H, d', J —8, ArH TSA), 7.66 (2H, d, J 7.5, ArH OFm), 7.81 (3H, bs, 
NH3 ), 7.90 (2H, br d, J 7.0, ArH OFm); & (63 MHz, DMSO d 6  ) 20.9 (CH3Ar), 31.5 
& 34.9 ((CH 2)2C00), 46.3 (OCH2CH), 66.1 (OCH2CH), 120.4 (2 x ArH OFm), 
125.2 (2 x ArH OFm), 125.6 (2 x ArH TSA), 127.4 (2 x ArH OFm), 128.0 (2 x ArH 
OFm), 128.4 (2 x ArH TSA), 138.2 (ArCH 3) 140.9 (2 x C OFm), 143.7 (2 x C 
OFm), 145.3 (ArSO 3 ), 170.4 (COO); Found (FAB) MH 440.15431, C 24H26N05 S 
requires 440.153 17. 
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The general procedure (6.7.7) was followed using purified Boc-Abz-OFm (76d) (458 
mg, 1.10 mmol), TFA (5 ml) and TSA (241 mg, 1.27 mmol), to afford the title 
compound as a buff solid (461 mg, 86 %). 
Mp 173-175°C (decomposes); Vmax (KBr)/cm' 1702 (ester C=O), 1602 & 1578 
(aromatic C=C), 1224, 1177& 1033 (SO 3 -), 814 (p-disubstituted Ar-H), 755 & 741 
(o-disubstituted Ar-H); 8H  (360 MHz, DMSO d 
6  ) 2.29 (3H, s, CH3Ar), 4.43 (1H, t, J 
6.0, OCH2CH), 4.62 (2H, d, J 6.5, OCH2CH), 6.62 (1H, ddd, J 8.0, 7.0, 1.0, ArH 
Abz), 6.84 (1H, dd, J8.5, 1.0, ArHAbz), 7.13 (2H, dd, J8.5, 0.5, ArHTSA), 7.29 
(1H, ddd, J8.5, 7.0, 1.5, ArHAbz), 7.34 (2H, dt, J7.5, 1.0, ArHOFm), 7.42 (2H, br 
tJ7.5, ArHOFm), 7.50 (2H, d', J-8, ArHTSA), 7.61 (1H, dd, J8.0, 1.5, ArHAbz), 
7.69 (2H, d, J 7.5, ArH OFm), 7.92 (2H, d, J 7.5, ArH OFm); E, (63 MHz, DMSO 
d 6  ) 21.7 (CH 3Ar), 47.3 (OCH2CH), 66.5 (OCH2CH), 110.9 (ArCOO), 117.3 (ArH 
Abz), 118.4 (ArH Abz), 121.1 (2 xArH OFm), 125.8 (2 xArH OFm), 126.4(2 xArH 
TSA), 128.1 (2 x ArH OFm), 128.6 (2 x ArH OFm), 129.1 (2 x ArH TSA), 131.3 
(ArH Abz), 135.1 (ArH Abz), 138.8 (ArCH 3), 141.7 (2 x C4 OFm), 144.7 (2 x C4 
OFm), 146.1 (Ar50 3 ), 167.8 (COO); Found (FAB) MH 488.15222, C 28H26N05 S 
requires 488.15317. 
6.9.9 9'-Fluorenylmethyl Naoxy(benzotriazo11 "-yl)-2-methylalaninate 78a 
The general procedure outlined above (6.7.14) was followed using TSA-Aib-OFm 
(77a) (0.5 g, 1.05 mmol) and KOBt (182 mg, 1.05 mmol) in methanol (20 ml). 
Trituration with copious ether furnished the desired salt as a chalky white solid (0.36 
g, 82 %). 
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6.9.10 9 1-Fluorenylmethyl 	cis-2- [ammonium-oxy-(benzotriazol-1 "-yl)]-l- 
cyclopentanoate 78b 
The general procedure outlined above (6.7.14) was followed using crude TSA-Acp-
OFm (77b) (assume :!~ l.0 mmol) and KOBt (173 mg, 1.0 mmol) in methanol (10 ml). 
Attempts at trituration with copious ether caused the product to oil out, so the crude 
product was used directly as a solution in DMF. 
6.9.11 9-Fluorenylmethyl Na oxy (benzotriazo1_1 '-y1)--a1aninate 78c 
The general procedure outlined above (6.7.14) was followed using a suspensiont  of 
TSA-j3-Ala-OFm (77c) (2.0 g, 4.55 mmol) in MeOH (150 ml) and KOBt (0.79 g, 
4.55 mmol). The final precipitate was filtered off and the filtrate concentrated and 
triturated with copious ether to afford the desired salt as an off-white solid (1.60 g, 
87%). 
6.9.12 9-Fluorenylmethyl Naoxy(benzotriazo11  '-yl)-anthranilate 78d 
Small scale attempt at salt exchange via the general method (6.7.14) gave no 
appreciable amount of product. Instead the salt exchange was attempted in situ 
(6.9.12). 
6.9.13 (1R,2R)-1-N-(9'-Fluorenylmethoxycarbonyl)-2-(ammonium 	chloride)- 
aminocyclohexane 80 
HCI.H2N'N 
A solution of (1R,2R)-(-)-1,2-diaminocyclohexane (0.50 g, 4.38 mmol) in diethyl 
ether (100 ml) was added dropwise, with stirring, to a cooled (iceIH 20 bath) solution 
of 9-fluorenylmethyl chioroformate (1.29 g, 5.04 mmol) in diethyl ether (100 ml) (-1 
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h). 163  The resulting white precipitate was filtered and dried (1.43 g). Unfortunately, 
the solid proved to be insoluble in all solvents suitable for NMR analysis. 'H and ' 3C 
NMR analysis of a suspension in DMSO d 6 proved too broad to assign accurately but 
resembled the spectrum predicted for a mixture of the dichloride salt and the desired 
mono-protected product. 
Vmax (KBr)/cm' 3393 (urethane NH), 3306 (ammonium NH), 293 9b (saturated C-H), 
1679 (urethane C=O), 1602 (aromatic CC), 1541br (amide II & ammonium NH & 
aromatic C=C), 1498 (aromatic C=C), 759 & 737 (o-disubstituted Ar-H); Found 
(FAB) MH 337.19176, C21 H25N202 requires 337.19160. 
6.10 Library Synthesis 
6.10.1 4(NaMethoxycarbonylvalyloxymethylfluorenyl9? yl) phenoxymethy1 
polystyrene 73a 
The general procedure previously described (6.8.1.) was followed using activated 
Wang resin (72) (assume :0.9 mmol/g - 3.0 g, :!~2.7 mmol) in DMF (30 ml), with 
TSA-Val-OFm (65b) (3.79 g, 8.1 mmol) in DMF (15 ml), catalytic DMAP (33 mg, 
0.27 mmol) and NMM (0.89 ml, 8.1 mmol). Analysis (see 6.8.10 for JR and gel 
phase ' 3C NMR data) indicated successful coupling to furnish the title compound. 
0.45 mmol/g (Fm), 57 %; Cleavage 9:10:1 TFA/DCMIH 20: LCMSA  R 18.7 mm; 
m/z (ES-MS) 296 (MW). 
6. 102 4(Na methoxycarbonylphenylalanyloxymethy1fluorenyl9?..yl)... 
phenoxymethyl polystyrene 73c 
0 
N 
0"( 	 H 
0 
was unable to find any solvent in which this salt would dissolve. 
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The general procedure previously described (6.8.1) was followed using activated 
Wang resin (72) (assume :0.9 mmollg - 2.0 g, :!~ 1.8 mmol) in DMF (10 ml), with 
TSA-Phe-OFm (65a) (2.78 g, 5.4 mmol) catalytic DMAP (22 mg, 0.18 mmol) and 
NMM (0.59 ml, 5.4 mmol) in DMF (10 ml). Analysis indicated successful coupling 
to furnish the title compound. 
0.45 mmol/g (Fm), 59 %; Vm  (DCM)/cm' 3427 (NH), 1722br (ester & urethane 
C=O), 1602 & 1584 (aromatic C=C), 1513 (amide II urethane NH), 1494 (aromatic 
C=C); 8c (63 MHz, CD 2C12, gel) 38.1 (CHCH 2Ph), 46.9 (OCH2CH), 55.2 
(CHCH2Ph), 66.8 (CH2000) 67.2 (OCH2CH), 70.1 (CH2OAr), 114.7 (2 x m-
ArHCH20), 120.1 (2 x ArH OFm), 125.2 (2 x ArH OFm), 127.3 (2 x ArH OFm), 
128.0 (2 x ArH OFm), 128.7 (2 x ArH Phe), 129.4 (2 x ArH Phe), 130.0 (2 x o-
ArHCH20), 136.2 (ipso-C Phe), 141.4 (2 x C OFm), 143.8 (2 x C OFm), 155.9 
(OCONH), 171.7 (COOCH 2); Cleavage 9:10:1 TFA/DCMIH 20: LCMSA  R1 21.4 
mm; m/z (ES-MS) 344 (MH), C 23H22NO2 requires 344.16505. 
6.10.3 
phenoxymethyl polystyrene 81a 
0 
0,01 	H4 0 
The general procedure outlined above (6.8.3) was followed using resin-bound Wang-
Val-OFm (73a) (-P0.45 mmol/g - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 p1, 1.08 mmol) and a solution of crude HOBt-Gly-OFm (66c) (- 0.84 
mmol) in DMF (15 ml). Analysis confirmed successful coupling of the protected 
amino acid to furnish the title compound. 
0.54 mmol/g, 100 %* (Fm); Vmax  (DCM)/cm' 3425 & 3332br (2° amide & urethane 
NH), 1748 (ester C=O) 1716 (urethane C=0), 1681 (amide I C=O), 1602 & 1584 
(aromatic C=C), 1514br (amide II & urethane NH), 1494 (aromatic C=C); ö (63 
MHz, CDC13 , gel) 17.7 (CH(CH3CBH3)),  19.1 (CH(CAH3CBH3)),  30.9 (CH(CH 3)2), 
41.1 (NHCH2CO), 46.4 (OCH 2CH), 60.1 (CHCH(CH3 )2), 66.8 (CH2000NH), 67.2 
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(OCH2CH), 69.9 (CH20Ar), 114.6 (2 x m-ArHCH20) 1  119.9 (2 x ArH OFm), 124.8 
(2 x ArH OFm), 127.0 (2 x ArH OFm), 127.8 (2 x ArH OFm), 129.8 (2 x o-
ArHCH20), 141.1 (2 x C4 OFm), 143.2 (2 x C OFm); Cleavage 9:10:1 
TFAIDCMIH20: LCMSA R 9.1 mm; m/z (ES-MS) 353 (MH), 375 (MNa). 
6.10.4 
phenoxymethyl polystyrene 74a 
The general procedure previously described (6.8.3) was followed using PS-Wang-
Val-OFrn (73a) (-0.45 mmollg - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 j.il, 1.08 mmol) and a solution of HOBt-Phe-OFm (66a) (402 mg, 0.84 
mmol) in DMF (15 ml). Analysis (see 6.8.12 for IR and gel phase ' 3C NMR data) 
confirmed successful coupling of the protected amino acid to furnish the title 
compound as a single diastereomer. 
0.57 mmol/g, 100 %* (Fm); Cleavage 9:10:1 TFA/DCM!H 20: LCMSA  R1 21.1 mm 
(single diastereomer); m/z (ES-MS) 443 (MW), 465 (MNa). 
6.10.5 4(NaMethoxycarbonylvalyl2 '-methylalanyloxymethylfluorenyl-9' '-yl)-
phenoxymethyl polystyrene 81b 
oj~:~-O N 	 0 
0 
The general procedure outlined above (6.8.3) was followed using PS-Wang-Val-
OFm (73a) (0.45 mmollg - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 j.xl, 1.08 mmol) and a solution of HOBt-Aib-OFm (78a) (350 mg, 0.84 
mmol) in DMF (15 ml). Analysis confirmed successful coupling of the dialkylated 
amino acid ester to furnish the title compound. 
0.43 mmol/g (Fm), 88 %; Vmax  (DCM)/cm' 3427 & 3330br (2° amide & urethane 
NH), 1716br (ester & urethane C=0), 1674 (amide I C=O), 1602 & 1584 (aromatic 
C=C), 15 l4br (amide II & urethane NH), 1494 (aromatic C=C); ö (63 MHz, CDC1 31  
140 
Experimental 
gel) 17.7 (CH(CIH3CBHMI  18.9  (CH(CAH3CBH3)),  22.4  (N}TIC(C4H3CBH3)),  24.4 
(NHC(CAH3 CBH3)), 31.0 (CH(CH 3 )2), 46.8 (OCH2CH), 56.3 (NHC(CH 3 )2), 60.0 
(CHCH(CH3)2), 66.8br (OCH2CH & CH2000NH), 69.8 (CH 2OAr), 114.5 (2 x m-
ArHCH20), 119.8 (2 x ArH OFm), 124.8 (2 x ArH OFm), 127.0 (2 x ArH OFm), 
127.6 (2 x ArH OFm), 129.7 (2 x o-ArHCH 20)1  141.1 (2 x C OFm), 143.4 (2 x C 
OFm); Cleavage 9:10:1 TFAIDCM/H 20: LCMSA R 16.9 mm; m/z (ES-MS) 381 
(MW), 403 (MNa). 
6.10.6 4-(N'-Methoxycarbonylvalyl-cis-(amino-(2'-carboxymethy1fluorenyl-9' '-
yl)-cyclopentyl)-phenoxymethyl polystyrene 81c 
	








The general procedure outlined above (6.8.3) was followed using PS-Wang-Val-
OFm (73a) (0.45 mmol/g - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 jil, 1.08 mmol) and a solution of crude HOBt-Acp-OFm (78b) ( 0.84 
mmol) in DMF (15 ml). Analysis confirmed successful coupling of the cyclic amino 
acid ester to furnish the title compound as a mixture of cis diastereomers. 
0.49 mmol/g (Fm), 100 %*; Vmax  (DCM)/cm 1 3420 & 3330br (2° amide & urethane 
NH), 1723br (ester & urethane C=O), 1674 (amide I C=O), 1602 & 1584 (aromatic 
C=C), 1513br (amide II & urethane NH), 1494 (aromatic C=C); 6 (63 MHz, CDC1 31  
gel) 17.5 & 17.6 (2 x CH(C4H3CBH3)),  19.1 (2 x CH(CAH3CBH3)),  21.9 
(NHCHCH2 CH2), 28.3 (CH2CH2CHCO), 31.0 (CH(CH3)2), 31.5 (N}{CHCH 2CH2), 
46.3 (NHCHCHCO), 46.7 (OCH 2CH), 51.9 (NHCHCHCO), 60.2br (CHCH(CH 3)2), 
66.2 (C1-I2000NH), 66.6 (OCH 2CH), 69.9 (CH20Ar), 114.6 (2 x m-ArHCH 20), 
119.9 (2 x ArH OFm), 124.8 (2 x ArH OFm), 127.1 (2 x ArH OFm), 127.8 (2 x ArH 
OFm), 129.8 (2 x o-ArHCH 20); Cleavage 9:10:1 TFA/DCM/H 20: LCMSA  R, 18.5 









The general procedure outlined above (6.8.3) was followed using PS-Wang-Va!-
OFm (73a) (—'0.45 mmol/g - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 p.1, 1.08 mmol) and a partial suspension of HOBt-13-Ala-OFm (78c) (338 
mg, 0.84 mmol) in DMF (15 ml). Analysis confirmed successful coupling of the 13-
amino acid ester to furnish the title compound. 
0.65 mmo!/g (Fm), 100 %*; Vmax  (DCM)/cm' 3429 & 3333br (2° amide & urethane 
NH), 1732br (ester & urethane C=O), 1674 (amide I C=O), 1602 & 1584 (aromatic 
CC), 1513br (amide II & urethane NH), 1494 (aromatic C=C); 8 (63 MHz, 
CD2C121  gel) 18.1 (CH(C4H 3CBH3)) , 19.5  (CH(CAH3CBH3)),  31.6 (CH(CH3)2), 34.4 & 
35.4 (NHCH2 CH2CO), 47.2 (OCH 2CH), 60.8 (CHCH(CH3) 2), 66.8 (OCH2CH & 
CH2000NH), 70.5 (CH2OAr), 115.0 (2 x m-ArHCH 20), 120.5 (2 x ArH OFm), 
125.5 (2 x ArH OFm), 127.7 (2 x ArH OFm), 128.3 (2 x ArH OFm), 130.3 (2 x o-
ArHCH20), 141.7 (2 x C OFm), 144.2 (2 x C4 OFm); Cleavage 9:10:1 
TFAIDCM!H20: LCMSA  R 12.0 mm; m/z (ES-MS) 367 (MW), 389 (MNa). 
6.10.8 
phenoxymethyl polystyrene 81e 
0 
The general procedure outlined above (6.8.3) was followed using PS-Wang-Phe-
OFm (73c) (-0.45 mmollg - 600 mg, 0.28 mmol), TBTU (694 mg, 2.16 mmol), 
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NMM (238 jil, 2.16 mmol) and a solution of crude HOBt-Gly-OFm (78c) (-j 1.68 
mmol) in DMF (30 ml). Analysis confirmed successful coupling of the glycine ester 
to furnish the title compound. 
0.43 mmol/g (Fm), 98 %; v, (DCM)/cm' 3421 & 3332br (2° amide & urethane 
NH), 1716br (ester & urethane C=O), 1682 (amide I C=O), 1602 & 1584 (aromatic 
C=C), 15 l4br (amide II & urethane NH), 1494 (aromatic C=C); 8 (63 MHz, CDC1 31  
gel) 38.1 (CHCH 2Ph), 41.2 (NHCH 2CO), 46.3 (OCH 2CH), 55.9 (CHCH2Ph), 67.1 
(OCH2CH & CH 2000NH), 69.9 (CH 20Ar), 114.5 (2 x m-ArHCH20), 119.9 (2 x 
ArH OFm), 124.8 (2 x ArH OFm), 127.0 (2 x ArH OFm), 127.7 (2 x ArH OFm), 
128.4 (2 x ArH Phe), 129.1 (2 x ArH Phe), 129.7 (2 x o-ArHCH20), 136.1 (ipso-C 
Phe), 141.1 (2 x C OFm), 143.2 (2 x C OFm); Cleavage 9:10:1 TFAIDCMIH20: 
LC-MS' R1 17.8 mm; m/z (ES-MS) 401 (MW), 423 (MNa). 
6.10.9 







The general procedure outlined above (6.8.3) was followed using PS-Wang-Phe-
OFm (73c) (—'0.45 mmol/g - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 j.tl, 1.08 mmol) and a solution of HOBt-Val-OFm (66b) (362 mg, 0.84 
mmol) in DMF (15 ml). Analysis confirmed successful coupling of the valine ester 
to furnish the title compound as a single diastereomer. 
0.42 mmol/g (Fm), 98 %; Vm  (DCM)/cm' 3420 & 3322br (2° amide & urethane 
NH), 1716br (ester & urethane C=O), 1682 (amide I C=0), 1602 & 1584 (aromatic 
C=C), 15 l4br (amide II & urethane NH), 1494 (aromatic C=C); ö (63 MHz, CDC1 31  
gel) 17.4 (CH(CH 3 C8H3)), 18.6 (CH(CAH3CBH3)),  30.9 (CH(CH 3)2), 38.1 
(CHCH2Ph), 46.6 (OCH2CH), 56.0 (CHCH 2Ph), 57.2 (CHCH(CH3) 2), 66.6 (OCH2CH 
& CH2000NH), 69.8 (CH2OAr), 114.5 (2 x m-ArHCH 20), 119.9 (2 x ArH OFm), 
143 
Experimental 
124.7 (2 x ArH OFm), 127.0 (2 x ArH OFm), 127.7 (2 x ArH OFm), 128.4 (2 x ArH 
Phe), 129.1 (2 x ArH Phe), 129.7 (2 x o-ArHCH 20), 136.1 (ipso-C Phe), 141.1 (2 x 
C OFm), 143.2 (2 x C OFm); Cleavage 9:10:1 TFA/DCM/H 20: LCMSA R 20.7 
mm (single diastereomer); m/z (ES-MS) 443 (MW), 465 (MNa). 
6.10.10 
yl)-phenoxymethyl polystyrene 81g 
The general procedure outlined above (6.8.3) was followed using PS-Wang-Phe-
OFm (73c) (-0.45 mmollg - 300 mg, 0.14 mmol), TBTU (347 mg, 1.08 mmol), 
NMM (119 tl, 1.08 mmol) and a partial suspension of HOBt-3-Ala-OFm (78c) (338 
mg, 0.84 mmol) in DMF (15 ml). Analysis confirmed successful coupling of the 
glycine salt to furnish the title compound. 
0.37 mmol/g (Fm), 86 %; Vmax  (DCM)/cm' 3425 & 3328br (2° amide & urethane 
NH), 1723br (ester & urethane C=O), 1678 (amide I C=0), 1602 & 1584 (aromatic 
C=C), 1514br (amide II & urethane NH), 1494 (aromatic C=C); & (63 MHz, CDC1 31  
gel) 33.5 & 34.5 (NHCH 2GH2CO), 38.7 (CHCH 2Ph), 46.5 (OCH2CH), 56.1 
(CHCH2Ph), 66.2 (OCH2CH), 66.6 (CH 2000NH), 69.8 (CH20Ar), 114.5 (2 x m-
ArHCH20), 119.9 (2 x ArH OFm), 124.7 (2 x ArH OFm), 127.0 (2 x ArH OFm), 
127.7 (2 x ArH OFm), 128.3 (2 x ArH Phe), 129.0 (2 x ArH Phe), 129.7 (2 x o-
ArHCH20), 136.2 (ipso-C Phe), 141.1 (2 x C OFm), 143.4 (2 x C OFm); Cleavage 
9:10:1 TFA/DCM/H20: LC-MS' R 18.4 mm; m/z (ES-MS) 415 (MW), 437 (MNa). 
6.10.11 General procedure for coupling of second or subsequent amino acid 
where exchange to HOBt salt has not been possible 
Resin-bound amino acid fluorenylmethyl ester (1 eq) was deprotected with 20 % 
piperidine in DMF (3 x 10 m11300 mg resin; 15 min ea), washed (DMF x 3) and 
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neutralised with 3 % acetic acid in DCM (4 x 12 ml/300 mg resin; 5 min ea). After 
washing (DMF x 3) the resin was treated with a solution of TBTU (8 eq) and NMM 
(8 eq) in DMF (15 m11300 mg resin) for ~40 mm. The activated resin was filtered 
and washed (DMF x 3), before finally swelling in a solution/suspension of the amino 
acid fluorenylmethyl ester tosylate or hydrochloride salt (6 eq), HOBt hydrate (6 eq 
w.r.t. HOBt) and Et 3N (6 eq) in DMF (15 ml/300 mg resin). The suspension was 
spun at ambient temperature (>15 h) before filtering, washing according to the 
standard protocol and drying under vacuum. 
6.10.12 4(NaMethoxycarbonylvalylamino(2t_carboxymethy1fluoreny1..9! Ly1).. 
benzyl)-phenoxymethyl polystyrene 81h - attempted synthesis 
o V 0
N&O 
o ro ol 
The general procedure detailed above (6.10.11) was followed using PS-Wang-Val-
OFm (73a) (assume :!~0.9 mmol/g - 150 mg, 0.14 mmol), TBTU (347 mg, 1.08 
mmol), NMM (119 j.tl, 1.08 mmol) and a solution of TSA-Abz-OFm (77d) (395 mg, 
0.81 mmol), Et3N (113 jil, 0.81 mmol) and HOBt hydrate (:!~ 15% H20) (129 mg, 0.81 
mmol w.r.t. HOBt) in DMF (8 ml). Initial analysis by acidic cleavage and ES-MS 
did not display the expected mass ion. Also, JR analysis indicated that the resin could 
still be in an activated form due to the presence of a strong stretch Vmax 1817 cm', 
with the coupling of the amino acid not occurring to any detectable extent. 
6.10.13 4(Na methoxycarbonylvalylpheny1a1anyloxyethyl)-phenOxymethyI 
polystyrene 81i 
00 
OAN N O 
H 
o 
The general procedure outlined above (6.10.11) was followed using PS-Wang-Val- 
OFm (73a) (assume :!~0.9 mmol/g - 300 mg, 0.27 mmol), TBTU (694 mg, 2.16 
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mmol), NMM (237 tl, 2.16 mmol) and a solution of L-phenylalanine ethyl ester 
hydrochloride (372 mg, 1.62 mmol), Et 3N (226 tl, 1.62 mmol) and HOBt hydrate 
(:!~ 15% H20) (258 mg, 1.62 mmol w.r.t. HOBt) in DMF (15 ml). Analysis confirmed 
successful coupling of the ethyl ester to furnish the title compound as a single 
diastereomer. 
Vmax  (DCM)/cm' 3423 & 3328br (2° amide & urethane NH), 1732br (ester & 
urethane C0), 1682 (amide I C0), 1602 & 1584 (aromatic C=C), 151 4br (amide 
II & urethane NH), 1494 (aromatic C=C), 826 (p-disubstituted Ar-H); & (63 MHz, 
CD2C12, gel) 14.3 (OCH2CH3), 17.9 (CH(C4H3CBH3)), 19.3 (CH(CAH3 CBH3)) ,  31.4 
(CH(CH3)2), 38.2 (CHCH2Ph), 53.6 (CHCH 2Ph), 60.6 (CHCH(CH3) 2), 61.8 
(OCH2CH3), 67.0 (CH2000NH), 70.3 (CH 20Ar), 114.9 (2 x m-ArHCH 20), 127.3 
(ArH Phe), 128.8 (2 x ArH Phe), 129.7 (2 x ArH Phe), 130.1 (2 x o-ArHCH 20), 
136.5 (ipso-C Phe), 156.7 (OCONH), 171.2br (CONH & COO); Cleavage 9:10:1 
TFAIDCMIH20: LCMSB R 18.6 mm (single diastereomer); m/z (ES-MS) 293 
(MW). 
6.10.14 General procedures for coupling of third building block into library 
6.10.14.1 Building block = HOBt salt of amino acid 
Resin-bound dipeptide fluorenylmethyl ester (assume :5:0.45 mmollg, 200 mg, 0.09 
mmol) was deprotected with 20 % piperidine in DMF (3 x 6 ml; 15 min ea), washed 
(DMF x 3) and neutralised with 3 % acetic acid in DCM (4 x 8 ml; 5 min ea). After 
washing (DMF x 3) the resin was treated with a solution of TBTU (231 mg, 0.72 
mmol) and NMM (79 p1, 0.72 mmol) in DMF (10 ml) for ~!40 mm. The activated 
resin was filtered and washed (DMF x 3), before finally swelling in a solution of the 
HOBt ammonium salt of the amino acid fluorenylmethyl ester (0.54 mmol) in DMF 
(10 ml). The suspension was spun at ambient temperature (>15 h) before filtering, 
washing according to the standard protocol and drying under vacuum. 
6.10.14.2 Building block = amine 
Resin-bound dipeptide fluorenylmethyl ester (assume :50.45 mmol/g, 200 mg, 0.09 
mmol) was deprotected with 20 % piperidine in DMF (3 x 6 ml; 15 min ea), washed 
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(DMF x 3) and neutralised with 3 % acetic acid in DCM (4 x 8 ml; 5 min ea). After 
washing (DMF x 3) the resin was treated with a solution of TBTU (231 mg, 0.72 
mmol) and NMM (79 j.tl, 0.72 mmol) in DMF (10 ml) for ~:40 mm. The activated 
resin was filtered and washed (DMF x 3), before finally swelling in a solution of 
amine (0.54 mmol), HOBt hydrate (0.54 mmol w.r.t. HOBt) in DMF (10 ml). The 
suspension was spun at ambient temperature (>15 h) before filtering, washing 
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The general procedure previously described (6.10.14.1) was followed using PS-
Wang-Val-Phe-OFm (74a) and a solution of HOBt-Phe-OFm (66a) (258 mg, 0.54 
mmol) in DMF (10 ml). Analysis confirmed successful coupling of the amino acid 
ester to furnish the title compound as a mixture of diastereomers. 
0.35 mmol/g (Fm), 61 %; Vmax  (DCM)/cm' 3417 & 3307br (2° amide & urethane 
NH), 1715br (ester & urethane C=O), 1694 & 1668 (2 x amide I C=O), 1602 & 1585 
(aromatic C=C), 1514br & 1509 (2 x amide II & urethane NH), 1494 (aromatic 
C=C); 8c (63 MHz, CD2C121  gel) 17.9 (CH(C4H3CBH3)), 19.2 (CH(CAH3CBH3)),  31.1 
(CH(CH3)2), 38.0 (2 x CHCH2Ph), 46.8 (OCH2CH), 54.Obr (2 x CHCH2Ph), 60.6 
(CHCH(CH3)2), 67.2 (OCH2CH & CH2000NH), 70.1 (CH2OAr), 114.7 (2 x m-
ArHCH20), 120.1 (2 x ArH OFm), 125.2 (2 x ArH OFm), 127.4 (2 x ArH OFm), 
128.0 (2 x ArH OFm), 128.6 (4 x ArH Phe), 129.4br (4 x ArH Phe & 2 x o-
ArHCH20), 136.2br (2 x ipso-C Phe), 141.4 (2 x C OFm), 143.8 (2 x C OFm); 
Cleavage 9:10:1 TFA/DCMIH 20: LCMSA R 25.6 & 26.3 mm (two diastereomers); 




yl)-phenoxymethyl polystyrene 75b 
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The general procedure outlined above (6.1 0.14.1) was followed using PS-Wang-Val-
Gly-OFm (81a) and a solution of HOBt-Phe-OFm (66a) (258 mg, 0.54 mmol) in 
DMF (10 ml). Analysis confirmed successful coupling of the ester protected amino 
acid to furnish the title compound as a single diastereomer. 
0.34 mmollg (Fm), 68 %; Vmax  (DCM)/cm 1 3419 & 3321br (2° amide & urethane 
NH), 1715br (ester & urethane C=O), 1668 (2 x amide I C=O), 1602 & 1584 
(aromatic C=C), 15 l4br (2 x amide II & urethane NH), 1494 (aromatic C=C); & (63 
MHz, CD2C12 , gel) 17.8 (CH(C4H3CBH3)),  19.2 (CH(CAH3CBH3)),  31.1 (CH(CH 3)2), 
37.8 (CHCH2Ph), 42.9 (NHCH20), 46.7 (OCH2CH), 53.6 (CHCH2Ph), 60.6 
(GHCH(CH3)2), 67.1 (OCH2CH & CH2OCONH), 70.0 (GH 2OAr), 114.6 (2 x m-
ArHCH 20), 120.0 (2 x ArH OFm), 125.1 (2 x ArH OFm), 127.3 (2 x ArH OFm), 
127.9 (2 x ArH OFm), 128.6 (2 x ArH Phe), 129.3 (2 x ArH Phe), 129.9 (2 x o-
ArHCH20), 136.2 (ipso-C Phe), 141.3 (2 x C4 OFm), 143.6(2 x C4 OFm); Cleavage 
9:10:1 TFAIDCMJH20: LCMSA  R 20.5 mm (single diastereomer); m/z (ES-MS) 
500 (MW), 522 (MNa). 
6.10.17 4(NrMethoxycarbonylvaly1(2 '-methyl)-alanylaminobenzyl)-
phenoxymethyl polystyrene 75c 
0 O'a 
The general procedure outlined above (6.10.14.2) was followed using resin-bound 
dipeptide (81b) up until the neutralisation step, where the volatility of the DCM 
caused the top of the spinning isolute tube to fly off with complete loss of the resin 
sample. The reaction was therefore repeated using freshly prepared PS-Wang-Val- 
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Aib-OFm (assume 0.9 mmol/g, 200 mg, 0.18 mmol). The new sample of resin was 
deprotected with 20 % piperidine in DMF (3 x 6 ml; 15 min ea), washed (DMF x 3) 
and neutralised with 3 % acetic acid in DCM (4 x 8 ml; 5 min ea). After washing 
(DMF x 3) the resin was treated with a solution of TBTU (462 mg, 1.44 mmol) and 
NMM (158 j.il, 1.44 mmol) in DMF (10 ml) for ~:40 mm. The activated resin was 
filtered and washed (DMF x 3), before finally swelling in a solution of benzylamine 
(118 jtl, 1.08 mmol) and HOBt hydrate (172 mg, 1.08 mmol w.r.t. HOBt) in DMF 
(10 ml). The suspension was spun at ambient temperature (>15 h) before filtering, 
washing according to the standard protocol, and drying under vacuum. Analysis 
confirmed successful coupling of benzylamine to the bulky dipeptide to afford the 
title compound. 
Vmax  (DCM)/cm' 3429 & —3370br (2 x 2° amide & urethane NH), 1715 (urethane 
C=O), 1684 & 1681 (2 x amide I C=O), 1602 & 1584 (aromatic C=C), 1514br & 
1505 (2 x amide II & urethane NH), 1494 (aromatic C=C); 8 (63 MHz, CD 2C121  gel) 
18.4 (CH(C4H3CBH3)),  19.2  (CH(CAH3CBH3)),  24.6  (NHC(C4H3CBHM,  26.3 
(NHC(CAH3 CBH3)), 30.6 (CH(CH3)2), 43.4 (NHCH 2Ph), 57.4 (NHC(CH 3)2), 61.8 
(CHCH(CH 3)2), 66.9 (CH2000NH), 70.1 (CH2OAr), 114.5 (2 x m-ArHCH20), 
128.lbr (5 x ArHCH2NH - masked by polymer aromatics), 130.0 (2 x o-ArHCH 20), 
145.2 (ArCH2NH - masked by resin signal); Cleavage 9:10:1 TFAIDCM/H 20: LC-
MS' R1 11.4 mm; m/z (ES-MS) 292 (MW). 
6.10.18 4-(N'-Methoxycarbonylvalyl-cis-{amino- 12'-carboxyamino-(4' '-chioro)-











The general procedure outlined above (6.1 0.14.2) was followed using PS-Wang-Val-
Acp-OFm (81c) and a solution of p-chloro-aniline (69 mg, 0.54 mmol) and HOBt 
hydrate' (86 mg, 0.54 mmol w.r.t. HOBt) in DMF (10 ml). Analysis confirmed 
successful coupling of the aromatic amine to furnish the title compound as a single 
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diastereomer. Due to the mixture of diastereomers the gel phase ' 3C NMR was fairly 
broad and complex, however proposed assignments are detailed below. 
Vmax  (DCM)/cm' 3420 & 33 l4br (2° amide & urethane NH), 1715 (urethane C=O), 
1668 & 1652 (2 x amide I C=O), 1602 & 1584 (aromatic C=C), 1514br & 1504 (2 x 
amide II & urethane NH), 1494 (aromatic C=C); E (63 MHz, CD 2C121  gel) 17.5 (2 x 
CH(CIH3CBH3)), 19.2 (2 x CH(CAH3CBH3)),  22.4 & 23.1 (2 x NHCHCH2 CH2), 
28.4br (2 x COCHCH2CH2), 31.3br & 33.2br (2 x CH(CH 3)2 & 2 x NHCHCI-1 2CH2), 
46.1 & 46.7 (2 x COCHCH 2CH2), 51.8 & 53.2 (2 x NHGHCH2CH2), 60.4br (2 x 
CHCH(CH3 )2), 66.8 (CH2000NH), 70.1 (CH20Ar), 114.7 (2 x m-ArHCH 20), 
128.lbr (p-chloroaniline obscured), 129.9 (2 x o-ArHCH 20), 171.9br (2 x CONH); 
Cleavage 9:10:1 TFAJDCMJH20: LC-MS 8 R1 21.0 mm (two cis diastereomers); m/z 
(ES-MS) 338 (MH/C1 35), 340 (MH/C1 37), 360 (MNa/C1 35), 362 (MNaICl37). 
6.10.19 	(1 	 '-phenyl)-ethyl)- 
phenoxymethyl polystyrene 75e 
0 
O'J:: 	0 H 0 
	0 --ro 
The general procedure outlined above (6.10.14.2) was followed using PS-Wang-Va!-
13-Ala-OFm (81d) and a solution of (R)-(+)-a-methylbenzylamine (70 [il, 0.54 
mmol) and HOBt hydrate (86 mg, 0.54 mmol w.r.t. HOBt) in DMF (10 ml). Analysis 
confirmed successful coupling of the chiral amine to furnish the title compound as a 
single diastereomer. 
V,nax  (DCM)/cm' 3428 & 3299br (2° amide & urethane NH), 1714 (urethane C0), 
1668 & 1654 (2 x amide I C=O), 1602 & 1584 (aromatic C=C), 1538 & 1514 (2 x 
amide II & urethane NH), 1494 (aromatic C=C); & (63 MHz, CD 2C12 , gel) 17.9 
(CH(C4H 3CBHMI 19.3  (CH(CAH3CBH3)),  22.1 (CHCH3), 31.4 (CH(CH 3)2), 35.8 (one 
or both of NHCH2CH2CO, one perhaps masked by polymer benzylics, 40.6br), 49.0 
(NHCHCH3), 60.6 (CHCH(CH3)2), 66.7 (CH2000NH), 70.1 (CH2OAr), 114.7 (2 x 
m-ArHCH 20), 128.1 (2 x ArHCH), 128.6 (2 x ArHCH), 129.9 (2 x o-ArHCH 20), 
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170.5 (CONE), 171.9 (CONH); Cleavage 9:10:1 TFA/DCMIH 20: LCMSB R, 15.9 
mm (single diastereomer); m/z (ES-MS) 292 (MH), 314 (MNa 1 ). 
6.10.20 4(Na 
Methoxycarbonylphenylalanylglycylphenylalanyloxymethylfluorenyl-9'-yl)-
phenoxymethyl polystyrene 75f 
OA N N N 
H 	 H 
jr-"O JZ r, 
The general procedure previously described (6.10.14.1) was followed using PS-
Wang-Phe-Gly-OFm (81e) and a solution of HOBt-Phe-OFm (66a) (258 mg, 0.54 
mmol) in DMF (10 ml). Analysis confirmed successful coupling of the amino acid 
ester to furnish the title compound as a single diastereomer. 
0.24 mmol/g (Fm), 60 %; Vmax  (DCM)/cm' 3418 & 3324s (2 x 2° amide & urethane 
NH), 1715br (ester & urethane C=O), 1684 & 1681 (2 x amide I C=O), 1602 & 1585 
(aromatic C=C), 1514 & 1505 (2 x amide II & urethane NH), 1494 (aromatic C=C); 
(63 MHz, CDC13 , gel) 37.7br (2 x CHCH2Ph), 43.1 (NHCH2CO), 46.8 (OCH2CH), 
53.6 (OCOCHCH2Ph), 56.4 (NHCOCHCH2Ph), 67.2 (OCH2CH & CH2000NH), 
70.0 (CH2OAr), 114.7 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 125.2 (2 x ArH 
OFm), 127.3 (2 x ArH OFm), 128.0 (2 x ArH OFm), 128.6 (4 x ArH Phe), 129.4br (4 
x ArH Phe & 2 x o-ArHCH 20), 141.4 (2 x C OFm), 143.6 (2 x C OFm); Cleavage 
9:10:1 TFA/DCMJH20: LC-MS' R 25.1 mm (single diastereomer); m/z (ES-MS) 




valylphenylalanyloxymethylfluorenyl-9'-yl)-phenoxymethyl polystyrene 75g 
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The general procedure previously described (6.10.14.1) was followed using resin-
bound dipeptide (811) (assume 0.45 mmollg, 140 mg, 0.06 mmol) and a solution of 
HOBt-Phe-OFm (66a) (182 mg, 0.38 mmol) in DMF (7 ml). Analysis confirmed 
successful coupling of the amino acid ester to furnish the title compound as a 
mixture of diastereomers. 
0.41 mmollg (Fm), 100 %*; Vmax  (DCM)/cm' 3418 & 3307br (2° amide & urethane 
NH), 1738 (ester), 1715 (urethane C=O), 1684 & 1681 (2 x amide I C=O), 1602 & 
1585 (aromatic C=C), 1515 & 1505 (2 x amide II & urethane NH), 1494 (aromatic 
C=C); ö (63 MHz, CD 2C12 , gel) 17.5 & 18.0 (2 x CH(C 4H3C8H3)), 19.1 (2 x 
CH(CAH 3 CBH 3)), 31.2 (2 x CH(CH 3)2), 38.0 (2 x CHCH 2Ph), 46.8 (OCH2CH), 53.6 
(OCOCHCH2Ph), 56.1 (NHCOCHCH2Ph), 58.3 (2 x CHCH(CH 3)2), 67.2 (OCH 2CH 
& CH2000NH), 70.1 (CH2OAr), 114.7 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 
125.2 (2 x ArH OFm), 127.3 (2 x ArH OFm), 128.0 (2 x ArH OFm), 128.6 (4 x ArH 
Phe), 129.4br (4 xArH Phe & 2 x o-ArHCH 20), 136.4br (2 x ipso-CPhe), 141.4(2 x 
C4 OFm), 143.7 (2 x C OFm), 171.6br (2 x CONH & COO); Cleavage 9:10:1 
TFAIDCMIH20: LCMSA R 26.4 & 27.1 mm (two diastereomers); m/z (ES-MS) 590 
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The general procedure previously described (6.10.14.1) was followed using PS-
Wang-Phe--Ala-OFm (81g) and a solution of crude HOBt-Gly-OFm (66c) (— 0.54 
mmol) in DMF (10 ml). Analysis confirmed successful coupling of the amino acid 
ester to furnish the title compound. 
0.33 mmollg, 92 % (Fm); Vmax  (DCM)/cm' 3420 & 3344br (2 x 2° amide & urethane 
NH), 1715br (ester & urethane C=O), 1682 & 1652 (2 x amide I C=O), 1602 & 1584 
(aromatic C=C), 1514br & 1505 (2 x amide II & urethane NH), 1494 (aromatic 
C=C); 6c (63 MHz, CD2C121  gel) 36.Obr (NHCH 2 CH2CO), 38.5 (CHCH2Ph), 41.4 
(NHCH2CO), 46.7 (OCH2 CH), 56.6 (CHCH2Ph), 66.8 (CH 2000NH), 67.3 
(OcH2CH), 70.1 (CH20Ar), 114.7 (2 x m-ArHCH 20), 120.1 (2 x ArH OFm), 125.2 
(2 x ArH OFm), 128.Obr (4 x ArH OFm & 2 x ArH Phe), 129.6br (2 x ArH Phe & (2 
x o-ArHCH 20), 137.0 (ipso-C Phe), 141.3 (2 x C OFm), 143.6 (2 x C OFm), 
172.lbr (2 x CONH & COO); Cleavage 9:10:1 TFAIDCM/H20: LCMSA  R 19.4 
mm; m/z (ES-MS) 472 (MW), 494 (MNa). 
6.10.23 (1 'R,2 	 '-(2'- 
aminocarboxymethylfluorenyl-9"-yl)-cyclohexyll }-phenoxymethyl polystyrene 
75i ° 0 0 
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The general procedure detailed above (6.10.11) was followed using PS-Wang-Phe-
Gly-OFm (81e) (assume :!~0.45 mmollg - 60 mg, 0.03 mmol), TBTU (69 mg, 0.22 
mmol), NMM (24 p1, 0.22 mmol) and a milky suspension of crude 1-(9'-
fluorenylmethoxycarbonyl)-2-(hydrochloride)-( 1R,2R)- 1 ,2-diaminocyclohexane (80) 
(60 mg, -M.16 mmol), Et3N (23 j.il, 0.16 mmol) and HOBt hydrate (:!~ 15% H20) (26 
mg, 0.16 mmol w.r.t. HOBt) in DMF (6 ml). After spinning for 16 h, the still opaque 
reaction mixture was drained away and the resin washed and dried in the usual 
manner. JR analysis indicated that there was no activated complex left and after 
cleavage ES-MS indicated that there was a trace presence of the desired product. The 
sample was too small and weak for meaningful gel phase ' 3C NMR analysis. 
0.04 mmol/g, 10 % (Fmoc); Vmax  (DCM)/cm' 3416 & 3319br (2 x 2° amide & 2 x 
urethane NH), 1716br (2 x urethane C=O), 1682br (2 x amide I C=O), 1602 & 1584 
(aromatic C=C), 1513br (2 x amide II & 2 x urethane NH), 1494 (aromatic C=C), 
826 (p-disubstituted Ar-H); Cleavage 9:10:1 TFAIDCMIH 20: LCMSA R 19.2 mm 
(weak); m/z (ES-MS) 541 (MW), 319 (MW- Fmoc). 
6.11 Transformations of the Dipeptide -Derived 5(411) -Oxazolone 




Typical procedure - salt-free phenylalanine methyl ester was prepared by dissolving 
L-phenylalanine methyl ester hydrochloride (9.06 g, 42 mmol) in sodium hydroxide 
solution (1.0 M, 60 ml), and extracting with DCM (3 x 60 ml). After drying 
(Na2 SO4), the combined organic extracts of phenylalanine methyl ester were filtered 
directly into a solution of carbobenzyloxy-L-valine (10.05 g, 40 mmol) in DCM (60 
ml) and the resulting solution cooled to 0 °C. DCC (8.25 g, 40 mmol) was then 
added, immediately giving rise to the formation of a white precipitate. After stirring 
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at 0°C for 1 h the reaction was allowed to warm to room temperature and left stirring 
for a further 16 h. The white precipitate of DCU was removed by filtration and the 
solution was washed with H 20 (3 x 80 ml), 2 M hydrochloric acid (80 ml) and 
saturated NaHCO 3 solution (80 ml). After drying (Na 2SO4), the solution was filtered 
and the solvent removed under reduced pressure to afford the crude dipeptide 84 as a 
white gummy solid (16.41 g, 99 %). 'H NMR indicated 84 was present as a single 
diastereomer. 
Vm  (thin film)/cm' 3298br (NH), 1743 (ester C=O), 1692 (urethane & amide I), 
1536 (amide II & aromatic C=C); oH (250 MHz, CDCI 3) 0.85-0.99 (6H, m, 
CH(CH3)2), 2.03-2.13 (1H, m, CH(CH020 .08-3.12 (2H, m, CHCH2Ph), 3.71 (3H, s, 
OCH3), 3.94-4.00 (1H, m, CHCH(CH3)2), 4.86 (1H, dt, J 8.0, 6.0, CHCH2Ph), 5.10 
(2H, s br, OCH2Ph), 5.30-5.35 (1H, m, OCONH), 6.27 (1H, d, J 8.0, CONH), 7.06-
7.09 (2H, m, Ar-H), 7.21-7.35 (8H, m, Ar-H); O (63 MHz, CDC1 3 ) 17.5 
(CH(C 4H3CBH3) , 19.0  (CH(CAH3CBH3),  30.9 (CH(CAH3CBH3),  37.8 (CHCH2Ph), 52.2 
(OCH3), 53.0 (CHCH 2Ph), 60.2 (CHCH(CH 3)2), 127.9, 128.0, 128.1, 128.4, 128.5 & 
129.1 (10 x Ar-H), 135.4 & 136.1 (2 x ArCH 2), 156.2 (OCONH), 170.7 & 171.5 
(CHCONH & COO); mlz (El) 413 (M). 
6.11.2 N-(Benzyloxycarbonyl)-valinylphenylalanine 85 
o1 0 
OH 
To a solution of crude 84 (6.45 g, 15.6 mmol) suspended in THF/water (1:1) (90 ml) 
was added lithium hydroxide monohydrate (1.31 g, 31.2 mmol). The resulting 
mixture was allowed to stir at room temperature for 2.5 h before acidification with 2 
M HC1 (15 ml) and extraction with DCM (3 x 100 ml). The combined organic 
extracts were dried (Na 2SO4) and concentrated under reduced pressure to afford 
crude 85 as a yellow solid (5.35 g). Recrystallisation from CHC1 3 (ca 30 ml) 
furnished pure 85 as a white powder (3.10 g, 50 %). 
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Mp 175-176 °C, Lit.' 167-168 °C; [a]-11.4 (c 0.5, MeOH), Lit.' -13.3 (c 1.0, 
MeOH); V m  (Nujol) 3337 (OH), 1733 (CO urethane), 1632 (carboxyl C=O), 1522 
(amide II); oH (250 MHz, DMSO d6) 0.80 (3H, d, J6.5, CH(CAH3CBH3)) ,  0.81 (3H, d, 
J 6.5, CH(CAH3 CBH3)), 1.85-1.99 (1H, m, CH(CH3)2), 2.90 (1H, dd, J 14.0, 9.0, 
CHCHA HBPh), 3.06 (1H, dd, J 14.0, 5.0, CHCHAHBPh), 3.90 (1H, dd, J 9.0, 7.5, 
CHCH(CH3)2), 4.41-4.50 (1H, m, CHCH AHBPh), 5.03 (2H, s, OCH2Ph), 7.14-7.28 
(6H, m, Ar-H & CONI]), 7.30-7.40 (5H, m, Ar-I]), 8.19 (1H, d, J 7.5, OCONII), 
12.72 (111, br s, OH); O (63 MHz, DMSO d 6) 18.2 (CH(C4H3CBHMI  19.2 
(CH(CAH 3 CBH 3)), 30.6 (CFI(CAH3CBH3)),  36.9 (CHCH 2Ph), 53.5 (CHCHPh), 60.2 
(CHCH(CAH 3CBHM , 65.5 (OCH 2Ph), 126.6 (p-Ar-H), 127.8 (Ar-H), 127.9 (p-Ar-H), 
128.3 (2 x Ar-H), 128.5 (2 x Ar-H), 129.3 (2 x Ar-H), 137.2, 137.6, (2 x ArCH 2), 
156.1 (OCONH), 171.3, 173.0 (2 x CO); Found (El) 398.18444 (M), C 22H2605N2 
requires 398.18417. 
6.11.3 (1S,4'RS 1-(Benzyloxycarbonylamino)-1-(4'-benzyl-5'-oxo-4 ',5'-dihydro-
oxazol-2'-yl)-2-methyl propane 86 
PZ9 
To a cooled (0 °C) suspension of 85 (2.32 g, 5.8 mmol) in DCM (70 ml), was added 
EDCI (1.23 g, 6.4 mmol). After stirring for 45 min a colourless solution had formed 
and after a total of 17 h stirringt,  the reaction mixture was washed with H 20, HC1 (2 
M), water, saturated sodium bicarbonate solution, and finally H 20(70 ml ea). The 
organic phase was then dried (Na 2SO4) and concentrated to afford 86 as a white solid 
(2.11 g, 96 %) and mixture of (SR) and (S,5) diastereomers. 'H NMR indicated an 
18% diastereomeric excess w.r.t. (S,5). 
OH (200 MHz, CDC1 3) 0.50 (3H, d, J 7.0, CH(CAH3CBH3),  m), 0.75 (3H, d, J 7.0, 
CH(CAH3CBH3), M), 0.77 (6H, d, J7.0, CH(CAH3CBH3),  M & m), 1.87-1.98 (2H, m, 





 M & m), 3.05-4.34 (4H, m, CHCH2Ph, M & m), 4.34-4.51 (4H, m, 
CHCH2Ph, CHCH(CH3 )
21 
 M & m), 5.03-5.21 (6H, m, OCH2Ph, NH, M & m), 7.12-
7.28 (10H, m, Ar-H, M & m), 7.31-7.45 (10H, m, Ar-H, M & m); ö (63 MHz, 
CDCI3) 16.6 (CH(C4H3CBH3),  m), 17.2 (CH(C4H3CBH3),  M), 18.4 (CH(CAH3 CBH3), 
m), 18.5 (CH(CAH3CBH3),  M), 30.4 (CH(CH3)21  m), 30.5 (CH(CH3)21  M), 36.2 
(CHCH2Ph, m), 36.5 (CHCH2Ph, M), 54.7 (CHCH2Ph, m), 55.0 (CHCH2Ph, M), 
65.3 (CHCH(CH 3)
21 
 m), 65.4 (CHCH(CH3 )
21 
 M), 67.0 (CH 2000NH, m), 67.1 
(CH2000NH, M), 127.2(2 xp-Ar-H, M & m), 127.9(2 xAr-H, M), 128.0(2 xAr-
H, m), 128.1 (2 xp-Ar-H, M & m), 128.3 (2 xAr-H, M), 128.4(6 xAr-H, M & m), 
129.5 (4 x Ar-H, M & m), 134.5 (ArCH 2CH, m), 134.6 (ArCH 2CH, M), 135.9 
(ArCH201  M), 136.0 (ArCH 20 1  m), 155.9 (2 x OCONH, M & m), 164.3 (C=N, M), 
164.7 (C=N, m), 176.9 (2 x CHCOO, M & m); m/z (El) 380 (M). 
6.11.3.1 (1S,4 'R) 1-(Benzyloxycarbonylarnino)-1-(4 '-benzyl-5 '-oxo-4 ',S '-dihydro-
oxazol-2 '-yl) -2-rn ethyl propane 86a 
H4 	 H 
The solid (86) was recrystallised from boiling CH 2C12/light petroleum (1:8), cooled 
and filtered to afford a white solid 86a (1.22 g, 55 %): 64 % d.e. w.r.t. (SR). 
Rf (Light petroleum:EtOAc, 2:1) 0.30; Mp 116.5-117.8 °C; Vmax  (KBr)/cm' 1829 
(oxazolone C=O), 1716 (urethane C=O), 1674 (oxazolone C=N), 1558 (amide II); 6H 
(250 MHz, CDC13) 0.53 (3H, d, J 6.5, CH(CAH3CBH3)),  0.76 (3H, d, J 6.5, 
CH(CAH 3CBH3)) ,  1.86-1.96 (1H, m, CH(CH 3)2), 3.16 (1H, dd, J 14.0, 5.5, 
CHCHA HBPh), 3.26 (1H, dd, J 14.0, 5.0, CHCHAHBPh), 4.41-4.47 (2H, m, CHCH 2Ph 
& CHCH(CH3)2), 5.07 (1H, d, J 12.0, OCHA HBPh), 5.15 (1H, d, .J 12.0, OCHAHBPh), 
5.27 (1H, d, J9.0, NI]), 7.14-7.27 (5H, m, Ar-H), 7.40 (5H, bs, Ar-If); 6 (63 MHz, 
CDC13) 16.6 (CH(UIH3CBH3)), 18.4  (CH(CAH3CBH3)),  30.4 (CH(CH3)2), 36.2 
(CHCH2Ph), 54.7 (CHCHPh), 65.3 (CHCH(CH 3)2), 67.1 (OCH 2Ph), 127.2, 128.0, 
128.1, 128.4 & 129.5 (10 xAr-H), 134.5 (CH2Ph), 135.9 (CH2Ph), 155.9 (OCONH), 




6.11.3.2 (JS,4 'S) 1-(Benzyloxycarbonylarnino)-1-(4 '-benzyl-5 '-oxo-4 5 '-dihydro-
oxazol-2 '-yl) -2-rn ethyl propane 86b 
0 ' N HI 
0 
Y" H 
Subsequent concentration of the mother liquor yielded 86b as a white powder (0.59 
g, 27 %): 91 % d.e. w.r.t. (S,5). 
Rf (Light petroleum:EtOAc, 2:1) 0.34; Vmax  (KBr)/cm' 1830 (oxazolone C0), 1717 
(urethane C=O), 1654 (oxazolone C=N), 1540 (amide II); 5H  (250 MHz, CDC13) 0.77 
(6H, d, J 7.0, CH(CH3CBH3)), 1.93-1.98 (1H, m, CH(CH3)2), 3.11 (1H, dd, J 14.0, 
6.0, CHCHA HBPh), 3.25 (1H, dd, J 14.0, 5.0, CHCHAHBPh), 4.38 (1H, dd, J 9.5, 5.5, 
CHCH(CH3)2), 4.47-4.5 1 (1H, m, CHCH2Ph), 5.12 (2H, s, OCH2Ph), 5.12-5.18 (1H, 
m, NH), 7.12-7.25 (5H, m, Ar-H), 7.36 (5H, bs, Ar-H); 5 c (63 MHz, DEPT, CDC13) 
17.1 (CH(C4H3CBH3)), 18.5 (CH(CAH3CBH3)),  30.5 (CH(CH3)2), 36.5 (CHCH2Ph), 
55.0 (CHCH2Ph), 65.4 (CHCH(CH 3)2), 67.1 (OCH 2Ph), 127.2, 128.0, 128.1, 128.3, 
128.4, & 129.5 (10 x Ar-H), 134.5 (CHCH 2Ph), 135.9 (OCH2Ph), 155.8 (OCONIH), 
164.3 (C=N), 176.9 (COOCH); Found (El) M 380.17285, C 22H24N204 requires 
380.17361. 
6.11.4 General procedure for synthesis of dipeptide-derived resin-bound 5(411)-
oxazolones 88a-b 
Resin-bound fluorenylmethyl ester-protected dipeptide (1 eq) was treated with 20 % 
piperidine in DMF (x 3; 15 min ea), washed (DMF x 3) and neutralised with 3 % 
acetic acid in DCM (x 4; 5 min ea). After washing this time with DCM (x 3), the 
deprotected resin was treated with EDCI (3 eq) in DCM (-1 5 mug resin) and spun at 
room temperature (>15 h). The resin slurry was filtered, washed according to the 
standard protocol and dried under vacuum. 
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6.11.5 (1 'S,4' 'RS")-4- LN-Methoxycarbonyl-2 '-methyl--i '-(4' '-benzyl-5' '-oxo- 




The general procedure outlined above (6.11.4), was followed using PS-HMPA-Val-
Phe-OFm (69a) (assume !~0.9 mmollg - 400 mg, 0.36 mmol) with EDCI (206 mg, 
1.08 mmol). Analysis confirmed that cyclisation to the 5(4H)-oxazolone had 
occurred yielding the title compound as a mixture of (S,S) and (SR) diastereomers. 
Vm  (DCM)/cm' 3428 (2° amide & urethane NH), 1823 (oxazolone C=O), 1722 
(urethane C=O), 1 673br (oxazolone CN & amide I C=O), 1602 (aromatic C=C), 
1510 (amide II NH), 1492 (aromatic C=C); 8 (63 MHz, CD 2C121  gel) 16.9 & 17.4 (2 
x CH(C4H3CBHM I  18.7 (2 x CH(CAH3CBH3)),  30.7 (2 x CH(CH0 206.7 & 36.9 (2 x 
CH2Ph), 55.1 & 55.5 (2 x CHCH2Ph), 65.7 & 65.8 (2 x CHCH(CH 3)2), 66.7 
(CH2000NH), 67.6 (CH20Ar), 114.8 (2 x m-ArHCH 20), 127.4 (ArH Phe), 128.6(2 
x ArH Phe), 129.8 (2 x ArH Phe), 135.3 (ipso-C Phe); Cleavaget  9:10:1 
TFAIDCM/H20: m/z (ES-MS) 265 (MH + H20). 
6.11.6 (1 'S,4' 'RS)-4- N-Methoxycarbonyl-2 '-methyl-i '-(4' '-benzyl-5' '-oxo-
4' ',S' '-dihydro-oxazol-2' '-yl)-aminopropyl] -phenoxymethyl polystyrene 88b 
ojç9 
W 0 )~'~ 	 0 
The general procedure outlined above (6.11.4), was followed using PS-Wang-Val- 
Phe-OFm (74a) (assume :0.9 mmol/g - 700 mg, 0.63 mmol) with EDCI (361 mg, 
treatment with TFA results in hydrolysis of the 5(4H)-oxazolone 
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1.89 mmol). Analysis confirmed that cyclisation to the 5(411)-oxazolone had 
occurred yielding the title compound as a mixture of (S,S) and (SR) diastereomers. 
Vmax  (DCM)/cm' 3429 (urethane NH), 1826 (oxazolone C=O), 1722 (urethane C=O), 
1673br (oxazolone C=N & amide I C=O), 1602 & 1585 (aromatic C=C), 1513 
(amide II NH), 1493 (aromatic C=C), 826 (p-disubstituted Ar-H); 5 c (63 MHz, 
CD2C12 , gel) 16.8 & 17.4 (2 x CH(C4H3CBH3)),  18.7 (2 x CH(CAH3CBH3)),  30.7 (2 x 
CH(CH3)2), 36.7 & 36.9 (2 x CH2Ph), 55.0 & 55.4 (2 x CFICH2Ph), 65.7 & 65.8 (2 x 
CHCH(CH3 )2), 67.0 (CH2000NH), 70.1 (CH 20Ar), 114.8 (2 x m-ArHCH 20), 127.4 
(ArH Phe), 128.6 (2 x ArH Phe), 129.8 (2 x ArH Phe), 130.1 (2 x o-ArCH 20), 135.4 
(ipso-C Phe), 177.4 (2 x CHCOO); Cleavaget  9:10:1 TFA/DCMIH 20: m/z (ES-MS) 
265 (MH + H20). 
6.11.7 General procedure for nucleophilic ring-opening of resin-bound 5(411)-
oxazolones 88a-b 
6.11.7.1 Amines 
To a slurry of the polymer-supported 5(411)-oxazolone (1 eq) in NMP (1 ml/50 mg 
resin), was added the nucleophile (3 eq) along with DMAP (0.5 eq). The resulting 
suspension was agitated at room temperature (>15 h), before filtering, washing 
according to the standard protocol and drying. 
6.11.7.2 Amino acid salts 
Polymer-supported 5(4R)-oxazolone (1 eq) was suspended in a solution of the 
ammonium salt of the amino acid fluorenylmethyl ester tosylate (3 eq) and DMAP 
(3.5 eq) in DMF/NMP (1 ml/40 mg resin). The resin slurry was spun at room 
temperature (>15 h), before being filtered, washed according to the standard protocol 
and dried. 
6.11.7.3 Alcohols 
Resin-bound 5(411)oxazolone (1 eq) was suspended in a mixture of MeOHIDMF 
(1:1) (1 m1120 mg resin). Triethylamine (0.5 eq) was added and the reaction rotated 
"roll" 
Experimental 
at room temperature (>15 h), before filtering, washing according to the standard 
protocol and drying. 
6.11.8 4(Na-Methoxycarbonylva1y1D,Lpheny1alanylaminobenzy1) 
phenoxymethyl polystyrene 89a 
0 
OANN m H 0 
The general procedure detailed above (6.11.7.1) was followed using resin-bound 
oxazolone 88b (assume :0.45 mmol/g, 100 mg, 0.05 mmol), benzylamine (14.8 tl, 
0.14 mmol) and DMAP (-2.5 mg, 0.02 mmol). Analysis indicated successful ring-
opening to furnish the title compound as a mixture of diastereomers. 
Vmax  (DCM)/cm' 3424 & 3298br (2° amide & urethane NH), 1716 (urethane C=O), 
1674 & 1651 (2 x amide I C=O), 1602br (aromatic C=C), 1549br (2 x amide II & 
urethane NH), 1494br (aromatic CC); ö (63 MHz, CD 2C121  gel) 18.2br (2 x 
CH(CAH 3CBH 3)) ,  19.1br (2 x CH(CAH3CBH3)),  31.5 (2 x CH(CH3)2), -40 (2 x 
CHCH2Ph - masked by polymer backbone), -54br (2 x CHCH 2Ph - obscured by 
solvent), -61br (2 x CHCH(CH 3)2), 66.8 (CH2000NH), 70.1 (CH2OAr), 114.7 (2 x 
m-ArHCH 20), 128.2br (all other ArH obscured by polymer back-bone); Cleavage 
9:10:1 TFA/DCMIH 20: LCMSA R 5.5br & 8.3br mm (two diastereomers); m/z (ES-
MS) 354 (MW), 376 (MNa). 
6.11.9 (1 'R)-4- [NaMethoxycarbonyIvalyJD,Lphenylalany1amino1 '-(phenyl)-
ethyl-phenoxyacetyl aminomethyl polystyrene 89b 
O'f~ 0 4c 
The general procedure detailed above (6.11.7.1) was followed using resin-bound 
oxazolone 88a (assume :!~0.9 mmollg, 120 mg, 0.11 mmol), (R)-(+)-a- 
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methylbenzylamine (42 tl, 0.32 mmol) and DMAP (-6.5 mg, 0.05 mmol). Analysis 
indicated successful ring-opening to afford the desired compound as a mixture of 
diastereomers. 
Vmax  (DCM)/cm' 3425 & 3304br (2° amide & urethane NH), 1711 (urethane C=O), 
1677br (3 x amide I C=O), 1602 & 1581 (aromatic C=C), 1509br (3 x amide II & 
urethane NH), 1493 (aromatic C=C), 828 (p-disubstituted Ar-H); & (63 MHz, 
CD2C12, gel) 18.2br (2 x CH(C4H3CBH3)),  19.1br (2 x CH(CAH3CBH3)),  22.lbr (2 x 
CHCH3), 31.1 & 31.5 (2 x CH(CH 3)2), 38.4 (2 x CHCH2Ph - partially obscured by 
polymer backbone), 48.9 (NHCHCH 3), 53.2br (2 x CHCH2Ph - partially obscured by 
solvent), 61.2br (2 x CHCH(CH 3)2), 66.4 (CH2OCONH), 67.6 (CH2OAr), 114.7 (2 x 
m-ArHCH 20), 128.2br & 128.5br (10 x ArH Phe - obscured by polymer back-bone), 
129.5 (2 x o-ArHCH 20), 137.1br (2 x ipso-C); Cleavage 9:10:1 TFAIDCM/H 20: LC-
MS' R 20.8 & 21.6 mm (two diastereomers); m/z (ES-MS) 368 (MW). 
6.11.10 4- 
aminobenzyll-phenoxymethyl polystyrene 89c 
ooi 
;
N _- 6N 1~ '-0 
The general procedure detailed above (6.11.7.1) was followed using resin-bound 
oxazolone 88b (assume :0.45mmol/g, 100 mg, 0.05 mmol), N-methylbenzylamine 
(17.6 tl, 0.14 mmol) and DMAP (-2.5 mg, 0.02 mmol). Analysis indicated 
successful ring-opening by the secondary amine to afford the desired compound as a 
mixture of diastereomers. 
Vmax  (DCM)/cm' 3417 & 3302br (2° amide & urethane NH), 1716br (ester & 
urethane C=O), 1684 & 1644br (2 x amide I C=O), 1602 & 1583 (aromatic C=C), 
15 l4br (2 x amide II & urethane NH), 1494 (aromatic C=C); ö (63 MHz, CD 2C12 , 
gel) 17.7 (CH(C4H3CBH3)),  19.3  (CH(CAH3CBH3)),  31.5 (CH(CH3)2), 39.3 (2 x 
CHCH2Ph), 50.4 & 51.3 (NCH3 CH2Ph), 53.2br (2 x CHCH 2Ph - partially obscured 
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by solvent), 60.3 (CHCH(CH 3)2), 66.8 (CH2000NH), 70.2 (CH2OAr), 114.7 (2 x m-
ArHCH20), 128. lbr (10 x ArH Phe - obscured by polymer back-bone), 129.7 (2 x o-
ArHCH20) 1  136.Sbr (2 x ipso-C); Cleavage 9:10:1 TFA!DCM/H20: 
LCMSB  R, 22.4 
& 23.2 mm (two diastereomers); m/z (ES-MS) 368 (MH), 390 (MNa). 
6.11.11 




H 	 6HH 
0 
0 
The general procedure detailed above (6.11.7.1) was followed using resin-bound 
oxazolone 88a (assume <0.5mmollg, 60 mg, 0.03 mmol), methylamine 
hydrochloride salt (6 mg, 0.09 mmol) as a suspension in NMP (1.5 ml) and 
stoichiometrict DMAP (11 mg, 0.09 mmol) to mop up the acid released. Analysis 
indicated successful ring-opening by the primary amine to afford the desired 
compound as a mixture of diastereomers. 
V max  (DCM)/cm' 3427 & 33 l5br (3 x amide & urethane NH), 1714 (urethane C=O), 
1682br & 1652 (3 x amide I C=O), 1602br (aromatic CC), 1513br (3 x amide II & 
urethane NIL-I), 1494 (aromatic C=C); & (63 MHz, CD 2C12, gel) 17.7 
(CH(C4H3CBHM I  19.3 (CH(CAH3 CBH3)), 31.5 (CH(CH 3)2), 39.3 (2 x CHCH 2Ph), 
50.4 & 51.3 (NCH 3 CH2Ph), 53.2br (2 x GHCH2Ph - partially obscured by solvent), 
60.3 (CHCH(CH3)2), 66.8 (CH2000NH), 70.2 (CH2OAr), 114.7 (2 x m-ArHCH 20), 
128.lbr (10 x ArH Phe - obscured by polymer back-bone), 129.7 (2 x o-ArHCH 20), 
136.5br (2 x ipso-C); Cleavage 9:10:1 TFA/DCMIH20: LCMSA R 1.2 & 1.3 mm 





phenoxymethyl polystyrene 89e 
A 
I 	
O N N N NH22 
HI 
OLO 
The general procedure detailed above (6.11.7.1) was followed using resin-bound 
oxazolone 88b (assume :!~0.45 mmol/g, 100 mg, 0.05 mmol), hydrazine hydrate (:!~55 
% H20) (9.34 j.il, 0.14 mmol) and DMAP (-2.5 mg, 0.02 mmol). Analysis indicated 
successful ring-opening the desired compound as a mixture of diastereomers. 
Vmax  (DCM)/cm' 3420 & 3293 (2° amide, urethane and hydrazine NH), 1714 
(urethane C=O), 1674 & 1652 (2 x amide I C=O), 1602 & 1584 (aromatic C=C), 
1514br (2 x amide II & urethane NH), 1494 (aromatic CC); 5 c (63 MHz, CD 2C121  
gel) 18.Obr (2 x CH(C4H3 CBH3)), 19.2br (2 x CH(CAH 3 CBH3)), 31.5 (2 x CH(CH3 )2), 
38.5 & 38.7 (2 x CHCH 2Ph - partially obscured by polymer backbone), 53.2br (2 x 
CHCH2Ph - partially masked by solvent), 60.7br (2 x CHCH(CH 3)2), 66.8 
(CH2000NH), 70.1 (CH20Ar), 114.8 (2 x m-ArHCH 20), 128.2br (all other Ar-H 
obscured by polymer back-bone), 137.Obr (ipso-C Phe); Cleavage 9:10:1 





0 H OjCr H 
	 H 
The general procedure detailed above (6.11.7.2) was followed using resin-bound 
oxazolone 88a (assume :0.40 mmollg, 49 mg, 0.02 mmol) with TSA-Phe-OFm 
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(65a) (31 mg, 0.06 mmol) and DMAP (9 mg, 0.07 mmol) in DMF (1 ml). Analysis 
indicated successful ring-opening to yield the desired tripeptide as a mixture of 
diastereomers. Gel phase ' 3C NMR analysis was not feasible due to the small sample 
size. 
Loading 0.23 mmollg (Fm), 61 %; Vmax  (DCM)/cm' 3424 & 3306br (2 x amide & 
urethane NH), 1732 & 1715 (ester & urethane CO), 1694br & 165 1 b (2 x amide I 
C=O), 1601br (aromatic C=C), 1538, 1519 & 1504br (2 x amide II & urethane NH & 
aromatic C=C); Cleavage 9:10:1 TFAJDCM/H 20: LCMSA R 26.1 & 26.7 mm (two 
diastereomers); m/z (ES-MS) 591 (MW), 613 (MNa). 
6.11.14 4-(N'-Methoxycarbony1valy1-D,L-phenyla1any1oxymethyl)-
phenoxymethyl polystyrene 91 
0 	 0 
0Xc0 0 
The general procedure previously described (6.11.7.3) was followed using resin-
bound oxazolone 88b (assume :0.45 mmol/g, 150 mg, 0.07 mmol) and triethylamine 
(5 p.1, 0.04 mmol) in MeOFIIDMF (1:1) (6 ml). Analysis indicated successful ring-
opening by the alcohol to afford the title compound as a mixture of diastereomers. 
Vmax  (DCM)/cm' 3422 & 3324br (2° amide & urethane NH), 1716br (ester & 
urethane C0), 1679 (amide I C0), 1602 & 1585 (aromatic C=C), 15 l4br (amide 
II & urethane NH), 1494 (aromatic C=C), 826 (p-disubstituted Ar-H); 6  (63 MHz, 
CD2C12 , gel) 17.3 & 17.7 (2 x CH(C4H3CBH3)),  19.1 & 19.3 (2 x CH(CAH 3 CBH3)), 
31.2 (2 x CH(CH 3)2), 38.1 (2 x CHCH 2Ph), 52.4 (OCH 3), 53.4 (2 x CHCH2Ph), 60.4 
(2 x CHCH(CH 3)2), 66.9 (CH2000NH), 70.2 (CH2OAr), 114.8 (2 x m-ArHCH 20), 
127.2 (ArH Phe), 128.7 (2 x ArH Phe), 129.4 (2 x ArH Phe), 130.0 (2 x o-
ArHCH20), 136.3 (ipso-C Phe); Cleavage 9:10:1 TFA/DCM/H 20: LCMSB R 18.2 
& 19.5 mm (two diastereomers); m/z (ES-MS) 279 (MW). 
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6.11.15 (1S)-1-(Benzyloxycarbonylamino)-1-(4'-benzylidene-5 1 -OxO-4',5'-
dihydro-oxazol-2 1 -yl)-2-methyl propane 94 
A solution of DDQ (170 mg, 0.75 mmol) in dry dimethoxyethane (2 ml) was added 
to a solution of (1 S,4RS)- 1 -(Benzyloxycarbonylamino)- 1 -(4'-benzyl-5 '-oxo-4',5 
dihydro-oxazol-2'-yl)-2-methyl propane (86) (285 mg, 0.75 mmol) in dry 
dimethoxyethane (4 ml). 2,4,6-Collidine (99 tl, 0.75 mmol) was added to the red 
solution, turning it deep red/black and the resulting solution stirred, under argon, at 
room temperature for 24 h. The red precipitate was filtered off and the filtrate 
concentrated to a dark red oil (516 mg). Column chromatography eluting with light 
petroleum/ether (5:1), furnished the title compound as a white solid (41 mg, 14 
which decomposed rapidly when stored at room temperature. 
Rf (Light petroleum: ether, 5:1) 0.12; (Found: C, 69.77; H, 5.70; N, 7.34; C24H29N04 
requires C, 69.83 H, 5.86; N 7.40); [a]°  -41 (c 0.50, MeOH); Vmax  (KBr)/cm' 3309 
(urethane NH), 1799 (oxazolone C0), 1784, 1695 (urethane C0), 1687 & 1658 
(amide I C=O, alkene C=C, oxazolone C=N), 1539 (amide II), 768 & 688 (mono-
substituted Ar-H); SH (250 MHz, CDC13) 0.98 (3H, d, J 7.0, CH(CAH3CBH 3)), 1.05 
(3H, d, J7.0, CH(CAH 3CRH3)), 2.24-2.32 (1H, m, CHCH(CH 3)2), 4.74 (1H, dd, J9.5, 
5.5, NHCHCH(CH3)2), 5.15 (2H, s, OCH2Ph), 5.40 (1H, d, J9.5, NH), 7.21 (1H, s, 
C=CHPh), 7.29-7.45 (8H, m, Ar-H), 8.03-8.11 (2H, m, 2 x o-Ar-HCH=C); S (63 
MHz, CDC13) 17.4 (CH(C4H3CBH3)) , 18.8  (CH(CAH 3 CBH3)), 31.3 (CHCH(CH 3)2), 
55.2 (CHCH(CH 3)2), 67.2 (OCH2Ph), 128.0, 128.2, 128.5, 128.8, 131.4, 132.4 & 
133.1 (10 xAr-H & CCHPh), 132.8 (C=CHPh), 135.9 (OCH2Ph), 155.9 (OCONH), 




6.11.16 (1 'S)-4- [N-Methoxycarbonyl-2 '-methyl-i '-(4' '-benzylidene-5' '-oxo-
4' ',5' '-dihydro-oxazol-2 ' '-yl)-aminopropyl] -phenoxymethyl polystyrene 95 
ooi N;POZ 
Typical procedure - resin-bound 5(411)-Oxazolone (88b) (assume :!~0.9 mmol, 500 
mg, 0.45 mmol), was allowed to swell in dimethoxyethane (5 ml) before being 
treated with a solution of DDQ (306 mg, 1.35 mmol) in dimethoxyethane (3 ml). The 
resin slurry was spun at room temperature (15 h), before being washed according to 
the standard protocol and then resubjected to the original reaction conditions. After 
reacting for a further 15 h the resin was filtered, washed as before and dried. 
Analysis indicated almost complete conversion to the title compound, which 
appeared to be a single geometric isomer. Traces of unoxidised starting material 
were detected by ES-MS and also hindered interpretation of the gel phase ' 3C NMR 
spectrum. 
Vmax  (DCM)/cm' 3427 (2° amide & urethane NH), 1805 (oxazolone C=O), 1722 
(urethane C0), 1660br (amide I C=O, alkene C=C, oxazolone C=N), 1602 & 1584 
(aromatic C=C), 1514 (amide II), 1493 (aromatic C=C), 827 (p-disubstituted Ar-H); 
ö (63 MHz, CD2CI21  gel) 17.6 (CH(CAH3CBH3)),  19.0 (CH(CAH3CBH3)),  31.4 (2 x 
CFI(CH02), 55.7 (CHCH(CH 3)2), 67.1 (CH2000NH), 70.1 (CH20Ar), 114.8 (2 x m-
ArHCH20), 128.2 & 129.0 (4 x Ar-H), 130.0 (2 x o-ArHCH 20), 131.6 & 132.6 (Ar-
H & C=CHPh); Cleavaget  9:10:1 TFA/DCMIH 20: m/z (ES-MS) 263 (MH + H20), 
281 (MH + 2 x H20); Cleavage 1:1 TFAIDCM: m/z (ES-MS) 245 (MH), 263 (MH 
+H20). 
treatment with TFA results in almost hydrolysis of the 5(4H)-oxazolone 
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6.11.17 4- 	 - 
phenoxymethyl polystyrene 96 
(i 
,ky H 
H 	 I 
0 0 
The general procedure previously described for 5(4H)-oxazolones (6.11.7.3), was 
followed using resin-bound 4-arylidene 5(4H)-oxazolone (95) (assume :50.45 
mmol/g, 82 mg, 0.04 mmol) and triethylamine (2.6 id, 0.02 mmol) in MeOHIDMF 
(1:1) (4 ml). Analysis indicated successful ring-opening by the alcohol to afford the 
title compound as a single stereoisomer. 
Vmax  (DCM)/cm' 3418 & 3307br (2° amide & urethane NH), 1721 & 1741br (ester & 
urethane & amide I C=O), 1612 (alkene C=C), 1602 & 1584 (aromatic C=C), 15 l4br 
(amide II & urethane NH), 1494 (aromatic C=C), 827 (p-disubstituted Ar-H); 6 (63 
MHz, CD 2C12 , gel) 17.7 (CH(CAH3CBH3)),  19.2  (CH(CAH3CBH3)),  30.8 (CH(CH3 )2), 
52.6 (OCH3), 60.7 (CHCH(CH3)2), 67.0 (CH2000NH), 70.1 (CH 2OAr), 114.7 (2 x 
m-ArHCH 20), 128.1 (ArH Phe & C=CHPh obscured by polymer backbone), 128.7 
(2 x ArH Phe), 129.6 (2 x ArH Phe), 130.0 (2 x o-ArHCH 20), 132.8 (ipso-C Phe); 
Cleavage 9:10:1 TFAIDCMIH 20: LC-MS" R 16.9 mm (single diastereomer); m/z 









The general procedure detailed above (6.11.7.2) was followed using resin-bound 4-
arylidene 5(411')-oxazolone 95 (assume :0.5 mmollg, 80 mg, 0.04 mmol) with TSA-
Phe-OFm (65a) (62 mg, 0.12 mmol) and DMAP (17 mg, 0.14 mmol) in NMP (2 ml). 
Analysis indicated successful ring-opening to yield the desired tripeptide as a single 
diastereomer. Gel phase ' 3C NMR analysis was of poor quality due to sample size 
and too broad to interpret successfully. 
Loading 0.16 mmol/g (Fm); Vmax  (DCM)/cm' 3427 & 33 l7br (2° amide & urethane 
NH), 1714br (ester & urethane C=O), 1682br (3 x amide I C=O and alkene CC), 
1602br (aromatic C=C), 1513br (3 x amide II & urethane NH), 1494 (aromatic 
C=C); Cleavage 9:10:1 TFAIDCMJH 20: LC -MS' R 26.9 mm (single diastereomer); 
m/z (ES-MS) 588 (MW), 610 (MNa). 
6.11.19 





Resin-bound 4-arylidene 5(4H)-oxazolone 95 (assume :f ~-0.9 mmol/g, 150 mg, 0.14 
mmol) was suspended in a suspension of TSA-13-Ala-OFm (77c) (178 mg, 0.41 
mmol), NMM (45 .tl, 0.41 mmol) and DMAP (2.5 mg, 0.02 mmol) in NMP (2 ml). 
The resin slurry was spun at room temperature (>15 h), before being filtered, washed 
according to standard protocol and dried. Analysis confirmed successful ring-
opening to yield the desired dehydro-tripeptide as a single diastereomer. However, 
the gel phase ' 3C NMR spectrum obtained was very weak and of fairly poor quality, 
indicating that the reaction had not gone to completion. 
0.09 mmollg (Fm); Vmax  (DCM)/cm' 3423 & 3324br (2 x amide & urethane NH), 
171 6br (ester & urethane C0), 1 694br (2 x amide I C=O & alkene C=C), 1602 & 
1585 (aromatic C=C), 151 4br (2 x amide II & urethane NH), 1494 (aromatic C=C); 
(63 MHz, CD2 C121  gel) 17.6 (CH(C4H3CBH3)),  19.2  (CH(CAH3CBH3)),  31.1 
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(CH(CH3 )2), 33.9 & 35.8 (NHCH2CH2CO), 46.9 (OCH2CH), 60.1 (CHCH(CH 3)2), 
67.2 (OCH2CH & CH2000NH), 70.1 (CH20A01 114.8 (2 x m-ArHCH 20), 120.1(2 
x ArH OFm), 128.lbr (6 x ArH OFm, 3 x ArH Phe and C=CH masked by broad 
polymer backbone), 129.5 (2 x ArH Phe), 130.0 (2 x o-ArHCH 20); Cleavage 9:10:1 
TFAIDCM/H20: LCMSA  R 20.0 mm (single diastereomer); m/z (ES-MS) 512 
(MW), 534 (MNa). 
6.11.20 (1S,4'RS)-1-(Benzyloxycarbonylamino)-2-methyl-1- [4'-(prop-2' '-enyl)-
4'-benzyl-5'-oxo-4 1,51-dihydro-oxazol-2 
yl] 




Typical procedure - to the reaction vessel containing anhydrous THF (20 ml), was 
added freshly-distilled allyl bromide (130 jtl, 1.5 mmol) and NaHMDS (0.6 M in 
toluene, 1.23 ml, 0.74 mmol) before cooling to 0 °C. A solution of (1S,4'RS)-1-
(benzyloxycarbonylamino)- 1 -(4'-benzyl-5'-oxo-4',5 '-dihydro-oxazol-2'-yl)-2-methyl 
propane (86) (0.23 g, 0.6 mmol) in THF (10 ml) was added dropwise with stirring, 
resulting in a yellow solution and formation of a white precipitate. The reaction was 
allowed to warm to 7 °C with constant stirring and the progress monitored by tic. 
After 100 min no starting material remained, and the reaction was quenched with 
saturated ammonium chloride solution (20 ml) followed by water (25 ml). The 
aqueous phase was separated and extracted with EtOAc (3 x 75 ml) and the 
combined organic extracts dried (Na 2 SO4) and concentrated. The resulting yellow oil 
was then redissolved in CHC1 3 and finally concentrated to afford a yellow oil (0.28 
g). Purification by flash-column chromatography with EtOAc/light petroleum (1:3) 
as eluent, was carried out using a minimum amount of silica gel to avoid 
decomposition of the product. 101 was obtained as a pale yellow oil (0.13 g, 52 
'H NMR indicated a 55 % diastereomeric excess of the (SR) product. 
Rf (EtOAc:light petroleum, 1:4), 0.48); Vmax  (thin film)/cm' 1819 (oxazolone C=O), 
1728 (urethane C0), 1674 (oxazolone C=N), 1519 (amide II); oH (250 MHz, 
CDCI3) 0.50 (3H, d, J 7.0, CH(CAH3CBH3),  M), 0.68 (3H, d, J 7.0, CH(CAH3CBH3), 
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M), 0.75 (611, d, J 7.0, CH(CAH3CBH3), m), 1.77-1.85 (214, m, CH(CH 3)21  M & m), 
2.61 (411, br d, J7.5, CH2CH=CH2, M & m), 3.06 (1H, d, J 13.5, CHAHBPh, M), 3.14 
(1H, d, J 13.5, CHAHBPh, M), 3.04-3.17 (211, m, CH2Ph, m), 4.23-4.29 (111, m, 
CHCH(CH3)
21 
 m), 4.35 (111, dd, J9.5, 6.0, CHCH(CAH3CBH3), M), 5.06-5.18 (10H, 
m, OCH2Ph, CH=CH2 & NH, M & m), 5.51-5.65 (2H, m, CH2CHCH2, M & m), 
7.08-7.23 (10H, m, Ar-H, M & m), 7.32-7.37 (1011, m, Ar-H, M & m); ö (63 M1-lz, 
CDC13) 16.9 (CH(C4H 3CB113), M), 17.0 (CH(C4H 3 CB113), m), 18.5 (2 x 
CH(CAH3 CBH3), M & m), 30.3 (CH(CH 3)
21 
 m), 30.5 (CH(CH3)
21 
 M), 40.9 
(CH2CH=CH2, M), 41.4 (CH2CH=CH2, m), 42.4 (CCH2Ph, M), 42.7 (CCH 2Ph, m), 
54.8 (2 x CHCH(CH 3)
21 
 M &m), 67.0 (2X OCH2Ph, M & m), 73.9 (CCOO, M), 
74.0 (CCOO, m), 77.1 (2 x CH 2 CH=CH2, M & m), 120.7 (CH2CH=CH2, m), 120.8 
(CH2CH=CH2, M), 127.2, 127.3, 128.0, 128.1, 128.2, 128.4, 130.0, 130.1 & 130.4 
(20 x Ar-H, M & m), 134.1 (2 x CH2Ar, M & m), 136.0(2 x CH2Ar, M & m), 155.7 
(2 x OCONH, M & m), 163.0 (2 x N=CO, M & m), 178.5 (2 x COO, M & m); 
Found (El) M 420.20659, C 25H28N204 requires 420.20491. 
6.11.21 
3-yl) amide 102a 
H 
- OyN o 
0 /  
To a cooled (0 °C) solution of 5(411)-oxazolone 86 (0.46 g, 1.2 mmol) in anhydrous 
THF (5 ml) was added NaHMDS (0.6 M in toluene, 2.47 ml, 1.48 mmol), dropwise 
with stirring. The reaction was monitored by tic (toluene/EtOAc, 2:1) and after 5 h 
the reaction was quenched with saturated ammonium chloride solution (3.5 ml) and 
H20(3.5 ml). The aqueous phase was separated and extracted with EtOAc (3 x 15 
ml) and the combined organic extracts were dried (Na 2SO4) and concentrated. After 
redissolving in CHC1 3 the solvent was removed under reduced pressure to yield a 
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pale yellow solid (0.45 g). The product was purified by flash-column 
chromatography on silica gel with toluene/EtOAc (2:1) as eluent, and along with a 
number of other by-products, 102a was isolated as a white solid (152 mg, 24 %). 'H 
NMR indicated a (2:1) ratio of diastereomers. 
Rf (Toluene:EtOAc, 2:1), 0.16); Vm  (thin film)/cm' 3273 (NH), 1774 (ketone C0), 
1716br (urethane, lactam & amide I C=O), 1604 (aromatic C=C), 1538 (amide II & 
urethane NH), 1498 (aromatic C=C), 751 & 700 (mono-disubstituted Ar-H); 5 H (250 
MHz, CDC1 3) 0.43 (1H, dd, J 13.5, 12.0, CHCHAHBPh, m), 0.75 (1H, dd, J 13.5, 
12.0, CHCHAHBPh, M), 0.90 (3H, d, J 7.0, CH(CAH3CBH3),  M), 0.93 (3H, d, J 7.0, 
CH(CAH3 CBH3) ,  M), 0.96 (3H, d, .J 7.0, CH(CAH3CBH3),  m), 1.04 (3H, d, J 7.0, 
CH(CAH3 CBH3) ,  m), 2.00-2.10 (1H, m, CHCH(CH 3 )2 , M), 2.23 (1H, dt, J 7.0, 3.5, 
CH(CH3)
21 
 m), 2.58 (1H, dd, J 13.5, 3.5, CHCHAHBPh, m), 2.65 (1H, dd, J 13.5, 3.5, 
CHCHAHBPh, M), 2.95-3.10 (1H, br d, C4CHA HBPh, M), 3.26 (1H, br d, J 12.0, 
C4CHAHBPh, M), 3.61 (1H, d, J 13.0, C4CHA HBPh, m), 3.94 (1H, dd, J 3.5, 1.0, 
CHCH(CH 3 )
21 
 m), 4.08 (1H, m, CHCH(CH3)2 , M), 4.22' (1H, br dd, J --'12, 3.0, 
CHCHAHBPh, m), 4.28 (1H, dd, J 12.0, 2.5, CHCHAHBPh, M), 4.35 (1H, d, J 13.0, 
C4CHAHB , m), 5.11 (2H, br s, OCH2Ph, M), 5.26 (1H, d, J9.0, NHCHCH(CH3)21  M), 
5.87 (1H, br s, NHCHCHAHBPh, M), 5.93 (1H, br s, NHCHCHAHBPh, m), 6.20 (1H, 
br s, NHCHCH(CH 3)2 , m), 6.75-6.80 (4H, m, ArH, m & M), 7.06-7.41 (28H, m, 26 
x ArH & 2 x CHCONHC 4, m & M); Found (FAB) MH 528.24937, C 31 H34N305 
requires 528.24985. 
6.11.22 
3-yl) amide 102b 
To a cooled (0°C) solution of 5(411)-oxazolone 86 (1.0 g, 2.60 mmol) in anhydrous 
THF (120 ml), was added NaHMDS, 0.6 M in toluene (5.2 ml, 3.12 mmol), dropwise 
over 20 mm. The solution turned yellow and was allowed to stir (0°C - room 
temperature) for a total of 5 h. The reaction was quenched by pouring into saturated 
ammonium chloride solution (80 ml), H 20 (80 ml) was added and the product 
extracted with EtOAc (3 x 120 ml). The combined organic extracts were dried 
(Na2SO4), concentrated, dissolved in CHC1 31  to aid removal of EtOAc, and 
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concentrated to furnish a pale yellow foam (1.03 g). Purification by flash column 
chromatography eluting with toluene/EtOAc (2:1) furnished the title compound as a 
white solid (266 mg, 19 %). 'H NMR confirmed that it was a single diastereomer. 
Rf (toluene:EtOAc, 2:1), 0.24); Vm  (thin film)/cm' 3282 (NH), 1777 (ketone C=O), 
1710br (urethane, lactam & amide I C=O), 1606 & 1585 (aromatic C=C), 1534 
(amide II & urethane NH), 1498 (aromatic C=C), 749 & 700 (mono-disubstituted 
Ar-H); oH  (250 MHz, CDC13) 0.72 (1H, dd, J 13.5, 11.5, CHCHA HBPh), 0.91 (3H, d, 
J 7.0, CH(CAH3CBH3),  0.93 (3H, d, J 7.0, CH(CAH 3CBH3)), 2.01-2.11 (1H, m, 
CH(CH3)2), 2.64 (1H, dd, J 13.5, 3.5, CHCHAHBPh), 2.95-3.02 (1H, br d, 
CCHA HBPh), 3.29 (1H, br d, J -42, CCHAHBPh,), 4.15 (1H, br dd, J 9.0, 7.0, 
NHCHCH(CH 3) 2), 4.29 (1H, dd, J 11.5, 3.5, CHCHAHBPh), 5.08 (1H, d, J 11.5, 
OCHA HBPh), 5.14 (1H, d, J 11.5, OCHAHBPh), 5.36 (1H, d, J9.0, NHCHCH(CH 3 )2), 
5.92 (1H, br s, NHCHCH AHBPh), 6.77' (2H, dd, J-8, -2, 2 x ArR), 7.04-7.40 (13H, 
m, 13 x ArII), 7.62 (1H, s, CHC4NHCO); O (63 MHz, CDC13) 17.9 
(CH(CAH 3CBHM I  18.8 (CH(CAH 3 CBH3)) ,  31.6 (CH(CH3)2), 35.5 (CHPh), 38.5 
(CH2Ph), 58.7 (CHCH 2Ph), 63.2 (CHCH(CH 3)2), 63.8 (NHC4CH2Ph), 67.0 
(OCH2Ph), 125.1, 126.8, 127.8, 127.9, 128.0, 128.3, 128.5, 128.6, 128.7, 128.8, 
130.0 & 130.9 (15 xAr-H), 132.2 (C4 COCH), 135.9 (CH2Ph), 136.1 (CH2Ph), 136.8 
(OCH2Ph), 156.3 (OCONH), 171.4 (CONH), 171.6 (CONE); m/z (APCi) 528 
(MW). 
6.12 Preliminary Studies on SynPhaseTm MD Crowns 
6.12.1 4- [Hydroxymethyl-(4'-nitrophenylcarbonate)] -phenoxyacetamido 
SynPhase MD 106 
NO 
0 
4-(Hydroxymethyl)-phenoxyacetamido SynPhase MD crowns (1.8 .imole/crown' T - 
30 crowns, 54 imo1e) were suspended in dry DCM (10 ml) before addition of a 
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solution of p-nitrophenyl chioroformate (109 mg, 0.54 mmole). Anhydrous pyridine 
(44 p1, 0.54 mmole) was added and the suspension of crowns agitated very gently at 
room temperature, under argon. After 40 h the crowns were washed according to 
standard laboratory prototcol and dried. Two crowns were retained for p-nitrophenyl 
analysis and the remaining crowns reacted on (6.12.2). 
Loading 0.2 jtmole/g (p-nitro). 
6.12.2 4-(Na-Methoxycarbony1va1y1oxymethy1fluoreny19?y1) 
phenoxyacetamido SynPhase MD 107 
4-[Hydroxymethyl-(4'-nitrophenylcarbonate)]-phenoxyacetamido SynPhase MD 
crowns (106) (assume :! ~ 1.8 p.mole/crown - 28 crowns, 50.4 l.tmole) were suspended 
in a solution of TSA-Val-OFm (65b) (236 mg, 0.50 mmole) in DMFt  (20 ml). A 
catalytic portion of DMAP (10 %) was added along with NMM (55 p1, 0.50 
mmole) and the suspension of crowns was shaken very gently at room temperature 
(12 h). The crowns were washed with MeOH (x 3) and DCM (x 1) and dried. One 
crown was cleaved, one retained for loading analysis and the remaining crowns 
reacted on (6.12.3). 
Loading 0.1 j.tmol/g (Fm); Cleavage 9:10:1 TFA/DCM/H 20: LCMSA R 9.2 mm 
(broad and weak); m/z (ES-MS) 296 (MW). 




phenoxyacetamido SynPhase MD 108 
r0 
; 
Val-OFm-bound SynPhase MD crowns (107) (assume :!~ 1.8 [tmole/crown - 26 
crowns, 46.8 j.tmole) were deprotected with a solution of 20 % piperidine in DMF (3 
x 20 ml; 15 min ea), before washing (MeOH x 3) and (DCM x 1). The crowns were 
then treated with 3 % acetic acid in DCM (4 x 20 ml; 5 min ea), washed with MeOH 
(x 3) and DCM (x 1) before suspending in a solution of TBTU (150 mg, 0.47 mmol) 
and NMM (51 p1, 0.47 mmol) in DMF (16 ml). After shaking for 1 h, the crowns 
were washed with MeOH (x 2) and finally suspended in a solution of HOBt-Phe-
OFm (66a) (224 mg, 0.47 mmol) in DMF (16 ml) and agitated at room temperature 
for 12 h. The crowns were washed with MeOH (x 3) and DCM (x 1) and dried under 
vacuum. Two crowns were cleaved and analysed by LC-MS which indicated the 
coupling had occurred, but only gave a very weak signal. Fm analysis was carried 
out on a further two crowns also indicating a low yield of the product. 
Loading 0.5 tmoIIg (Fm); Cleavage 9:10:1 TFA/DCMIH 20: LCMSA R 21.4 mm 
(very weak); m/z (ES-MS) 443 (MH). 
6.12.4 (1 'S)-4- [N-Methoxycarbonyl-2 '-methyl-i '-(4' '-benzylidene-5' '-oxo-4' ',5' '-





H 	 HI 
* _,,N 0 0 0 
Val-Phe-OFm-bound SynPhase MD crowns (108) (assume :! ~ 1 .8 .tmole/crown - 12 
crowns, 21.6 tmo1e) were deprotected with a solution of 20 % piperidine in DMF (3 
x 10 ml; 15 min ea), before washing (MeOH x 3) and (DCM x 1). The crowns were 
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then treated with 3 % acetic acid in DCM (4 x 10 ml; 5 min ea), washed with MeOH 
(x 3) and DCM (x 1) before suspending in a solution of EDCI (41 mg, 0.22 mmol) in 
DCM (10 ml). After shaking (>24 h), the crowns were washed with MeOH (x 3) and 
DCM (x 1) and dried under vacuum. Acidic cleavage of two crowns, followed by 
ES-MS analysis only showed a very faint trace of the mass ion of the hydrolysed 
5(411)-oxazolone, indicating a very poor yield at this stage if at all. 
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